[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is also known as:\n* Acrokeratosis paraneoplastic\nNote: These terms are synonyms, and both terms refer to the same medical condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastic.\n2. Both terms refer to the same medical condition.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is also known as Acrokeratosis paraneoplastic.",
      "Both terms refer to the same medical condition."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both rare genetic disorders that are characterized by overgrowth and developmental delays, but they have some differences in their clinical features and genetic causes.\nWeaver syndrome is caused by mutations in the PHLPP2 gene, which encodes a protein involved in the regulation of the PI3K/Akt signaling pathway. The main features of Weaver syndrome include:\n* Overgrowth (gigantism)\n* Developmental delays and intellectual disability\n* Distinctive facial features, such as a large head, prominent eyes, and a wide nasal bridge\n* Skeletal abnormalities, such as joint hypermobility and short stature\n* Cardiovascular problems, such as hypertension and cardiac defects\n* Increased risk of cancer\nSotos syndrome, on the other hand, is caused by mutations in the NSD1 gene, which encodes a protein involved in the regulation of chromatin remodeling and transcriptional elongation. The main features of Sotos syndrome include:\n* Overgrowth (gigantism)\n* Developmental delays and intellectual disability\n* Distinctive facial features, such as a large head, prominent eyes, and a wide nasal bridge\n* Skeletal abnormalities, such as joint hypermobility and short stature\n* Cardiovascular problems, such as hypertension and cardiac defects\n* Increased risk of cancer\nWhile both disorders share some similarities in terms of their clinical features, Weaver syndrome is generally considered to be a milder disorder compared to Sotos syndrome. Weaver syndrome typically has a more gradual onset of symptoms, and the overgrowth is less pronounced compared to Sotos syndrome. Additionally, the facial features of Weaver syndrome are less distinctive than those seen in Sotos syndrome.\nIn summary, while Weaver syndrome and Sotos syndrome share some similarities, they are distinct disorders with different genetic causes and clinical features.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome is caused by mutations in the PHLPP2 gene.\n2. Sotos syndrome is caused by mutations in the NSD1 gene.\n3. Both Weaver syndrome and Sotos syndrome are characterized by overgrowth (gigantism) and developmental delays.\n4. Weaver syndrome generally has a more gradual onset of symptoms compared to Sotos syndrome.\n5. The overgrowth is less pronounced in Weaver syndrome than in Sotos syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome is caused by mutations in the PHLPP2 gene.",
      "Sotos syndrome is caused by mutations in the NSD1 gene.",
      "Both Weaver syndrome and Sotos syndrome are characterized by overgrowth (gigantism) and developmental delays.",
      "Weaver syndrome generally has a more gradual onset of symptoms compared to Sotos syndrome.",
      "The overgrowth is less pronounced in Weaver syndrome than in Sotos syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Weaver syndrome is caused by mutations in the EZH2 gene, not the PHLPP2 gene.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "JASPAR (Junkunc Alignment of Sequence Protein Alignments) is a database of transcription factor binding site (TFBS) profiles for various organisms. Here are the releases of the JASPAR database:\n1. JASPAR Release 1 (1999): This was the first release of the JASPAR database, containing TFBS profiles for 14 organisms, including humans, mice, and yeast.\n2. JASPAR Release 2 (2002): This release added TFBS profiles for 11 additional organisms, including Drosophila and C. elegans.\n3. JASPAR Release 3 (2006): This release improved the quality of the TFBS profiles and added new organisms, including the zebrafish and the nematode Caenorhabditis elegans.\n4. JASPAR Release 4 (2010): This release included improved TFBS profiles for all organisms, as well as new features such as the ability to search for conserved TFBSs across multiple species.\n5. JASPAR Release 5 (2014): This release included improved TFBS profiles for all organisms, as well as new features such as the ability to search for TFBSs in non-coding RNA sequences.\n6. JASPAR Release 6 (2017): This release included improved TFBS profiles for all organisms, as well as new features such as the ability to search for TFBSs in the context of specific genomic features, such as gene deserts or enhancers.\n7. JASPAR Release 7 (2020): This is the latest release of the JASPAR database, which includes improved TFBS profiles for all organisms, as well as new features such as the ability to search for TFBSs in the context of specific epigenetic marks.\nIt's worth noting that the JASPAR database is constantly being updated and improved, so there may be additional releases beyond these listed here.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first release of the JASPAR database was in 1999 and contained transcription factor binding site (TFBS) profiles for 14 organisms.\n2. JASPAR Release 2 was in 2002, adding TFBS profiles for 11 additional organisms.\n3. The 2006 release of the JASPAR database (Release 3) added zebrafish and the nematode Caenorhabditis elegans to its profiles.\n4. JASPAR Release 4, which occurred in 2010, included new features such as the ability to search for conserved transcription factor binding sites across multiple species.\n5. The latest release stated in the response is JASPAR Release 7 in 2020, which incorporates new features, including the ability to search for TFBSs in the context of specific epigenetic marks.",
    "llama-2-7b-chat-hf_fact": [
      "The first release of the JASPAR database was in 1999 and contained transcription factor binding site (TFBS) profiles for 14 organisms.",
      "JASPAR Release 2 was in 2002, adding TFBS profiles for 11 additional organisms.",
      "The 2006 release of the JASPAR database (Release 3) added zebrafish and the nematode Caenorhabditis elegans to its profiles.",
      "JASPAR Release 4, which occurred in 2010, included new features such as the ability to search for conserved transcription factor binding sites across multiple species.",
      "The latest release stated in the response is JASPAR Release 7 in 2020, which incorporates new features, including the ability to search for TFBSs in the context of specific epigenetic marks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN: Without the exact numbering convention the JASPAR database used for its releases or detailed release notes, it's difficult to confirm or refute the statement about Release 2 in 2002 adding TFBS profiles for 11 additional organisms.\n3. UNKNOWN: The inclusion of zebrafish and Caenorhabditis elegans in the 2006 JASPAR database release (Release 3) cannot be confirmed or refuted without specific release information.\n4. UNKNOWN: The statement regarding JASPAR Release 4 in 2010 and its new features is specific, but without access to the release notes or historical data of JASPAR, its truth cannot be validated.\n5. UNKNOWN: It is not possible to confirm if JASPAR Release 7 occurred in 2020 or if it included the described features without access to the up-to-date release information of the JASPAR database.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The KP4 protein is a protein encoded by the KP4 gene in some viruses, including the poxvirus. The KP4 protein plays a role in the regulation of the viral genome replication and transcription, and is involved in the evasion of the host immune response. It can also interact with host cell factors and modulate their activity to promote viral replication.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is encoded by the KP4 gene in some viruses, which includes the poxvirus.\n2. The KP4 protein is involved in the regulation of the viral genome replication and transcription.\n3. The KP4 protein plays a role in the evasion of the host immune response.\n4. The KP4 protein can interact with host cell factors.\n5. The interaction of KP4 protein with host cell factors modulates their activity to promote viral replication.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is encoded by the KP4 gene in some viruses, which includes the poxvirus.",
      "The KP4 protein is involved in the regulation of the viral genome replication and transcription.",
      "The KP4 protein plays a role in the evasion of the host immune response.",
      "The KP4 protein can interact with host cell factors.",
      "The interaction of KP4 protein with host cell factors modulates their activity to promote viral replication."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The KP4 protein is not encoded by viruses; it is a killer toxin encoded by the Ustilago maydis (corn smut fungus) and does not include the poxvirus.\n2. FALSE [correction]: The KP4 protein does not regulate viral genome replication and transcription; it is a fungal toxin that can inhibit yeast growth.\n3. TRUE: The KP4 protein is indeed involved in the evasion of the host's immune response, at least when considering the immune systems of other fungi.\n4. TRUE: The KP4 protein can interact with host cell factors of susceptible yeasts, such as receptors that allow it to enter the cell or carry out its toxic functions.\n5. TRUE: The interaction of KP4 protein with host cell factors can modulate their activity which includes promoting the fungal pathogen's survival, though it might not be accurate to talk about \"viral replication\" here, since it is a fungal protein.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (N-[4-(5-Iodonaphthalene-1-yl)-2-methylphenyl]-5-iodo-2-pyrimidinone) is a thyroid hormone analog that has been utilized in both experimental and clinical studies. DITPA is a potent agonist of the thyroid hormone receptor (TR) and has been used to study the role of thyroid hormones in various physiological processes, including metabolism, growth, and development.\nIn experimental studies, DITPA has been used to investigate the mechanisms of thyroid hormone action, the regulation of gene expression, and the effects of thyroid hormone deficiency or excess on various tissues and organs. For example, DITPA has been used to study the effects of thyroid hormone deficiency on fetal development during pregnancy, the regulation of lipid metabolism, and the role of thyroid hormones in the regulation of immune function.\nIn clinical studies, DITPA has been used as a tool for the diagnosis and treatment of thyroid disorders, such as hypothyroidism and hyperthyroidism. DITPA has been shown to be effective in suppressing the production of thyroid hormones in patients with hyperthyroidism, and it has also been used to stimulate the production of thyroid hormones in patients with hypothyroidism.\nHowever, it is important to note that DITPA is a potent and highly specific agonist of the TR, and its use in humans is associated with potential side effects, such as hyperthyroidism, tachycardia, and palpitations. As a result, DITPA is typically used in clinical settings only under close medical supervision and as part of a comprehensive treatment plan for thyroid disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a thyroid hormone analog that has been utilized in experimental and clinical studies.\n2. DITPA acts as a potent agonist of the thyroid hormone receptor (TR).\n3. It has been used to study the effects of thyroid hormone deficiency on fetal development during pregnancy.\n4. DITPA has been shown to be effective in suppressing the production of thyroid hormones in patients with hyperthyroidism.\n5. DITPA's use in humans can be associated with potential side effects, including hyperthyroidism, tachycardia, and palpitations.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a thyroid hormone analog that has been utilized in experimental and clinical studies.",
      "DITPA acts as a potent agonist of the thyroid hormone receptor (TR).",
      "It has been used to study the effects of thyroid hormone deficiency on fetal development during pregnancy.",
      "DITPA has been shown to be effective in suppressing the production of thyroid hormones in patients with hyperthyroidism.",
      "DITPA's use in humans can be associated with potential side effects, including hyperthyroidism, tachycardia, and palpitations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: DITPA has shown promise in experimental studies for conditions such as heart failure, but it is not used to suppress the production of thyroid hormones in patients with hyperthyroidism; this is typically achieved with antithyroid medications.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "COUGER (Comprehensive Upgrade of Genome-scale Regulatory Networks) is a tool used in bioinformatics for the comprehensive analysis and upgrade of genome-scale regulatory networks. It is designed to improve the accuracy and completeness of regulatory network models by integrating a wide range of data types, including gene expression profiles, protein-DNA interaction data, and genomic features. COUGER uses a Bayesian inference framework to integrate these data types and generate a more accurate and comprehensive model of the regulatory network. The tool can be used to study the regulation of gene expression in a variety of organisms, including bacteria, yeast, and humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. COUGER stands for Comprehensive Upgrade of Genome-scale Regulatory Networks.\n2. COUGER is used in bioinformatics for analyzing and upgrading genome-scale regulatory networks.\n3. The tool integrates a wide range of data types, such as gene expression profiles, protein-DNA interaction data, and genomic features.\n4. COUGER employs a Bayesian inference framework to integrate various data types.\n5. The tool can be applied to studying gene expression regulation in organisms including bacteria, yeast, and humans.",
    "llama-2-7b-chat-hf_fact": [
      "COUGER stands for Comprehensive Upgrade of Genome-scale Regulatory Networks.",
      "COUGER is used in bioinformatics for analyzing and upgrading genome-scale regulatory networks.",
      "The tool integrates a wide range of data types, such as gene expression profiles, protein-DNA interaction data, and genomic features.",
      "COUGER employs a Bayesian inference framework to integrate various data types.",
      "The tool can be applied to studying gene expression regulation in organisms including bacteria, yeast, and humans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: COUGER stands for Comprehensive Unbiased Reconstruction of Genome-Scale Regulatory Networks.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available for the treatment of tick-borne encephalitis (TBE). The most commonly used drugs are:\n1. Antiviral medications: Ribavirin, an antiviral drug, is the most commonly used treatment for TBE. It is effective in reducing the severity of symptoms and preventing complications.\n2. Corticosteroids: Corticosteroids, such as prednisone, are sometimes prescribed to reduce inflammation in the brain and alleviate symptoms.\n3. Antibiotics: In cases where TBE is caused by a bacterial infection, antibiotics such as doxycycline or azithromycin may be prescribed.\n4. Supportive care: Supportive care, such as rest, hydration, and pain management, is also important in managing TBE.\nIt's important to note that the best treatment approach for TBE may vary depending on the severity and location of the infection, as well as the individual patient's medical history and overall health. In some cases, a combination of these treatments may be used. Early diagnosis and treatment are critical in improving outcomes for patients with TBE.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ribavirin is an antiviral drug commonly used to treat tick-borne encephalitis (TBE).\n2. Corticosteroids like prednisone can be used to reduce inflammation in the brain caused by TBE.\n3. Antibiotics such as doxycycline or azithromycin may be prescribed for TBE if it is caused by a bacterial infection.\n4. Supportive care, which includes rest, hydration, and pain management, is a part of managing TBE.\n5. Early diagnosis and treatment of tick-borne encephalitis are critical for improving patient outcomes.",
    "llama-2-7b-chat-hf_fact": [
      "Ribavirin is an antiviral drug commonly used to treat tick-borne encephalitis (TBE).",
      "Corticosteroids like prednisone can be used to reduce inflammation in the brain caused by TBE.",
      "Antibiotics such as doxycycline or azithromycin may be prescribed for TBE if it is caused by a bacterial infection.",
      "Supportive care, which includes rest, hydration, and pain management, is a part of managing TBE.",
      "Early diagnosis and treatment of tick-borne encephalitis are critical for improving patient outcomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ribavirin is not commonly used to treat tick-borne encephalitis (TBE); it is more often used for other viral infections such as hepatitis C. Treatment for TBE mainly focuses on supportive care.\n2. TRUE: Corticosteroids like prednisone may be used in severe cases to reduce inflammation in the brain caused by TBE.\n3. FALSE [correction]: Tick-borne encephalitis is a viral infection, so antibiotics such as doxycycline or azithromycin would not be prescribed for TBE as they are used to treat bacterial infections.\n4. TRUE: Supportive care is indeed a critical part of managing TBE, as there is no specific cure for the virus.\n5. TRUE: Early diagnosis and supportive treatment for tick-borne encephalitis can be crucial for improving patient outcomes, although there is no specific antiviral treatment for TBE.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "There are several genome browsers that provide DNA shape annotations, including:\n1. UCSC Genome Browser: The University of California, Santa Cruz (UCSC) Genome Browser provides DNA shape annotations using the Circos tool, which generates circular maps of genomic regions and their associated features.\n2. Ensembl Genome Browser: The Ensembl Genome Browser provides DNA shape annotations using the Circos tool, as well as other tools such as Bedtools and HISAT2.\n3. Genome Graph Explorer (GGE): GGE is a web-based genome browser that provides DNA shape annotations using a variety of tools, including Circos, Bedtools, and HISAT2.\n4. OpenGenomeBrowser (OGB): OGB is a web-based genome browser that provides DNA shape annotations using a variety of tools, including Circos, Bedtools, and HISAT2.\n5. Bioconductor: Bioconductor is a collection of R packages for genomics analysis, including several tools for DNA shape annotation, such as Circos, Bedtools, and HISAT2.\n6. G Browser: G Browser is a web-based genome browser that provides DNA shape annotations using a variety of tools, including Circos, Bedtools, and HISAT2.\n7. Genome Atlas (GAT): GAT is a web-based genome browser that provides DNA shape annotations using a variety of tools, including Circos, Bedtools, and HISAT2.\n8. Genomic Architecture: Genomic Architecture is a web-based genome browser that provides DNA shape annotations using a variety of tools, including Circos, Bedtools, and HISAT2.\n9. Chromatin Atlas (ChA): ChA is a web-based genome browser that provides DNA shape annotations using a variety of tools, including Circos, Bedtools, and HISAT2.\n10. Epigenome Atlas (EpiAtlas): EpiAtlas is a web-based genome browser that provides DNA shape annotations using a variety of tools, including Circos, Bedtools, and HISAT2.\nPlease note that this is not an exhaustive list, and there may be other genome browsers available that provide DNA shape annotations.",
    "llama-2-7b-chat-hf_fact_raw": "1. The UCSC Genome Browser provides DNA shape annotations using the Circos tool.\n2. The Ensembl Genome Browser provides DNA shape annotations using the Circos tool, as well as other tools such as Bedtools and HISAT2.\n3. Genome Graph Explorer (GGE) is a web-based genome browser that provides DNA shape annotations.\n4. OpenGenomeBrowser (OGB) is a web-based genome browser that provides DNA shape annotations.\n5. Bioconductor includes R packages for genomics analysis and provides tools for DNA shape annotation.",
    "llama-2-7b-chat-hf_fact": [
      "The UCSC Genome Browser provides DNA shape annotations using the Circos tool.",
      "The Ensembl Genome Browser provides DNA shape annotations using the Circos tool, as well as other tools such as Bedtools and HISAT2.",
      "Genome Graph Explorer (GGE) is a web-based genome browser that provides DNA shape annotations.",
      "OpenGenomeBrowser (OGB) is a web-based genome browser that provides DNA shape annotations.",
      "Bioconductor includes R packages for genomics analysis and provides tools for DNA shape annotation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The UCSC Genome Browser may provide various annotations and visualization tools, but it is not specifically known for using the Circos tool to provide DNA shape annotations.\n2. FALSE [correction]: While the Ensembl Genome Browser does provide a range of tools and resources for genomic analysis, it does not use Circos for DNA shape annotations within its standard browser interface. Bedtools and HISAT2 are separate software tools used for genomic analysis, and not necessarily integrated with Ensembl for DNA shape annotations.\n3. UNKNOWN: Without specific reference to Genome Graph Explorer (GGE) and its capabilities, it's not possible to verify the accuracy of this statement.\n4. UNKNOWN: Similarly, without specific information about OpenGenomeBrowser (OGB) and its features, the truth of this statement cannot be determined.\n5. TRUE: Bioconductor does include R packages that are aimed at genomic analysis, and among its many packages, it is likely to have tools that could be used for DNA shape annotation, though it is not a tool in itself but a repository of packages.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene has been associated with several syndromes, including:\n1. EP300-related syndrome: This is a rare genetic disorder characterized by developmental delays, intellectual disability, and a variety of physical abnormalities, including distinctive facial features and skeletal abnormalities.\n2. EZH2-related overgrowth syndrome: This is a rare genetic disorder characterized by excessive growth and development, as well as various other physical and developmental abnormalities.\n3. Horta-Hitzemethven syndrome: This is a rare genetic disorder characterized by developmental delays, intellectual disability, and a variety of physical abnormalities, including distinctive facial features and skeletal abnormalities.\n4. Cdkn2a-related overgrowth syndrome: This is a rare genetic disorder characterized by excessive growth and development, as well as various other physical and developmental abnormalities.\n5. Cdkn2a-related developmental disorder: This is a rare genetic disorder characterized by developmental delays and intellectual disability, as well as various other physical and developmental abnormalities.\nIt is important to note that mutations in the EZH2 gene can also occur sporadically, without a clear family history, in certain types of cancer, including lymphoma and leukemia.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene are associated with EP300-related syndrome.\n2. EZH2-related overgrowth syndrome is connected to mutations in the EZH2 gene.\n3. The Horta-Hitzemethven syndrome is linked to mutations in the EZH2 gene.\n4. Mutations in the EZH2 gene are associated with Cdkn2a-related overgrowth syndrome.\n5. Mutations in the EZH2 gene can occur in certain types of cancer, including lymphoma and leukemia.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the EZH2 gene are associated with EP300-related syndrome.",
      "EZH2-related overgrowth syndrome is connected to mutations in the EZH2 gene.",
      "The Horta-Hitzemethven syndrome is linked to mutations in the EZH2 gene.",
      "Mutations in the EZH2 gene are associated with Cdkn2a-related overgrowth syndrome.",
      "Mutations in the EZH2 gene can occur in certain types of cancer, including lymphoma and leukemia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the EP300 gene, not the EZH2 gene, are associated with EP300-related syndromes.\n2. TRUE\n3. UNKNOWN: There is no well-known syndrome called \"Horta-Hitzemethven syndrome\" associated with the EZH2 gene in scientific literature. It may be a fictitious or incorrectly named syndrome, or it might be a very recent discovery not widely recognized at the time of my knowledge cutoff.\n4. FALSE [correction]: Mutations in the CDKN2A gene, not the EZH2 gene, are associated with Cdkn2a-related overgrowth syndrome.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition, including:\n1. p53: The tumor suppressor protein p53 is a well-known example of a protein that undergoes a dimer-to-tetramer transition. The p53 protein exists as a dimer in its inactive state, but upon DNA damage or other forms of cellular stress, it can transition to a tetrameric state, which is more active and capable of transcriptional activation.\n2. c-Myc: The c-Myc protein is a transcription factor that is involved in cellular proliferation, differentiation, and apoptosis. c-Myc exists as a dimer in its inactive state, but upon phosphorylation, it can transition to a tetrameric state, which is more active and capable of transcriptional activation.\n3. p73: The p73 protein is a tumor suppressor protein that is similar in structure and function to p53. Like p53, p73 exists as a dimer in its inactive state, but upon DNA damage or other forms of cellular stress, it can transition to a tetrameric state, which is more active and capable of transcriptional activation.\n4. STAT3: The STAT3 protein is a transcription factor that is involved in the regulation of inflammation and immune responses. STAT3 exists as a dimer in its inactive state, but upon phosphorylation, it can transition to a tetrameric state, which is more active and capable of transcriptional activation.\n5. FOXO1: The FOXO1 protein is a transcription factor that is involved in the regulation of metabolism, cellular stress responses, and longevity. FOXO1 exists as a dimer in its inactive state, but upon phosphorylation, it can transition to a tetrameric state, which is more active and capable of transcriptional activation.\n6. NF-κB: The NF-κB protein is a transcription factor that is involved in the regulation of inflammation and immune responses. NF-κB exists as a dimer in its inactive state, but upon phosph",
    "llama-2-7b-chat-hf_fact_raw": "1. The p53 protein can transition from a dimer to a tetramer upon DNA damage or cellular stress.\n2. The c-Myc protein is known to transition from a dimer to a tetramer upon phosphorylation.\n3. The p73 protein, which is similar to p53, can become a tetramer from a dimer in response to DNA damage or cellular stress.\n4. The STAT3 protein can transition from a dimer to a tetramer upon phosphorylation.\n5. The FOXO1 protein is capable of transitioning from a dimer to a tetramer upon phosphorylation.",
    "llama-2-7b-chat-hf_fact": [
      "The p53 protein can transition from a dimer to a tetramer upon DNA damage or cellular stress.",
      "The c-Myc protein is known to transition from a dimer to a tetramer upon phosphorylation.",
      "The p73 protein, which is similar to p53, can become a tetramer from a dimer in response to DNA damage or cellular stress.",
      "The STAT3 protein can transition from a dimer to a tetramer upon phosphorylation.",
      "The FOXO1 protein is capable of transitioning from a dimer to a tetramer upon phosphorylation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The c-Myc protein functions as a transcription factor and forms dimers, but it is not known to transition from a dimer to a tetramer upon phosphorylation.\n3. TRUE\n4. FALSE [correction]: The STAT3 protein typically functions as a dimer and does not transition to a tetramer upon phosphorylation.\n5. FALSE [correction]: The FOXO1 protein typically functions as a monomer or as part of a larger complex with other proteins, but it does not transition from a dimer to a tetramer upon phosphorylation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "One protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is Bcl-2 (B-cell lymphoma 2).",
    "llama-2-7b-chat-hf_fact_raw": "1. Bcl-2 (B-cell lymphoma 2) is a protein that interacts with phospholamban (PLN).\n2. Bcl-2 (B-cell lymphoma 2) is an anti-apoptotic protein.",
    "llama-2-7b-chat-hf_fact": [
      "Bcl-2 (B-cell lymphoma 2) is a protein that interacts with phospholamban (PLN).",
      "Bcl-2 (B-cell lymphoma 2) is an anti-apoptotic protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, several clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people. Here are some examples:\n1. A 2012 Cochrane review of 14 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults (odds ratio 0.63, 95% CI 0.45-0.89).\n2. A 2013 meta-analysis of 17 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults (odds ratio 0.67, 95% CI 0.53-0.85).\n3. A 2016 randomized controlled trial found that vitamin D supplementation (2000 IU/day) for 12 months reduced the incidence of falls by 43% in older adults with a history of falls (n=137).\n4. A 2017 randomized controlled trial found that vitamin D supplementation (1000 IU/day) for 12 months reduced the incidence of falls by 37% in older adults with a history of falls (n=107).\nIt is important to note that the optimal dose and duration of vitamin D supplementation for fall prevention is still unclear and may vary depending on individual factors such as age, sex, and baseline vitamin D status. Additionally, while vitamin D supplementation has been shown to reduce the incidence of falls, it may not necessarily eliminate falls entirely, and other factors such as exercise, balance training, and environmental modifications should also be considered in fall prevention strategies.",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2012 Cochrane review of 14 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults.\n2. A 2013 meta-analysis of 17 randomized controlled trials indicated that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults.\n3. A 2016 randomized controlled trial reported that vitamin D supplementation at a dose of 2000 IU/day for 12 months reduced the incidence of falls by 43% in older adults with a history of falls.\n4. A 2017 randomized controlled trial indicated that vitamin D supplementation at a dose of 1000 IU/day for 12 months reduced the incidence of falls by 37% in older adults with a history of falls.",
    "llama-2-7b-chat-hf_fact": [
      "A 2012 Cochrane review of 14 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults.",
      "A 2013 meta-analysis of 17 randomized controlled trials indicated that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults.",
      "A 2016 randomized controlled trial reported that vitamin D supplementation at a dose of 2000 IU/day for 12 months reduced the incidence of falls by 43% in older adults with a history of falls.",
      "A 2017 randomized controlled trial indicated that vitamin D supplementation at a dose of 1000 IU/day for 12 months reduced the incidence of falls by 37% in older adults with a history of falls."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: A 2013 meta-analysis of randomized controlled trials indicated an association between vitamin D supplementation and reduced risk of falls in older adults, but the exact number of trials reviewed should be verified as it may not be exactly 17.\n3. UNKNOWN\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells. Jarid2 (also known as KAT2A) is a histone methyltransferase that is involved in the regulation of chromatin structure and gene expression, particularly in the context of T cell differentiation and function. miR-155 is a microRNA that is known to play a role in the regulation of Th17 cell differentiation and function, and has been implicated in a number of autoimmune diseases.\nStudies have shown that Jarid2 and miR-155 are co-regulated in Th17 cells, and that Jarid2 is required for the proper expression of miR-155. Specifically, Jarid2 has been shown to bind to the promoter region of the miR-155 gene and to mediate its transcriptional activation.\nFurthermore, miR-155 has been shown to target and regulate the expression of genes involved in Th17 cell differentiation and function, including the transcription factor retinoic acid-related orphan receptor gamma t (ROR-γt), which is a key regulator of Th17 cell differentiation.\nOverall, the association between Jarid2 and miR-155 in Th17 cells suggests that these two molecules may play a coordinated role in regulating Th17 cell differentiation and function, and may be potential targets for the development of new therapies for autoimmune diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is involved in the regulation of chromatin structure and gene expression in T cell differentiation and function.\n2. miR-155 plays a role in the regulation of Th17 cell differentiation and function and is implicated in autoimmune diseases.\n3. Jarid2 and miR-155 are co-regulated in Th17 cells.\n4. Jarid2 is required for the proper expression of miR-155 and binds to the promoter region of the miR-155 gene to mediate its transcriptional activation.\n5. miR-155 targets and regulates the expression of genes involved in Th17 cell differentiation and function, including the transcription factor ROR-γt.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is involved in the regulation of chromatin structure and gene expression in T cell differentiation and function.",
      "miR-155 plays a role in the regulation of Th17 cell differentiation and function and is implicated in autoimmune diseases.",
      "Jarid2 and miR-155 are co-regulated in Th17 cells.",
      "Jarid2 is required for the proper expression of miR-155 and binds to the promoter region of the miR-155 gene to mediate its transcriptional activation.",
      "miR-155 targets and regulates the expression of genes involved in Th17 cell differentiation and function, including the transcription factor ROR-γt."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: JARID2 (Jumonji and AT-rich interaction domain containing 2) is known to be involved in chromatin remodeling and gene expression regulation, which can influence T cell differentiation and function.\n2. TRUE: miR-155 is a microRNA that has been established as playing a crucial role in the regulation of Th17 cell differentiation and function, and it has been implicated in the pathogenesis of various autoimmune diseases.\n3. UNKNOWN: Without specific research or evidence presented in the context, the co-regulation of Jarid2 and miR-155 in Th17 cells cannot be conclusively determined.\n4. FALSE [correction]: Jarid2 does not typically bind directly to the promoter regions of genes to mediate transcriptional activation. Jarid2 is part of the Polycomb Repressive Complex 2 (PRC2) and influences gene expression through histone modification, not direct DNA binding. Therefore, it is unlikely that Jarid2 is required for the proper expression of miR-155 by binding to its promoter region for transcriptional activation as stated.\n5. TRUE: miR-155 is known to target multiple genes that are involved in immune responses, including those related to Th17 cell differentiation. It has been reported in the scientific literature that miR-155 can target and regulate genes that are important for Th17 cell functions, though the specific mention of ROR-γt, a transcription factor essential for the differentiation of Th17 cells, would need to be verified with current research.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster contains 9 genes: Hoxd1, Hoxd2, Hoxd3, Hoxd4, Hoxd5, Hoxd6, Hoxd7, Hoxd8, and Hoxd9.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 9 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 9 genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster contains 9-11 genes, depending on the sources and classification, but typically it is most commonly recognized as containing 9 genes (HOXD1 to HOXD13, excluding HOXD10, HOXD11, and HOXD12 which are missing due to evolutionary deletions).",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein Kinase 1 (CK1) is a serine/threonine protein kinase that phosphorylates a variety of substrates in cells. The phosphorylation consensus motifs for CK1 are:\n1. Ser/Thr-Pro-Pro-X-X-Ser/Thr (where X is any amino acid)\nThis motif is recognized by the catalytic subunit of CK1 and is found in the phosphorylation sites of many CK1 targets.\n2. Ser/Thr-Pro-X-X-Ser/Thr (where X is any amino acid)\nThis motif is also recognized by the catalytic subunit of CK1 and is found in the phosphorylation sites of some CK1 targets.\n3. Ser/Thr-Gly-X-X-Ser/Thr (where X is any amino acid)\nThis motif is recognized by the regulatory subunit of CK1 and is found in the phosphorylation sites of some CK1 targets.\n4. Thr-X-X-Ser/Thr (where X is any amino acid)\nThis motif is recognized by the catalytic subunit of CK1 and is found in the phosphorylation sites of some CK1 targets.\nIt's worth noting that the consensus motifs for CK1 are not fixed and can vary depending on the specific substrate and context in which the kinase is active. Additionally, CK1 can also phosphorylate other sites on proteins that do not contain these consensus motifs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein Kinase 1 (CK1) is a serine/threonine protein kinase.\n2. A CK1 phosphorylation consensus motif is Ser/Thr-Pro-Pro-X-X-Ser/Thr, where X can be any amino acid.\n3. Another CK1 phosphorylation consensus motif is Ser/Thr-Pro-X-X-Ser/Thr, where X can be any amino acid.\n4. The regulatory subunit of CK1 recognizes the Ser/Thr-Gly-X-X-Ser/Thr motif, where X can be any amino acid.\n5. The catalytic subunit of CK1 recognizes the Thr-X-X-Ser/Thr motif, where X can be any amino acid.",
    "llama-2-7b-chat-hf_fact": [
      "Casein Kinase 1 (CK1) is a serine/threonine protein kinase.",
      "A CK1 phosphorylation consensus motif is Ser/Thr-Pro-Pro-X-X-Ser/Thr, where X can be any amino acid.",
      "Another CK1 phosphorylation consensus motif is Ser/Thr-Pro-X-X-Ser/Thr, where X can be any amino acid.",
      "The regulatory subunit of CK1 recognizes the Ser/Thr-Gly-X-X-Ser/Thr motif, where X can be any amino acid.",
      "The catalytic subunit of CK1 recognizes the Thr-X-X-Ser/Thr motif, where X can be any amino acid."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: CK1 phosphorylation consensus motifs are typically characterized by the presence of acidic residues surrounding a Ser or Thr, rather than the defined motif provided.\n3. TRUE\n4. FALSE [correction]: CK1 does not have a regulatory subunit; it is a monomeric enzyme.\n5. FALSE [correction]: The given motif does not specifically describe CK1 recognition sequences, and CK1 typically requires acidic residues in the -1, +1, +3 positions relative to the phosphorylatable Ser/Thr.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes several different proteins/isoforms, including:\n1. Aspartate beta-hydroxylase (ABH): This is the main isoform of the enzyme, which is involved in the biosynthesis of the neurotransmitter serotonin.\n2. Tissue inhibitor of metalloproteinases 1 (TIMP1): This isoform is a potent inhibitor of matrix metalloproteinases (MMPs), which are enzymes involved in the breakdown of the extracellular matrix.\n3. Matrix metalloproteinase 9 (MMP9): This isoform is a member of the MMP family, which are involved in the breakdown of the extracellular matrix and play a role in various physiological processes, including tissue remodeling and inflammation.\n4. Osteopontin (OPN): This isoform is a secreted protein that plays a role in the regulation of cellular responses to inflammation and tissue repair.\n5. Protein disulfide isomerase (PDI): This isoform is involved in the folding and stability of proteins, particularly those that contain disulfide bonds.\n6. Glutathione S-transferase (GST): This isoform is involved in the detoxification of harmful substances in the body, such as drugs and environmental toxins, by conjugating them with glutathione.\n7. Carbonic anhydrase (CA): This isoform is involved in the regulation of pH levels in the body, particularly in the brain and kidneys.\n8. Phospholipase A2 (PLA2): This isoform is involved in the breakdown of phospholipids in the body, which can lead to the production of inflammatory mediators.\n9. 5-Lipoxygenase (5-LO): This isoform is involved in the production of leukotrienes, which are pro-inflammatory mediators that play a role in various inflammatory responses.\n10. Fibrinogen-like protein 1 (FGL1): This is",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Empagliflozin was FDA approved in 2014. It was approved by the U.S. Food and Drug Administration (FDA) on June 28, 2014, for the treatment of type 2 diabetes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved in 2014.\n2. The U.S. Food and Drug Administration approved empagliflozin on June 28, 2014.\n3. Empagliflozin was approved for the treatment of type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved in 2014.",
      "The U.S. Food and Drug Administration approved empagliflozin on June 28, 2014.",
      "Empagliflozin was approved for the treatment of type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The U.S. Food and Drug Administration approved empagliflozin on August 1, 2014.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Loss of the protein Lon1 in the plant Arabidopsis thaliana has been shown to have several phenotypic effects, including:\n1. Increased sensitivity to oxidative stress: Lon1 plays a role in protecting against oxidative damage by scavenging reactive oxygen species (ROS). Mutants lacking Lon1 are more sensitive to oxidative stress, as evidenced by increased leaf chlorosis and reduced seedling growth.\n2. Altered cell wall structure and function: Lon1 is involved in the biosynthesis of cell wall components, such as cellulose and hemicellulose. Mutants lacking Lon1 have altered cell wall structure and function, leading to changes in plant growth and development.\n3. Impaired root development: Lon1 is expressed in the root meristem and plays a role in regulating root growth and differentiation. Mutants lacking Lon1 have reduced root length and altered root architecture.\n4. Delayed flowering time: Lon1 regulates floral transition in Arabidopsis, and mutants lacking Lon1 have a delayed flowering time.\n5. Reduced seed production: Lon1 is involved in the regulation of seed size and number. Mutants lacking Lon1 have reduced seed production and altered seed size.\n6. Changes in hormone biosynthesis and signaling: Lon1 regulates the biosynthesis of plant hormones, such as auxin and ethylene. Mutants lacking Lon1 have altered hormone levels and signaling, leading to changes in plant growth and development.\n7. Altered defense responses: Lon1 is involved in the regulation of defense responses to pathogens and abiotic stressors. Mutants lacking Lon1 have reduced defense responses and are more susceptible to pathogens.\n8. Changes in transcriptional regulation: Lon1 regulates the expression of a number of genes involved in various cellular processes. Mutants lacking Lon1 have altered gene expression profiles, leading to changes in plant growth and development.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutants of Arabidopsis thaliana lacking Lon1 are more sensitive to oxidative stress, causing increased leaf chlorosis and reduced seedling growth.\n2. Lon1 protein is involved in the biosynthesis of cell wall components like cellulose and hemicellulose, and its absence leads to altered cell wall structure and function in Arabidopsis thaliana.\n3. Impaired root development, including reduced root length and altered root architecture, is observed in Lon1-deficient Arabidopsis thaliana mutants.\n4. Arabidopsis thaliana mutants lacking Lon1 protein experience delayed flowering time.\n5. Loss of Lon1 protein in Arabidopsis thaliana results in reduced seed production and alterations in seed size.",
    "llama-2-7b-chat-hf_fact": [
      "Mutants of Arabidopsis thaliana lacking Lon1 are more sensitive to oxidative stress, causing increased leaf chlorosis and reduced seedling growth.",
      "Lon1 protein is involved in the biosynthesis of cell wall components like cellulose and hemicellulose, and its absence leads to altered cell wall structure and function in Arabidopsis thaliana.",
      "Impaired root development, including reduced root length and altered root architecture, is observed in Lon1-deficient Arabidopsis thaliana mutants.",
      "Arabidopsis thaliana mutants lacking Lon1 protein experience delayed flowering time.",
      "Loss of Lon1 protein in Arabidopsis thaliana results in reduced seed production and alterations in seed size."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Lon1 protein is associated with mitochondrial proteolysis and not directly involved in the biosynthesis of cell wall components like cellulose and hemicellulose. Its absence does not lead to altered cell wall structure and function due to its role in the biosynthesis process but may have indirect effects on various cellular processes.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe Lon1 protein plays a role in protein degradation within the mitochondria, impacting various aspects of plant physiology and development. Precise effects on leaf chlorosis, seedling growth, root development, flowering time, seed production, and seed size would require specific experimental evidence from scientific research. If such evidence is not given in the context provided, the statements would remain unknown unless the specific roles of Lon1 have been characterized in the literature regarding these phenotypic outcomes.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Yes, a linker histone called H3.3 exists in the yeast genome. H3.3 is a variant of the histone H3 protein that is specifically enriched at the centromeres and telomeres of yeast chromosomes, where it plays a role in the maintenance of chromosome stability and segregation during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. A linker histone called H3.3 exists in the yeast genome.\n2. H3.3 is a variant of the histone H3 protein.\n3. H3.3 is specifically enriched at the centromeres and telomeres of yeast chromosomes.\n4. H3.3 plays a role in the maintenance of chromosome stability.\n5. H3.3 plays a role in segregation during cell division in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "A linker histone called H3.3 exists in the yeast genome.",
      "H3.3 is a variant of the histone H3 protein.",
      "H3.3 is specifically enriched at the centromeres and telomeres of yeast chromosomes.",
      "H3.3 plays a role in the maintenance of chromosome stability.",
      "H3.3 plays a role in segregation during cell division in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The linker histone in yeast is not called H3.3; instead, H3.3 is a variant of the core histone H3 found in higher eukaryotes, not yeast.\n2. TRUE\n3. FALSE [correction]: In higher eukaryotes, H3.3 is often enriched at active genes and regulatory elements, rather than centromeres and telomeres; in yeast, the centromeric and telomeric regions are associated with specialized histone variants, not specifically H3.3.\n4. TRUE – While the statement about H3.3 is generally true for higher eukaryotes, it may not apply to yeast. However, the role in maintaining chromosome stability is a known function of histone H3 variants in general.\n5. UNKNOWN – The specific role of H3.3 in yeast cell division is not clearly defined, especially since H3.3 is typically associated with higher eukaryotes. Histones do play a role in chromosome segregation, but attributing this specifically to H3.3 in yeast is not supported without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is some evidence to suggest that tomato juice may help lower cholesterol levels.\nOne study published in the Journal of Nutrition found that drinking 8 ounces of tomato juice daily for 12 weeks significantly reduced total cholesterol and LDL (bad) cholesterol levels in healthy adults. Another study published in the European Journal of Clinical Nutrition found that drinking 100 mL of tomato juice daily for 12 weeks reduced LDL cholesterol levels by 10% in patients with mild hypercholesterolemia.\nIt is thought that the lycopene and other antioxidants in tomato juice may help reduce cholesterol levels by inhibiting the absorption of dietary cholesterol in the gut, increasing the excretion of bile, and reducing the activity of enzymes involved in cholesterol synthesis.\nHowever, it's important to note that these studies were small and more research is needed to confirm these findings and establish the optimal dosage and duration of tomato juice consumption for cholesterol lowering effects. Additionally, tomato juice is just one part of a healthy diet and lifestyle that can help manage cholesterol levels, and it should not be relied upon as the sole treatment for high cholesterol.",
    "llama-2-7b-chat-hf_fact_raw": "1. A study in the Journal of Nutrition reported that consuming 8 ounces of tomato juice daily for 12 weeks significantly reduced total cholesterol and LDL cholesterol levels in healthy adults.\n2. Another study from the European Journal of Clinical Nutrition observed a 10% reduction in LDL cholesterol levels in patients with mild hypercholesterolemia after drinking 100 mL of tomato juice daily for 12 weeks.\n3. The potential cholesterol-lowering effects of tomato juice are thought to be due to the presence of lycopene and other antioxidants.\n4. Lycopene and these antioxidants may reduce cholesterol levels by inhibiting the absorption of dietary cholesterol in the gut, increasing the excretion of bile, and reducing the activity of enzymes involved in cholesterol synthesis.\n5. The existing research on tomato juice's effect on cholesterol is based on small-scale studies, indicating a need for more broad research to confirm these results and determine proper dosages and consumption durations.",
    "llama-2-7b-chat-hf_fact": [
      "A study in the Journal of Nutrition reported that consuming 8 ounces of tomato juice daily for 12 weeks significantly reduced total cholesterol and LDL cholesterol levels in healthy adults.",
      "Another study from the European Journal of Clinical Nutrition observed a 10% reduction in LDL cholesterol levels in patients with mild hypercholesterolemia after drinking 100 mL of tomato juice daily for 12 weeks.",
      "The potential cholesterol-lowering effects of tomato juice are thought to be due to the presence of lycopene and other antioxidants.",
      "Lycopene and these antioxidants may reduce cholesterol levels by inhibiting the absorption of dietary cholesterol in the gut, increasing the excretion of bile, and reducing the activity of enzymes involved in cholesterol synthesis.",
      "The existing research on tomato juice's effect on cholesterol is based on small-scale studies, indicating a need for more broad research to confirm these results and determine proper dosages and consumption durations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE\n\nSince statements 1 and 2 mention specific research findings, without access to that research or further information confirming the outcomes of the studies mentioned, I cannot verify the accuracy of their claims. However, statements 3, 4, and 5 are generally true regarding the current understanding of lycopene, antioxidants, and the state of research in nutritional science.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Hsp70 and Hsp110 are protein chaperones that play a crucial role in regulating mRNA stability by modulating the translation and degradation of mRNAs.\nHsp70:\n* Hsp70 binds to the 3' untranslated region (UTR) of target mRNAs and protects them from degradation by the 5' to 3' exonuclease activity of the RNA-induced silencing complex (RISC).\n* Hsp70 also promotes the translation of mRNAs by blocking the activity of the RNA-binding protein, KHDRBS1, which is involved in the degradation of mRNAs.\n* Overexpression of Hsp70 has been shown to increase mRNA stability by reducing the degradation of mRNAs, leading to increased protein expression.\nHsp110:\n* Hsp110 is a molecular chaperone that specifically binds to the 3' UTR of mRNAs and protects them from degradation by the RISC complex.\n* Hsp110 also promotes the translation of mRNAs by blocking the activity of the RNA-binding protein, KHDRBS1, which is involved in the degradation of mRNAs.\n* Overexpression of Hsp110 has been shown to increase mRNA stability by reducing the degradation of mRNAs, leading to increased protein expression.\nIn summary, both Hsp70 and Hsp110 play a crucial role in regulating mRNA stability by protecting mRNAs from degradation and promoting their translation, leading to increased protein expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 binds to the 3' untranslated region (UTR) of target mRNAs and protects them from degradation by RNA-induced silencing complex (RISC) activity.\n2. Hsp70 promotes the translation of mRNAs by blocking the activity of the RNA-binding protein KHDRBS1.\n3. Overexpression of Hsp70 increases mRNA stability, leading to increased protein expression.\n4. Hsp110 specifically binds to the 3' UTR of mRNAs and protects them from degradation by the RISC complex.\n5. Overexpression of Hsp110 increases mRNA stability and leads to increased protein expression.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 binds to the 3' untranslated region (UTR) of target mRNAs and protects them from degradation by RNA-induced silencing complex (RISC) activity.",
      "Hsp70 promotes the translation of mRNAs by blocking the activity of the RNA-binding protein KHDRBS1.",
      "Overexpression of Hsp70 increases mRNA stability, leading to increased protein expression.",
      "Hsp110 specifically binds to the 3' UTR of mRNAs and protects them from degradation by the RISC complex.",
      "Overexpression of Hsp110 increases mRNA stability and leads to increased protein expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The specific binding of Hsp70 to the 3' UTR of mRNAs and its interaction with the RISC complex is not a well-known function of Hsp70, and could be dependent on the context of specific studies. However, generally Hsp70 is known for its chaperone activity in protein folding, not directly for mRNA stability.\n   \n2. UNKNOWN: It is not a widely recognized fact that Hsp70 promotes translation by blocking the activity of KHDRBS1, also known as Sam68. This statement may pertain to specific research findings but is not a broadly established function of Hsp70. Without additional context from the passage, the truth of this statement cannot be established.\n\n3. TRUE: It is known that Hsp70 and other heat shock proteins can increase mRNA stability and this can lead to increased protein expression due to their role in protecting proteins and possibly nucleic acids under stress conditions.\n\n4. UNKNOWN: Hsp110, a member of the Hsp70 family, is known to have chaperone activity and could potentially help with stabilizing proteins to prevent aggregation. However, without more context, it is unclear whether Hsp110 specifically binds to the 3' UTR of mRNAs to protect them from RISC-mediated degradation. This is a specific claim that would require reference to a study or research making this assertion.\n\n5. TRUE: Given that Hsp110 is a chaperone, its overexpression can promote protein stability and folding, which could indirectly increase mRNA stability. Increased mRNA stability can lead to increased protein expression, assuming the mRNA is being translated more efficiently as a result. However, the statement does not specify that this role is due to direct interaction with the 3' UTR or the RISC complex, so it maintains a level of truth in the general function of chaperones like Hsp110.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Deiodinases are enzymes that play a crucial role in regulating thyroid hormone metabolism. In skeletal muscle, there are two types of deiodinases present:\n1. Deiodinase type 1 (D1): D1 is the primary deiodinase isoform in skeletal muscle and is responsible for converting T4 to T3. T3 is the active form of thyroid hormone that plays a key role in regulating muscle contraction and metabolism.\n2. Deiodinase type 2 (D2): D2 is less abundant in skeletal muscle compared to D1, but it also plays a role in converting T4 to T3.\nBoth D1 and D2 deiodinases are essential for maintaining proper thyroid hormone levels in skeletal muscle, which is critical for muscle function and metabolism.",
    "llama-2-7b-chat-hf_fact_raw": "1. Deiodinase type 1 (D1) is present in skeletal muscle and converts T4 to T3.\n2. Deiodinase type 2 (D2) is also present in skeletal muscle and participates in the conversion of T4 to T3.\n3. D1 is the primary deiodinase isoform in skeletal muscle.\n4. D2 is less abundant in skeletal muscle compared to D1.\n5. Both D1 and D2 deiodinases in skeletal muscle are essential for maintaining proper thyroid hormone levels.",
    "llama-2-7b-chat-hf_fact": [
      "Deiodinase type 1 (D1) is present in skeletal muscle and converts T4 to T3.",
      "Deiodinase type 2 (D2) is also present in skeletal muscle and participates in the conversion of T4 to T3.",
      "D1 is the primary deiodinase isoform in skeletal muscle.",
      "D2 is less abundant in skeletal muscle compared to D1.",
      "Both D1 and D2 deiodinases in skeletal muscle are essential for maintaining proper thyroid hormone levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Deiodinase type 1 (D1) is not present in skeletal muscle; it is primarily present in the liver, kidneys, and thyroid.\n2. TRUE\n3. FALSE [correction]: Deiodinase type 2 (D2) is the primary deiodinase isoform in skeletal muscle, not D1.\n4. FALSE [correction]: D2 is more abundant in skeletal muscle compared to D1, which is not expressed in skeletal muscle.\n5. FALSE [correction]: Since D1 is not present in skeletal muscle, it is not essential for maintaining proper thyroid hormone levels in that tissue; D2 plays a more significant role in skeletal muscle.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Inflammatory caspase proteins are a group of proteins that play a role in the regulation of inflammation. Here are some examples of inflammatory caspase proteins:\n1. Caspase-1: Also known as interleukin-1β (IL-1β) converting enzyme (ICE), caspase-1 is a key regulator of inflammation and plays a role in the processing and activation of pro-inflammatory cytokines such as IL-1β and tumor necrosis factor-α (TNF-α).\n2. Caspase-3: Also known as caspase-8, this enzyme is involved in the regulation of apoptosis (programmed cell death) and inflammation. It plays a role in the activation of pro-inflammatory cytokines such as IL-1β and TNF-α.\n3. Caspase-7: This enzyme is involved in the regulation of inflammation and immune responses, and plays a role in the activation of pro-inflammatory cytokines such as IL-1β and TNF-α.\n4. Caspase-9: Also known as caspase-3-like protease, this enzyme is involved in the regulation of apoptosis and inflammation. It plays a role in the activation of pro-inflammatory cytokines such as IL-1β and TNF-α.\n5. Caspase-12: Also known as inflammatory caspase-12 (ICasp12), this enzyme is involved in the regulation of inflammation and immune responses. It plays a role in the activation of pro-inflammatory cytokines such as IL-1β and TNF-α.\n6. Caspase-13: Also known as cytokine-induced ICE-like protease (CYCLE), this enzyme is involved in the regulation of inflammation and immune responses. It plays a role in the activation of pro-inflammatory cytokines such as IL-1β and TNF-α.\n7. Caspase-14: Also known as interleukin-1β converting enzyme (",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is also known as interleukin-1β converting enzyme and plays a role in the processing and activation of pro-inflammatory cytokines such as IL-1β and TNF-α.\n2. Caspase-3, which is also referred to as caspase-8, is involved in the regulation of apoptosis and inflammation.\n3. Caspase-7 is an enzyme that regulates inflammation and immune responses, including the activation of pro-inflammatory cytokines IL-1β and TNF-α.\n4. Caspase-9, also known as caspase-3-like protease, is involved in the regulation of apoptosis and inflammation.\n5. Caspase-12, referred to as inflammatory caspase-12 (ICasp12), is associated with the regulation of inflammation and immune responses.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is also known as interleukin-1β converting enzyme and plays a role in the processing and activation of pro-inflammatory cytokines such as IL-1β and TNF-α.",
      "Caspase-3, which is also referred to as caspase-8, is involved in the regulation of apoptosis and inflammation.",
      "Caspase-7 is an enzyme that regulates inflammation and immune responses, including the activation of pro-inflammatory cytokines IL-1β and TNF-α.",
      "Caspase-9, also known as caspase-3-like protease, is involved in the regulation of apoptosis and inflammation.",
      "Caspase-12, referred to as inflammatory caspase-12 (ICasp12), is associated with the regulation of inflammation and immune responses."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Caspase-3 is involved in the regulation of apoptosis but is not also referred to as caspase-8. Caspase-8 is a separate enzyme that is also involved in the apoptosis process.\n3. FALSE [correction]: Caspase-7 is an enzyme that is primarily involved in the execution phase of apoptosis and is not directly involved in the activation of pro-inflammatory cytokines IL-1β and TNF-α.\n4. FALSE [correction]: Caspase-9 is involved in the regulation of apoptosis as an initiator caspase in the intrinsic pathway, but it is not known as caspase-3-like protease. Caspase-3 is a separate effector caspase in the apoptosis pathway.\n5. FALSE [correction]: Caspase-12 is involved in the regulation of inflammation and immune responses, but it is typically known for its role in modulating the inflammatory response to endoplasmic reticulum stress rather than being referred to as inflammatory caspase-12 (ICasp12). ICasp12 is not a standard nomenclature for caspase-12.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a link between Aurora B kinase and the polycomb protein Ring1B. Ring1B is a member of the polycomb repressive complex 2 (PRC2) and is involved in the regulation of gene expression, particularly during cell division. Aurora B kinase, on the other hand, is a serine/threonine kinase that plays a critical role in the proper separation of chromosomes during mitosis and meiosis.\nStudies have shown that Ring1B and Aurora B kinase interact and are involved in the regulation of each other's functions. For example, Ring1B has been shown to phosphorylate and activate Aurora B kinase, which is necessary for proper chromosome separation during cell division. Additionally, Aurora B kinase has been shown to regulate the localization and activity of Ring1B, particularly during meiosis.\nIn summary, there is a direct link between Aurora B kinase and Ring1B, and they work together to regulate various cellular processes, including chromosome separation and gene expression, during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ring1B is a member of the polycomb repressive complex 2 (PRC2).\n2. Ring1B is involved in the regulation of gene expression, particularly during cell division.\n3. Aurora B kinase is a serine/threonine kinase that plays a critical role in the proper separation of chromosomes during mitosis and meiosis.\n4. Ring1B can phosphorylate and activate Aurora B kinase.\n5. Aurora B kinase is found to regulate the localization and activity of Ring1B, especially during meiosis.",
    "llama-2-7b-chat-hf_fact": [
      "Ring1B is a member of the polycomb repressive complex 2 (PRC2).",
      "Ring1B is involved in the regulation of gene expression, particularly during cell division.",
      "Aurora B kinase is a serine/threonine kinase that plays a critical role in the proper separation of chromosomes during mitosis and meiosis.",
      "Ring1B can phosphorylate and activate Aurora B kinase.",
      "Aurora B kinase is found to regulate the localization and activity of Ring1B, especially during meiosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Ring1B does not phosphorylate and activate Aurora B kinase; rather, it is itself a ubiquitin ligase that adds ubiquitin tags to histones as part of its role in gene regulation. Aurora B kinase is the enzyme that phosphorylates various substrates during cell division.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are short sequences that are not present in the consensus splice site sequences but are still recognized by the splicing machinery. Here are some of the most frequent non-canonical sequence motifs found in vertebrates:\nDonor splice sites:\n1. GU-rich sequences: Non-canonical donor splice sites often contain GU-rich sequences, which are rich in guanine and uridine nucleotides. These sequences can be recognized by the splicing machinery and can lead to the inclusion of intron sequences in the final mRNA.\n2. AU-rich sequences: Some non-canonical donor splice sites contain AU-rich sequences, which are rich in adenine and uridine nucleotides. These sequences can also be recognized by the splicing machinery and can lead to the inclusion of intron sequences.\n3. GT-rich sequences: Some non-canonical donor splice sites contain GT-rich sequences, which are rich in guanine and thymine nucleotides. These sequences can be recognized by the splicing machinery and can lead to the inclusion of intron sequences.\nAcceptor splice sites:\n1. AG/GC-rich sequences: Non-canonical acceptor splice sites often contain AG/GC-rich sequences, which are rich in adenine and guanine or cytosine and guanine nucleotides. These sequences can be recognized by the splicing machinery and can lead to the inclusion of intron sequences in the final mRNA.\n2. UG-rich sequences: Some non-canonical acceptor splice sites contain UG-rich sequences, which are rich in uridine and guanine nucleotides. These sequences can also be recognized by the splicing machinery and can lead to the inclusion of intron sequences.\n3. AU-rich sequences: Some non-canonical acceptor splice sites contain AU-rich sequences, which are rich in adenine and uridine nucleotides. These sequences can also be recognized by the splicing machinery and can lead to the inclusion of intron sequences.\nIt's worth",
    "llama-2-7b-chat-hf_fact_raw": "1. Non-canonical donor splice sites in vertebrates often contain GU-rich sequences.\n2. Some non-canonical donor splice sites in vertebrates have AU-rich sequences.\n3. GT-rich sequences may also be found at non-canonical donor splice sites in vertebrates.\n4. Non-canonical acceptor splice sites in vertebrates can contain AG/GC-rich sequences.\n5. UG-rich and AU-rich sequences can be present at non-canonical acceptor splice sites in vertebrates.",
    "llama-2-7b-chat-hf_fact": [
      "Non-canonical donor splice sites in vertebrates often contain GU-rich sequences.",
      "Some non-canonical donor splice sites in vertebrates have AU-rich sequences.",
      "GT-rich sequences may also be found at non-canonical donor splice sites in vertebrates.",
      "Non-canonical acceptor splice sites in vertebrates can contain AG/GC-rich sequences.",
      "UG-rich and AU-rich sequences can be present at non-canonical acceptor splice sites in vertebrates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe reason for the UNKNOWN responses for statements 2 through 5 is that while it is known that canonical donor splice sites contain GT and canonical acceptor splice sites contain AG, variations can occur which may include GU-, AU-, or GC-rich sequences. However, without specific references or more detailed information, it's difficult to confirm the accuracy of these particular generalizations about non-canonical splice sites. Non-canonical splice sites can indeed deviate from the typical GT/AG rule, but the exact composition can vary widely.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "The activation of mTOR (mechanistic target of rapamycin) signaling pathway results in the acetylation of S6K1 (serine/threonine kinase 1).",
    "llama-2-7b-chat-hf_fact_raw": "1. The acetylation of S6K1 is a result of the activation of the mTOR signaling pathway.",
    "llama-2-7b-chat-hf_fact": [
      "The acetylation of S6K1 is a result of the activation of the mTOR signaling pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nReason: The statement about the acetylation of S6K1 as a result of the activation of the mTOR signaling pathway is very specific and would require expert knowledge in biochemistry or molecular biology, as well as specific scientific data or literature to confirm or refute. Without access to relevant and up-to-date scientific research or data on this topic, it is not possible to determine the accuracy of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that is caused by mutations in the CACNA1A gene. The CACNA1A gene encodes a subunit of the calcium channel alpha-1A subunit, which is involved in the regulation of neuronal excitability and synaptic transmission. Mutations in the CACNA1A gene lead to a loss of function of the calcium channel, resulting in an imbalance in the excitation and inhibition of neurons, leading to the characteristic episodes of ataxia, seizures, and other neurological symptoms associated with EA6.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 is caused by mutations in the CACNA1A gene.\n2. The CACNA1A gene encodes a subunit of the calcium channel alpha-1A subunit.\n3. The calcium channel alpha-1A subunit is involved in the regulation of neuronal excitability and synaptic transmission.\n4. Mutations in the CACNA1A gene can lead to a loss of function of the calcium channel.\n5. The loss of function in the calcium channel can result in an imbalance in the excitation and inhibition of neurons.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 is caused by mutations in the CACNA1A gene.",
      "The CACNA1A gene encodes a subunit of the calcium channel alpha-1A subunit.",
      "The calcium channel alpha-1A subunit is involved in the regulation of neuronal excitability and synaptic transmission.",
      "Mutations in the CACNA1A gene can lead to a loss of function of the calcium channel.",
      "The loss of function in the calcium channel can result in an imbalance in the excitation and inhibition of neurons."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that modify chromatin structure by adding methyl groups to histone proteins, and they play important roles in regulating chromatin dynamics and gene expression in both prokaryotes and eukaryotes.\nIn animals, chromomethylases are involved in various cellular processes, including gene expression, DNA repair, and cell fate determination. For example, the enzyme G9a (also known as KMT1A) is a histone methyltransferase that is known to be involved in the regulation of gene expression, cell fate determination, and DNA repair in animals. Similarly, the enzyme SUV39H1 is a histone methyltransferase that is involved in the regulation of gene expression and chromatin structure in animals.\nIn addition, chromomethylases have been implicated in a variety of animal diseases, including cancer and neurological disorders. For example, altered expression of chromomethylases has been observed in various types of cancer, and it is thought to play a role in the development and progression of cancer.\nOverall, chromomethylases are an important class of enzymes that play a central role in regulating chromatin dynamics and gene expression in animal genomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are enzymes that modify chromatin structure by adding methyl groups to histone proteins.\n2. Chromomethylases are found in both prokaryotes and eukaryotes.\n3. The enzyme G9a, also known as KMT1A, is involved in regulating gene expression, cell fate determination, and DNA repair in animals.\n4. The enzyme SUV39H1 is involved in the regulation of gene expression and chromatin structure in animals.\n5. Altered expression of chromomethylases has been observed in various types of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are enzymes that modify chromatin structure by adding methyl groups to histone proteins.",
      "Chromomethylases are found in both prokaryotes and eukaryotes.",
      "The enzyme G9a, also known as KMT1A, is involved in regulating gene expression, cell fate determination, and DNA repair in animals.",
      "The enzyme SUV39H1 is involved in the regulation of gene expression and chromatin structure in animals.",
      "Altered expression of chromomethylases has been observed in various types of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromomethylases are enzymes that modify DNA by adding methyl groups to cytosine residues, not histone proteins.\n2. FALSE [correction]: Chromomethylases have been primarily studied in plants, and while similar DNA methylation occurs in prokaryotes and eukaryotes, the term 'chromomethylase' is typically specific to certain DNA methyltransferases in plants.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Here are some popular packages in R/Bioconductor for transcription factor binding site (TFBS) analysis:\n1. ChIPseek: This package uses a Bayesian approach to predict TFBSs in chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq) data. It can also identify potential TFs and their binding motifs.\n2. HISAT2: This package is a part of the HISAT2 ChIP-seq pipeline, which can perform TFBS prediction, as well as other downstream analyses such as peak calling and motif analysis.\n3. DeepBind: This package uses a deep learning approach to predict TFBSs in ChIP-seq data. It can also predict the binding affinity and specificity of TFs.\n4. Prognosticate: This package uses a Bayesian approach to predict TFBSs in ChIP-seq data and also predicts the functional consequences of TF binding.\n5. TFBS-Pro: This package uses a machine learning approach to predict TFBSs in ChIP-seq data. It can also predict the binding affinity and specificity of TFs.\n6. ChromHMM: This package uses a hidden Markov model (HMM) to predict TFBSs in ChIP-seq data. It can also predict the binding affinity and specificity of TFs.\n7. CISTrome: This package uses a Bayesian approach to predict TFBSs in ChIP-seq data and also predicts the functional consequences of TF binding.\n8. PeakSeq: This package uses a Bayesian approach to predict TFBSs in ChIP-seq data and also predicts the binding affinity and specificity of TFs.\n9. TFBS-predictor: This package uses a machine learning approach to predict TFBSs in ChIP-seq data.\n10. TFSEARCH: This package uses a combination of machine learning and statistical methods to predict TFBSs in ChIP-seq data.\nPlease note that this is not an exhaustive list, and there are many other packages available in R/Bioconductor for TFBS analysis. The choice of package will depend on the specific requirements of the analysis and the research question being addressed.",
    "llama-2-7b-chat-hf_fact_raw": "1. ChIPseek is a package in R/Bioconductor that predicts transcription factor binding sites using a Bayesian approach.\n2. HISAT2 is part of the HISAT2 ChIP-seq pipeline in R/Bioconductor for transcription factor binding site prediction.\n3. DeepBind is a package in R/Bioconductor that uses deep learning to predict transcription factor binding sites.\n4. ChromHMM is an R/Bioconductor package that uses a hidden Markov model to predict transcription factor binding sites.\n5. CISTrome is an R/Bioconductor package that predicts transcription factor binding sites using a Bayesian approach.",
    "llama-2-7b-chat-hf_fact": [
      "ChIPseek is a package in R/Bioconductor that predicts transcription factor binding sites using a Bayesian approach.",
      "HISAT2 is part of the HISAT2 ChIP-seq pipeline in R/Bioconductor for transcription factor binding site prediction.",
      "DeepBind is a package in R/Bioconductor that uses deep learning to predict transcription factor binding sites.",
      "ChromHMM is an R/Bioconductor package that uses a hidden Markov model to predict transcription factor binding sites.",
      "CISTrome is an R/Bioconductor package that predicts transcription factor binding sites using a Bayesian approach."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ChIPseeker is the package in R/Bioconductor that annotates ChIP-seq data and predicts transcription factor binding sites, but it doesn't use a Bayesian approach for the prediction.\n2. FALSE [correction]: HISAT2 is an alignment program for mapping next-generation sequencing reads to the genome, not specifically a ChIP-seq pipeline nor is it primarily for the prediction of transcription factor binding sites in R/Bioconductor.\n3. FALSE [correction]: DeepBind is a tool that uses deep learning to predict DNA and RNA binding sites for transcription factors, but it is not a package in R/Bioconductor; it's a standalone tool.\n4. FALSE [correction]: ChromHMM is a tool that uses a hidden Markov model to characterize the epigenomic landscape of the cells, not specifically to predict transcription factor binding sites, and it is not an R/Bioconductor package; it's a standalone Java tool.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Here are some clinical trials related to the prevention of sarcopenia:\n1. \"Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2020) - This clinical trial aimed to evaluate the effectiveness of exercise and nutrition interventions in preventing sarcopenia in older adults.\n2. \"Effects of Resistance Training on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2019) - This clinical trial examined the effects of resistance training on sarcopenia in older adults.\n3. \"Nutritional Interventions to Prevent or Treat Sarcopenia: A Systematic Review\" (2019) - This clinical trial reviewed the effectiveness of various nutritional interventions in preventing or treating sarcopenia.\n4. \"Effects of Omega-3 Fatty Acid Supplementation on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" (2019) - This clinical trial investigated the effects of omega-3 fatty acid supplementation on sarcopenia in older adults.\n5. \"The Effects of Vitamin D and Omega-3 Fatty Acid Supplementation on Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2018) - This clinical trial evaluated the effects of vitamin D and omega-3 fatty acid supplementation on sarcopenia in older adults.\n6. \"Resistance Training and Nutritional Interventions to Prevent Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2018) - This clinical trial examined the effects of resistance training and nutritional interventions on sarcopenia in older adults.\n7. \"The Effects of Tai Chi Exercise on Sarcopenia in Older Adults: A Randomized Controlled Trial\" (2018) - This clinical trial investigated the effects of tai chi exercise on sarcopenia in older adult",
    "llama-2-7b-chat-hf_fact_raw": "1. A clinical trial titled \"Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" was conducted in 2020.\n2. The trial \"Effects of Resistance Training on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" took place in 2019 and focused on resistance training.\n3. A clinical trial named \"Nutritional Interventions to Prevent or Treat Sarcopenia: A Systematic Review\" was conducted in 2019.\n4. The trial \"Effects of Omega-3 Fatty Acid Supplementation on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" was undertaken in 2019 to study the impact of omega-3 fatty acids.\n5. In 2018, a clinical trial titled \"The Effects of Vitamin D and Omega-3 Fatty Acid Supplementation on Sarcopenia in Older Adults: A Randomized Controlled Trial\" evaluated vitamin D and omega-3 fatty acid supplementation effects.",
    "llama-2-7b-chat-hf_fact": [
      "A clinical trial titled \"Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" was conducted in 2020.",
      "The trial \"Effects of Resistance Training on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" took place in 2019 and focused on resistance training.",
      "A clinical trial named \"Nutritional Interventions to Prevent or Treat Sarcopenia: A Systematic Review\" was conducted in 2019.",
      "The trial \"Effects of Omega-3 Fatty Acid Supplementation on Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis\" was undertaken in 2019 to study the impact of omega-3 fatty acids.",
      "In 2018, a clinical trial titled \"The Effects of Vitamin D and Omega-3 Fatty Acid Supplementation on Sarcopenia in Older Adults: A Randomized Controlled Trial\" evaluated vitamin D and omega-3 fatty acid supplementation effects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe truth value of these statements regarding the timing, titles, and focuses of specific clinical trials cannot be determined without access to a database of clinical trials or specific publications pertaining to these studies. The details provided in the statements may be accurate or false, but without the proper sources to verify them, they remain unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins, but some of the most well-known and widely used include:\n1. The Membrane Protein Database (MPD): This database contains a collection of structurally and functionally annotated membrane protein sequences, including information on their membrane-spanning segments, transmembrane helices, and intracellular and extracellular domains.\n2. The Protein Data Bank (PDB): This database contains a large collection of 3D structures of proteins, including membrane proteins, and provides information on their molecular recognition features, such as binding sites, active sites, and binding interactions.\n3. The Membrane Protein Structural Database (MuSiC): This database contains a collection of 3D structures of membrane proteins, along with information on their membrane-spanning segments, transmembrane helices, and intracellular and extracellular domains.\n4. The INTREPID database: This database contains a collection of membrane protein structures and their associated functional data, including information on their molecular recognition features, such as binding sites, active sites, and binding interactions.\n5. The Membrane Protein Interaction Database (MPI-db): This database contains a collection of interactions between membrane proteins and other proteins, including information on the binding sites and the functional implications of these interactions.\n6. The Protein-Ligand Interaction Database (PLID): This database contains a collection of interactions between proteins and ligands, including information on the binding sites and the functional implications of these interactions.\n7. The Membrane Protein-Ligand Interaction Database (MPLI): This database contains a collection of interactions between membrane proteins and ligands, including information on the binding sites and the functional implications of these interactions.\n8. The Membrane Protein-Protein Interaction Database (MPPI): This database contains a collection of interactions between membrane proteins and other proteins, including information on the binding sites and the functional implications of these interactions.\nThese databases provide valuable information on the molecular recognition features of membrane proteins, which can be used to understand their function and to design drugs that target these proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Membrane Protein Database (MPD) contains annotated membrane protein sequences and information on their membrane-associated features.\n2. The Protein Data Bank (PDB) provides a large collection of 3D structures of proteins, including information on membrane proteins' molecular recognition features.\n3. The Membrane Protein Structural Database (MuSiC) offers 3D structures of membrane proteins and details on their membrane-spanning segments and domains.\n4. The INTREPID database includes a collection of membrane protein structures with associated functional data on molecular recognition features.\n5. The Protein-Ligand Interaction Database (PLID) contains interactions between proteins and ligands, with information on binding sites and functional implications.",
    "llama-2-7b-chat-hf_fact": [
      "The Membrane Protein Database (MPD) contains annotated membrane protein sequences and information on their membrane-associated features.",
      "The Protein Data Bank (PDB) provides a large collection of 3D structures of proteins, including information on membrane proteins' molecular recognition features.",
      "The Membrane Protein Structural Database (MuSiC) offers 3D structures of membrane proteins and details on their membrane-spanning segments and domains.",
      "The INTREPID database includes a collection of membrane protein structures with associated functional data on molecular recognition features.",
      "The Protein-Ligand Interaction Database (PLID) contains interactions between proteins and ligands, with information on binding sites and functional implications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE – The Membrane Protein Database (MPD) does contain annotated sequences of membrane proteins and information on membrane-associated features, although the current status or updates to the database might need verification as databases are often updated or replaced.\n2. TRUE – The Protein Data Bank (PDB) is known for providing a large collection of 3D structures of biological molecules, including proteins, with information on molecular features.\n3. UNKNOWN – While 'MuSiC' as an acronym could plausibly pertain to a database, without further context, it is unclear whether 'Membrane Protein Structural Database (MuSiC)' specifically exists or has the described features. The name 'MuSiC' does not immediately correspond to a widely-known database in the scientific community as of my last update, but it may exist as a lesser-known or niche database, or it might have been established after my knowledge cutoff date.\n4. UNKNOWN – Similar to statement 3, the 'INTREPID' database and its collection might exist, but without additional context or verification, the existence and features of such a database as described are not clear. 'INTREPID' is not a widely recognized database name in the scientific community based on the information available up to my knowledge cutoff date.\n5. TRUE – The Protein-Ligand Interaction Database (PLID) indeed exists to provide information on the interactions between proteins and ligands, including binding site and functional implication details, although the current status of this database and the breadth of its coverage would need to be verified.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Yes, rivaroxaban is metabolized in the kidneys. Rivaroxaban is metabolized by the liver and kidneys through the cytochrome P450 (CYP) enzyme system, with the main metabolic pathway involving the CYP3A4 enzyme. The kidneys play a significant role in the elimination of rivaroxaban, as they are responsible for excreting the drug and its metabolites in the urine. Therefore, renal impairment can affect the pharmacokinetics and pharmacodynamics of rivaroxaban, leading to changes in its efficacy and safety.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized by the liver and kidneys.\n2. The cytochrome P450 (CYP) enzyme system is involved in the metabolism of rivaroxaban.\n3. The CYP3A4 enzyme is the main pathway for rivaroxaban metabolism.\n4. The kidneys are responsible for excreting rivaroxaban and its metabolites in the urine.\n5. Renal impairment can affect the pharmacokinetics and pharmacodynamics of rivaroxaban.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized by the liver and kidneys.",
      "The cytochrome P450 (CYP) enzyme system is involved in the metabolism of rivaroxaban.",
      "The CYP3A4 enzyme is the main pathway for rivaroxaban metabolism.",
      "The kidneys are responsible for excreting rivaroxaban and its metabolites in the urine.",
      "Renal impairment can affect the pharmacokinetics and pharmacodynamics of rivaroxaban."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRalpha2 is a subtype of the retinoic acid receptor (RAR) family of nuclear receptors, which play a crucial role in regulating gene expression in the heart. Studies have shown that TRalpha2 regulates the expression of several genes involved in cardiac development, function, and disease. Some of the genes known to be regulated by TRalpha2 in the heart include:\n1. Cardiac troponin I (TNNI): TRalpha2 regulates the expression of TNNI, a key contractile protein in the heart.\n2. Brain natriuretic peptide (BNP): TRalpha2 regulates the expression of BNP, a hormone that plays a role in cardiac remodeling and failure.\n3. GATA4: TRalpha2 regulates the expression of GATA4, a transcription factor that is important for cardiac development and function.\n4. Nkx2.5: TRalpha2 regulates the expression of Nkx2.5, a transcription factor that is important for cardiac development and differentiation.\n5. Mef2c: TRalpha2 regulates the expression of Mef2c, a transcription factor that is important for cardiac hypertrophy and adaptation to stress.\n6. Atrial natriuretic peptide (ANP): TRalpha2 regulates the expression of ANP, a hormone that plays a role in cardiac remodeling and failure.\n7. Bcl-2 family members: TRalpha2 regulates the expression of Bcl-2 family members, such as Bax and Bcl-xL, which play a role in regulating apoptosis and cardiac function.\n8. Fibrinolytic genes: TRalpha2 regulates the expression of genes involved in fibrinolysis, such as tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1), which play a role in regulating cardiac remodeling and failure.\nThese genes are just a few examples of the many genes that are regulated by TRalpha2 in the heart. Dysregulation of these genes has been implicated in a variety of cardiac diseases, including heart failure, hypertension, and arrhyth",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 regulates the expression of Cardiac troponin I (TNNI) in the heart.\n2. TRalpha2 regulates the expression of Brain natriuretic peptide (BNP) in the heart.\n3. TRalpha2 regulates the expression of GATA4, which is important for cardiac development and function.\n4. TRalpha2 regulates the expression of Nkx2.5, a transcription factor important for cardiac development and differentiation.\n5. TRalpha2 regulates the expression of Mef2c, a transcription factor important for cardiac hypertrophy and adaptation to stress.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 regulates the expression of Cardiac troponin I (TNNI) in the heart.",
      "TRalpha2 regulates the expression of Brain natriuretic peptide (BNP) in the heart.",
      "TRalpha2 regulates the expression of GATA4, which is important for cardiac development and function.",
      "TRalpha2 regulates the expression of Nkx2.5, a transcription factor important for cardiac development and differentiation.",
      "TRalpha2 regulates the expression of Mef2c, a transcription factor important for cardiac hypertrophy and adaptation to stress."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe detailed regulation of gene expression in the heart by TRalpha2 (a thyroid hormone receptor isoform) is a highly specific topic that would require access to current scientific literature or specific domain knowledge to confirm. Since the statements are about precise molecular biological functions and interactions, without the specific context or reference from which these statements are drawn, it is not possible to determine the validity of these statements with certainty.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Here are some available biomedical question answering systems:\n1. PubMed: PubMed is a free database of biomedical literature maintained by the National Library of Medicine. It indexes over 29 million journal articles and other publications, and provides a question answering system that allows users to search for answers to biomedical questions.\n2. Biomedical Informatics Research Network (BIRN): BIRN is a question answering system that uses natural language processing and machine learning techniques to answer biomedical questions. It covers a wide range of topics in biomedicine and has been trained on a large corpus of biomedical literature.\n3. BioPortal: BioPortal is a question answering system developed by the National Center for Biotechnology Information (NCBI). It uses a combination of natural language processing and machine learning techniques to answer biomedical questions, and provides access to a wide range of biomedical databases and resources.\n4. Entrez: Entrez is a question answering system developed by the National Library of Medicine. It indexes a wide range of biomedical databases, including PubMed, GenBank, and Protein Data Bank, and provides a unified search interface for accessing these resources.\n5. Biomedical Information Retrieval System (BIRS): BIRS is a question answering system developed by the University of California, San Diego. It uses natural language processing and machine learning techniques to answer biomedical questions, and provides access to a wide range of biomedical databases and resources.\n6. Biomedical Question Answering System (BQAS): BQAS is a question answering system developed by the University of Texas Southwestern Medical Center. It uses natural language processing and machine learning techniques to answer biomedical questions, and provides access to a wide range of biomedical databases and resources.\n7. Biomedical Natural Language Processing (BioNLP) System: BioNLP is a question answering system developed by the University of Colorado Boulder. It uses natural language processing techniques to analyze biomedical text and extract relevant information, and can answer a wide range of biomedical questions.\n8. Biomedical Text Mining (BTM) System: BTM is a question answering system developed by the University of California, Los Angeles. It uses natural language processing and machine learning techniques to analyze biomedical text and extract relevant information, and can answer a wide range of bi",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMed is a free database of biomedical literature that provides a question answering system and indexes over 29 million journal articles and other publications.\n2. The Biomedical Informatics Research Network (BIRN) uses natural language processing and machine learning techniques to answer biomedical questions.\n3. BioPortal is a question answering system developed by the National Center for Biotechnology Information (NCBI).\n4. Entrez is a question answering system that indexes a wide range of biomedical databases and is developed by the National Library of Medicine.\n5. The Biomedical Information Retrieval System (BIRS) is developed by the University of California, San Diego and provides access to a range of biomedical databases and resources.",
    "llama-2-7b-chat-hf_fact": [
      "PubMed is a free database of biomedical literature that provides a question answering system and indexes over 29 million journal articles and other publications.",
      "The Biomedical Informatics Research Network (BIRN) uses natural language processing and machine learning techniques to answer biomedical questions.",
      "BioPortal is a question answering system developed by the National Center for Biotechnology Information (NCBI).",
      "Entrez is a question answering system that indexes a wide range of biomedical databases and is developed by the National Library of Medicine.",
      "The Biomedical Information Retrieval System (BIRS) is developed by the University of California, San Diego and provides access to a range of biomedical databases and resources."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: While PubMed is a free database of biomedical literature and does index over 29 million journal articles and other publications, it does not provide a question answering system.\n2. UNKNOWN\n3. FALSE [correction]: BioPortal is actually a repository of biomedical ontologies that provides access to their data via Web services but is not a question answering system. The National Center for Biotechnology Information (NCBI) developed PubMed, not BioPortal.\n4. FALSE [correction]: Entrez is indeed a search and retrieval system that indexes a wide range of biomedical databases. However, it is developed by the NCBI, not the National Library of Medicine (NLM). The NLM does provide PubMed as one of the databases accessible through Entrez.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The transcription factor that activates the bethanechol pathway is ABSCISIC ACID INSENSITIVE 3 (ABI3).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS\n\n(Note: The provided answer incorrectly refers to \"bethanechol pathway,\" which appears to be a mix-up as bethanechol is a drug and not linked to betalain biosynthesis. Moreover, the statement incorrectly identifies a transcription factor as ABI3, while ABI3 is actually a gene involved in seed maturation in plants and is not directly related to the transcriptional regulation of the betalain biosynthesis pathway.)",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "There are several technologies that are commonly used for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses. Here are some of the preferred technologies:\n1. TiO2-based enrichment: TiO2 is a common matrix used for phosphoprotein enrichment due to its high affinity for phosphate groups. Phosphorylated peptides are captured onto the TiO2 surface, followed by washing and elution of non-phosphorylated peptides.\n2. IMAC (Immobilized Metal Affinity Chromatography): IMAC is a widely used method for phosphoprotein enrichment, which utilizes metal ions (e.g., Ni2+) to bind phosphorylated peptides. The phosphorylated peptides are immobilized on the metal ion matrix, while non-phosphorylated peptides are washed away.\n3. Cation exchange chromatography: Cation exchange chromatography is a versatile technique that can be used for the enrichment of phosphorylated peptides based on their charge. Phosphorylated peptides are exchanged for cations, such as ammonium ions, and then separated based on their charge.\n4. Hydrophilic interaction liquid chromatography (HILIC): HILIC is a method that separates peptides based on their hydrophilicity. Phosphorylated peptides, which are more hydrophilic than non-phosphorylated peptides, are enriched using HILIC chromatography.\n5. Reversed-phase HPLC: Reversed-phase HPLC is a widely used technique for separating peptides based on their hydrophobicity. Phosphorylated peptides are enriched by binding to a hydrophobic stationary phase, while non-phosphorylated peptides are washed away.\n6. Micro-columns: Micro-columns are small columns with a small diameter, typically in the range of 10-50 μm. They are used for enriching phosphorylated peptides based on their size, which is advantageous for studying post",
    "llama-2-7b-chat-hf_fact_raw": "1. TiO2-based enrichment is used for phosphoprotein enrichment due to its high affinity for phosphate groups.\n2. Immobilized Metal Affinity Chromatography (IMAC) uses metal ions to bind phosphorylated peptides for their enrichment.\n3. Cation exchange chromatography is a technique that enriches phosphorylated peptides based on their charge.\n4. Hydrophilic interaction liquid chromatography (HILIC) separates peptides based on their hydrophilicity and enriches phosphorylated peptides.\n5. Reversed-phase High-Performance Liquid Chromatography (HPLC) separates peptides based on hydrophobicity and is used to enrich phosphorylated peptides.",
    "llama-2-7b-chat-hf_fact": [
      "TiO2-based enrichment is used for phosphoprotein enrichment due to its high affinity for phosphate groups.",
      "Immobilized Metal Affinity Chromatography (IMAC) uses metal ions to bind phosphorylated peptides for their enrichment.",
      "Cation exchange chromatography is a technique that enriches phosphorylated peptides based on their charge.",
      "Hydrophilic interaction liquid chromatography (HILIC) separates peptides based on their hydrophilicity and enriches phosphorylated peptides.",
      "Reversed-phase High-Performance Liquid Chromatography (HPLC) separates peptides based on hydrophobicity and is used to enrich phosphorylated peptides."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Reversed-phase High-Performance Liquid Chromatography (HPLC) separates peptides based on hydrophobicity, but it is not specifically used to enrich phosphorylated peptides. It is a general peptide separation method.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Palmini classification is used to rate the severity of a genetic disorder called Fabry disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Palmini classification is used to rate the severity of Fabry disease.",
    "llama-2-7b-chat-hf_fact": [
      "Palmini classification is used to rate the severity of Fabry disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Palmini classification is not used to rate the severity of Fabry disease; it is a classification system for focal cortical dysplasia. The severity of Fabry disease can be assessed using different tools and classification systems specific to the disease.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, some viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis is an inflammatory condition that affects the thyroid gland and is characterized by the sudden onset of symptoms such as fever, pain in the neck, and difficulty swallowing. While the exact cause of subacute thyroiditis is not fully understood, some studies have suggested that viral infections may play a role in its development.\nOne of the most well-known viruses associated with subacute thyroiditis is the thyroid gland-specific virus, TGV (Thyroid Gland Virus). TGV is a double-stranded RNA virus that is known to infect the thyroid gland and has been linked to the development of subacute thyroiditis in some studies.\nOther viruses that have been implicated in the etiology of subacute thyroiditis include:\n1. Herpesvirus: Herpesviruses, such as HSV (Herpes Simplex Virus) and HPV (Human Papillomavirus), have been shown to infect the thyroid gland and may contribute to the development of subacute thyroiditis.\n2. Adenovirus: Adenoviruses are known to infect the thyroid gland and have been linked to the development of subacute thyroiditis in some studies.\n3. Respiratory viruses: Respiratory viruses, such as influenza and respiratory syncytial virus (RSV), have been implicated in the development of subacute thyroiditis in some cases.\n4. Enteroviruses: Enteroviruses, such as Coxsackievirus and Enterovirus, have been linked to the development of subacute thyroiditis in some studies.\nIt is important to note that the exact role of viruses in the development of subacute thyroiditis is still being researched and debated, and more studies are needed to fully understand the relationship between viruses and this condition. However, viral infections are thought to play a role in the pathogenesis of subacute thyroiditis, and further research may lead to the development of new diagnostic and therapeutic strategies for this condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Subacute thyroiditis is an inflammatory condition of the thyroid gland with symptoms such as fever, pain in the neck, and difficulty swallowing. \n2. Some studies have suggested that viral infections may play a role in the development of subacute thyroiditis.\n3. The Thyroid Gland Virus (TGV) is a double-stranded RNA virus linked to the development of subacute thyroiditis.\n4. Herpesviruses like HSV and HPV can infect the thyroid gland and may contribute to the development of subacute thyroiditis.\n5. Adenoviruses and respiratory viruses, including influenza and respiratory syncytial virus (RSV), have been implicated in subacute thyroiditis in some cases.",
    "llama-2-7b-chat-hf_fact": [
      "Subacute thyroiditis is an inflammatory condition of the thyroid gland with symptoms such as fever, pain in the neck, and difficulty swallowing.",
      "Some studies have suggested that viral infections may play a role in the development of subacute thyroiditis.",
      "The Thyroid Gland Virus (TGV) is a double-stranded RNA virus linked to the development of subacute thyroiditis.",
      "Herpesviruses like HSV and HPV can infect the thyroid gland and may contribute to the development of subacute thyroiditis.",
      "Adenoviruses and respiratory viruses, including influenza and respiratory syncytial virus (RSV), have been implicated in subacute thyroiditis in some cases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There is no specific virus known as the \"Thyroid Gland Virus (TGV)\" linked to the development of subacute thyroiditis. Viral infections in general have been implicated as a potential cause.\n4. FALSE [correction]: Herpesviruses include herpes simplex viruses (HSV) and human papillomavirus (HPV), but HPV is not classified under the herpesviruses family. While HSV could be implicated in thyroid infections, HPV is not typically associated with the thyroid gland.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Yes, STAT3 (Signal Transducer and Activator of Transcription 3) is involved in EIF2AK2-dependent suppression of autophagy. EIF2AK2 (Eukaryotic Translation Initiation Factor 2-Associated Kinase 2) is a kinase that phosphorylates and inhibits the translation initiation factor eIF2α, leading to suppression of global protein synthesis. STAT3 is a transcription factor that is activated downstream of EIF2AK2 and plays a role in regulating autophagy. Inhibition of autophagy by EIF2AK2 has been shown to be mediated in part by the activation of STAT3, which can suppress the expression of autophagy-related genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is involved in EIF2AK2-dependent suppression of autophagy.\n2. EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2α.\n3. Phosphorylation of eIF2α by EIF2AK2 leads to suppression of global protein synthesis.\n4. STAT3 is activated downstream of EIF2AK2 and regulates autophagy.\n5. STAT3 can suppress the expression of autophagy-related genes.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is involved in EIF2AK2-dependent suppression of autophagy.",
      "EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2α.",
      "Phosphorylation of eIF2α by EIF2AK2 leads to suppression of global protein synthesis.",
      "STAT3 is activated downstream of EIF2AK2 and regulates autophagy.",
      "STAT3 can suppress the expression of autophagy-related genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The relationship between STAT3 and EIF2AK2-dependent suppression of autophagy is specific and requires verification from a reliable scientific source.\n2. TRUE: EIF2AK2, also known as PKR, is known to phosphorylate eIF2α, leading to the inhibition of the translation initiation factor.\n3. TRUE: Phosphorylation of eIF2α by EIF2AK2 indeed results in the downregulation of global protein synthesis.\n4. UNKNOWN: The claim that STAT3 is activated downstream of EIF2AK2 and regulates autophagy is a specific scientific statement that would require verification from credible scientific research or literature.\n5. TRUE: STAT3 has been reported to suppress the expression of autophagy-related genes, although it should be noted that the context and conditions under which this occurs can be complex and are a subject of ongoing research.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool for genomic analysis that is specifically designed for the analysis of chromatin structure and epigenetic marks. It is used to visualize and analyze the spatial organization of chromatin in cells, and to identify patterns and relationships between different regions of the genome.\nHere are some of the key ways in which Theatre can be used for genomic analysis:\n1. Chromatin structure visualization: Theatre can be used to visualize the three-dimensional structure of chromatin, including the locations of nucleosomes, chromatin loops, and other structural features. This can help researchers to understand how chromatin is organized in different regions of the genome and how this organization affects gene expression.\n2. Epigenetic mark analysis: Theatre can be used to visualize and analyze the distribution of epigenetic marks, such as histone modifications and DNA methylation, across the genome. This can help researchers to identify patterns and relationships between different epigenetic marks and to understand how they contribute to the regulation of gene expression.\n3. Genomic interaction analysis: Theatre can be used to visualize and analyze the interactions between different regions of the genome, including the interactions between promoters, enhancers, and other regulatory elements. This can help researchers to understand how these interactions contribute to the regulation of gene expression and to identify potential regulatory elements.\n4. Gene regulation analysis: Theatre can be used to visualize and analyze the regulation of specific genes, including the interactions between promoters, enhancers, and other regulatory elements. This can help researchers to understand how these interactions contribute to the regulation of gene expression and to identify potential regulatory elements.\n5. High-throughput sequencing data analysis: Theatre can be used to analyze high-throughput sequencing data, such as ChIP-seq and RNA-seq data, to identify patterns and relationships between different regions of the genome and to understand how they contribute to the regulation of gene expression.\nOverall, Theatre is a powerful tool for understanding the complex interactions between chromatin structure, epigenetic marks, and gene regulation, and it has a wide range of applications in the field of genomics.",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool designed for genomic analysis, specifically analyzing chromatin structure and epigenetic marks.\n2. The software can be used to visualize the three-dimensional structure of chromatin in cells.\n3. Theatre allows users to analyze the distribution of epigenetic marks, such as histone modifications and DNA methylation, across the genome.\n4. The tool facilitates genomic interaction analysis, including interactions between promoters, enhancers, and other regulatory elements.\n5. Theatre can be utilized to analyze high-throughput sequencing data, including ChIP-seq and RNA-seq data.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool designed for genomic analysis, specifically analyzing chromatin structure and epigenetic marks.",
      "The software can be used to visualize the three-dimensional structure of chromatin in cells.",
      "Theatre allows users to analyze the distribution of epigenetic marks, such as histone modifications and DNA methylation, across the genome.",
      "The tool facilitates genomic interaction analysis, including interactions between promoters, enhancers, and other regulatory elements.",
      "Theatre can be utilized to analyze high-throughput sequencing data, including ChIP-seq and RNA-seq data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Theatre is not commonly known as a software tool for genomic analysis. Instead, bioinformatics tools like HiCExplorer, 3D Genome Browser, or UCSC Genome Browser are used for analyzing chromatin structure and epigenetic marks. The name \"Theatre\" may be incorrect or fictional in this context.\n2. UNKNOWN: Without the correct identification of the software \"Theatre,\" the truth of this statement cannot be determined.\n3. UNKNOWN: The capabilities of \"Theatre\" for analyzing the distribution of epigenetic marks cannot be confirmed due to the potential incorrect identification of the software.\n4. UNKNOWN: Whether \"Theatre\" facilitates genomic interaction analysis is unclear due to the lack of information on this specific tool.\n5. UNKNOWN: The usage of \"Theatre\" to analyze high-throughput sequencing data can't be ascertained without proper identification of the software and its features.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the specific implementation and the length of the sequences. However, in general, the time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\nThe basic idea of the Smith-Waterman algorithm is to compute the similarity between two sequences by computing the similarity between their substrings. The algorithm scans the sequences one position at a time, and for each position, it computes the similarity between the two sequences based on the similarity of their substrings. The algorithm repeats this process until it reaches the end of the sequences.\nThe time complexity of this process can be broken down as follows:\n1. For each position in the shorter sequence, the algorithm needs to compare it with every position in the longer sequence, which takes O(n) time.\n2. For each position in the shorter sequence, the algorithm needs to compute the similarity between the shorter sequence and the longer sequence, which takes O(n) time.\n3. Therefore, the total time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\nIt's worth noting that this time complexity assumes that the sequences are compared one position at a time, and that the similarity between two positions is computed only once, even if the sequences are compared multiple times. In practice, the time complexity of the Smith-Waterman algorithm can be improved by using techniques such as caching the similarity values for frequently accessed positions, or using a more efficient data structure to store the similarity values.",
    "llama-2-7b-chat-hf_fact_raw": "1. The general time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\n2. The Smith-Waterman algorithm computes the similarity between two sequences by comparing their substrings.\n3. The algorithm operates by scanning sequences one position at a time and computing similarity scores.\n4. For each position in the shorter sequence, the Smith-Waterman algorithm requires a comparison with every position in the longer sequence, which takes O(n) time.\n5. Total time complexity can potentially be improved by techniques such as caching similarity values or using a more efficient data structure.",
    "llama-2-7b-chat-hf_fact": [
      "The general time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.",
      "The Smith-Waterman algorithm computes the similarity between two sequences by comparing their substrings.",
      "The algorithm operates by scanning sequences one position at a time and computing similarity scores.",
      "For each position in the shorter sequence, the Smith-Waterman algorithm requires a comparison with every position in the longer sequence, which takes O(n) time.",
      "Total time complexity can potentially be improved by techniques such as caching similarity values or using a more efficient data structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The general time complexity of the Smith-Waterman algorithm, which is used for sequence alignment, indeed is O(n^2), assuming n is the length of the shorter of the two sequences being aligned.\n\n2. TRUE: The Smith-Waterman algorithm indeed computes the similarity between two biological sequences (such as DNA, RNA, or protein sequences) by comparing their substrings and finding local alignments.\n\n3. TRUE: The algorithm operates by scanning the sequences one position at a time, computing similarity scores based on a scoring matrix that accounts for matches, mismatches, and gaps.\n\n4. FALSE [correction]: For each position in the shorter sequence, the Smith-Waterman algorithm actually requires a comparison with every position in the longer sequence for each cell in the dynamic programming matrix, which takes O(m) time for each cell, where m is the length of the longer sequence. Since this is done for every cell in an n by m matrix, the total time complexity is O(n*m). However, this statement might be misinterpreted as describing the cost for computing each cell (which is indeed O(n) if one considers the entire row computation), but the overall complexity is O(n*m) and not O(n) for each position in the shorter sequence.\n\n5. TRUE: Total time complexity can potentially be improved with various techniques that optimize the underlying computations, such as caching similarity values (memoization) or using more efficient data structures like advanced dynamic programming techniques or heuristics that focus on particular regions of the sequences.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 is a member of the Solute Carrier (SLC) family of proteins. Specifically, it is a member of the SLC16A subfamily, which is also known as the vesicular transport protein family.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the Solute Carrier (SLC) family of proteins.\n2. FLVCR1 belongs to the SLC16A subfamily.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the Solute Carrier (SLC) family of proteins.",
      "FLVCR1 belongs to the SLC16A subfamily."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: FLVCR1 is a member of the Major Facilitator Superfamily (MFS) of transporters, not the Solute Carrier (SLC) family.\n2. FALSE [correction]: Given that FLVCR1 is not part of the Solute Carrier (SLC) family, it does not belong to the SLC16A subfamily. It is part of the Major Facilitator Superfamily (MFS).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "GATA-1, a transcription factor crucial for regulating erythroid cell development, has been shown to interact with several proteins through various biochemical and functional assays. The biotinylation tagging approach has been used to identify several GATA-1 interacting partners. Here are some of the key partners identified:\n1. β-catenin: GATA-1 was shown to interact with β-catenin through its DNA-binding domain, suggesting a role for GATA-1 in regulating β-catenin function in erythroid cells.\n2. KAT2A: GATA-1 was found to interact with the histone acetyltransferase KAT2A, which is involved in regulating chromatin structure and gene expression.\n3. TFAP2A: GATA-1 was shown to interact with TFAP2A, a transcription factor that regulates erythroid cell development and differentiation.\n4. HMX1: GATA-1 was found to interact with HMX1, a homeobox transcription factor that plays a role in regulating erythroid cell development and differentiation.\n5. TFAP4: GATA-1 was shown to interact with TFAP4, a transcription factor that regulates the expression of genes involved in erythroid cell development and differentiation.\n6. RFX1: GATA-1 was found to interact with RFX1, a transcription factor that regulates the expression of genes involved in erythroid cell development and differentiation.\n7. NF-E2: GATA-1 was shown to interact with NF-E2, a transcription factor that regulates the expression of genes involved in erythroid cell development and differentiation.\n8. CBX3: GATA-1 was found to interact with CBX3, a chromodomain-containing protein that regulates the expression of genes involved in erythroid cell development and differentiation.\n9. HMGA2: GATA-1 was shown to interact with HMGA2, a non-histone chromosomal protein that regulates the expression of genes involved in erythroid cell development and differentiation.\n10. SUV39H1: GATA-1 was found to interact",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 interacts with β-catenin through its DNA-binding domain.\n2. GATA-1 interacts with the histone acetyltransferase KAT2A.\n3. GATA-1 interacts with the transcription factor TFAP2A, which is involved in erythroid cell development.\n4. GATA-1 interacts with the homeobox transcription factor HMX1.\n5. GATA-1 interacts with the transcription factor NF-E2.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 interacts with β-catenin through its DNA-binding domain.",
      "GATA-1 interacts with the histone acetyltransferase KAT2A.",
      "GATA-1 interacts with the transcription factor TFAP2A, which is involved in erythroid cell development.",
      "GATA-1 interacts with the homeobox transcription factor HMX1.",
      "GATA-1 interacts with the transcription factor NF-E2."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GATA-1 does not interact with β-catenin through its DNA-binding domain; instead, β-catenin typically interacts with members of the TCF/LEF family of transcription factors.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 (TATA-binding protein-associated factor 10) interacts with the GATA1 (GATA-binding protein 1) transcription factor to regulate the activation of gene expression, particularly in the context of erythroid cell differentiation. The interaction between TAF10 and GATA1 leads to the recruitment of RNA polymerase II and the initiation of transcription of genes involved in erythropoiesis. In summary, the outcome of TAF10 interacting with GATA1 is the activation of erythroid gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 interacts with the GATA1 transcription factor.\n2. The interaction between TAF10 and GATA1 regulates the activation of gene expression.\n3. TAF10 and GATA1 interaction is particularly important for erythroid cell differentiation.\n4. Following the interaction of TAF10 with GATA1, RNA polymerase II is recruited.\n5. The outcome of TAF10 interacting with GATA1 is the initiation of transcription of genes involved in erythropoiesis.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 interacts with the GATA1 transcription factor.",
      "The interaction between TAF10 and GATA1 regulates the activation of gene expression.",
      "TAF10 and GATA1 interaction is particularly important for erythroid cell differentiation.",
      "Following the interaction of TAF10 with GATA1, RNA polymerase II is recruited.",
      "The outcome of TAF10 interacting with GATA1 is the initiation of transcription of genes involved in erythropoiesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (DSS) available for chronic pain management. These systems are designed to help healthcare providers make informed decisions about the management of chronic pain, taking into account individual patient factors, such as medical history, lifestyle, and preferences. Some examples of DSS for chronic pain management include:\n1. Chronic Pain Management System (CPMS): This DSS is designed to help primary care physicians manage chronic pain in their patients. It provides a structured approach to assessing and managing chronic pain, including a pain severity scale, a medication management module, and a patient education module.\n2. PainAssessment.com: This DSS is an online tool that helps healthcare providers assess and manage chronic pain in their patients. It includes a pain assessment tool, a treatment planning module, and a patient education module.\n3. PainCare: This DSS is designed to help healthcare providers manage chronic pain in their patients. It includes a pain assessment tool, a treatment planning module, and a patient education module.\n4. Pain-Qol: This DSS is designed to assess and manage chronic pain in patients. It includes a pain severity scale, a quality of life assessment tool, and a treatment planning module.\n5. Chronic Pain Management Toolkit: This DSS is designed to help healthcare providers manage chronic pain in their patients. It includes a pain assessment tool, a treatment planning module, and a patient education module.\n6. Pain Management Collaborative (PMC): This DSS is designed to help healthcare providers manage chronic pain in their patients. It includes a pain assessment tool, a treatment planning module, and a patient education module.\n7. Chronic Pain Management System (CPMS): This DSS is designed to help primary care physicians manage chronic pain in their patients. It provides a structured approach to assessing and managing chronic pain, including a pain severity scale, a medication management module, and a patient education module.\n8. Pain Care Network (PCN): This DSS is designed to help healthcare providers manage chronic pain in their patients. It includes a pain assessment tool, a treatment planning module, and a patient education module.\n9. Chronic Pain Management (CP",
    "llama-2-7b-chat-hf_fact_raw": "1. Decision support systems (DSS) are available to help healthcare providers make decisions about managing chronic pain.\n2. The Chronic Pain Management System (CPMS) is a DSS that includes a pain severity scale, medication management module, and patient education module.\n3. PainAssessment.com is an online DSS that includes a pain assessment tool, treatment planning module, and patient education module.\n4. PainCare is a DSS that aids in the management of chronic pain with features such as a pain assessment tool and treatment planning module.\n5. Pain-Qol is a DSS for chronic pain that includes a pain severity scale and quality of life assessment tool.",
    "llama-2-7b-chat-hf_fact": [
      "Decision support systems (DSS) are available to help healthcare providers make decisions about managing chronic pain.",
      "The Chronic Pain Management System (CPMS) is a DSS that includes a pain severity scale, medication management module, and patient education module.",
      "PainAssessment.com is an online DSS that includes a pain assessment tool, treatment planning module, and patient education module.",
      "PainCare is a DSS that aids in the management of chronic pain with features such as a pain assessment tool and treatment planning module.",
      "Pain-Qol is a DSS for chronic pain that includes a pain severity scale and quality of life assessment tool."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN \n4. UNKNOWN\n5. UNKNOWN\n\nSince the correctness of statements 2 through 5 depends on the specific features and existence of the mentioned Decision Support Systems (DSS), without having access to current and detailed information about these systems, I cannot verify the accuracy of these statements. The names of the systems could either be accurate representations of real DSS or fabricated for the purpose of this task. Therefore, their truth value is indeterminable with the provided information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a secreted protein that localizes to the extracellular space and the Golgi apparatus. It can also be found in the cytoplasm and nucleus of cells, particularly in endothelial cells and immune cells, where it plays a role in angiogenesis and inflammation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is a secreted protein.\n2. Angiogenin localizes to the extracellular space.\n3. Angiogenin localizes to the Golgi apparatus.\n4. Angiogenin can be found in the cytoplasm of cells.\n5. Angiogenin can be found in the nucleus of cells.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is a secreted protein.",
      "Angiogenin localizes to the extracellular space.",
      "Angiogenin localizes to the Golgi apparatus.",
      "Angiogenin can be found in the cytoplasm of cells.",
      "Angiogenin can be found in the nucleus of cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Angiogenin does not primarily localize to the Golgi apparatus; it is known to be a secreted protein and is primarily found in the extracellular space, although it can also enter cells and localize to the nucleus and the cytoplasm.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine, a cardiovascular drug, inhibits the activation of kinase signaling pathways in the heart, specifically the Akt/PKB pathway, which is involved in cell survival and contractility. By inhibiting the activation of this pathway, ranolazine reduces the ability of the heart to respond to stress and promotes cardiac protection.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine is a cardiovascular drug.\n2. Ranolazine inhibits the activation of kinase signaling pathways in the heart.\n3. The Akt/PKB pathway, which is involved in cell survival and contractility, is specifically inhibited by ranolazine.\n4. Inhibition of the Akt/PKB pathway by ranolazine limits the heart's ability to respond to stress.\n5. Ranolazine promotes cardiac protection.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine is a cardiovascular drug.",
      "Ranolazine inhibits the activation of kinase signaling pathways in the heart.",
      "The Akt/PKB pathway, which is involved in cell survival and contractility, is specifically inhibited by ranolazine.",
      "Inhibition of the Akt/PKB pathway by ranolazine limits the heart's ability to respond to stress.",
      "Ranolazine promotes cardiac protection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Ranolazine primarily works by inhibiting the late sodium current (INa) in the heart muscle, thereby reducing intracellular sodium and calcium overload during ischemia. It is not primarily known for inhibiting kinase signaling pathways.\n3. FALSE [correction]: Ranolazine is not specifically known to inhibit the Akt/PKB signaling pathway, its main action is to inhibit the late phase of the inward sodium channel.\n4. UNKNOWN: Since ranolazine does not specifically inhibit the Akt/PKB pathway, the statement about its effects on the heart's response to stress in this context is difficult to determine without additional specific information.\n5. TRUE: By reducing intracellular sodium and calcium overload, ranolazine can help to reduce the metabolic consequences of ischemia, which can be considered a form of cardiac protection.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "No, the regulation of Vsr endonuclease is not entirely independent of the growth phase of bacteria. While Vsr is constitutively expressed in many bacterial species, its activity can be regulated in response to changes in the growth phase. For example, in E. coli, Vsr activity is highest during the exponential growth phase and decreases during the stationary phase. This is thought to be due to the degradation of the Vsr protein by the proteasome during the stationary phase. Additionally, the expression of the genes encoding Vsr's regulatory proteins, such as the VsrR regulatory protein, can also be regulated in response to changes in the growth phase.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is not entirely independent of the growth phase of bacteria.\n2. Vsr endonuclease is constitutively expressed in many bacterial species.\n3. In E. coli, Vsr endonuclease activity is highest during the exponential growth phase and decreases during the stationary phase.\n4. The degradation of the Vsr protein by the proteasome occurs during the stationary phase in bacteria.\n5. The genes encoding Vsr regulatory proteins can also be regulated in response to changes in the growth phase of bacteria.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is not entirely independent of the growth phase of bacteria.",
      "Vsr endonuclease is constitutively expressed in many bacterial species.",
      "In E. coli, Vsr endonuclease activity is highest during the exponential growth phase and decreases during the stationary phase.",
      "The degradation of the Vsr protein by the proteasome occurs during the stationary phase in bacteria.",
      "The genes encoding Vsr regulatory proteins can also be regulated in response to changes in the growth phase of bacteria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: Bacteria do not contain a proteasome system; instead, protein degradation is carried out by proteases. In E. coli, the ClpXP and Lon proteases are commonly responsible for degrading proteins in the stationary phase.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several computational tools available for the prediction of beta-barrel transmembrane proteins. Some of the commonly used tools include:\n1. TMHMM: This is a widely used tool for predicting the transmembrane helices in a protein. It uses a combination of sequence analysis and structural information to predict the transmembrane topology of a protein.\n2. Topo-TOPO: This tool uses a combination of sequence analysis and structural information to predict the transmembrane topology of a protein. It also predicts the orientation of the transmembrane helices and the presence of glycosylation sites.\n3. Predict-TMD: This tool uses a combination of sequence analysis and structural information to predict the transmembrane topology of a protein. It also predicts the orientation of the transmembrane helices and the presence of glycosylation sites.\n4. Bioinformatics tools such as SignalP, TMHMM, and Predict-TMD can be used to predict the presence of signal peptides in a protein.\n5. PHD-TOPO: This tool predicts the transmembrane topology of a protein based on the presence of hydrophobic regions in the protein sequence.\n6. SOSUI: This tool predicts the transmembrane topology of a protein based on the presence of hydrophobic regions in the protein sequence and the secondary structure of the protein.\n7. TOPOTOP: This tool predicts the transmembrane topology of a protein based on the presence of hydrophobic regions in the protein sequence and the secondary structure of the protein.\n8. Protter: This tool predicts the transmembrane topology of a protein based on the presence of hydrophobic regions in the protein sequence and the secondary structure of the protein.\n9. TM-align: This tool predicts the transmembrane topology of a protein based on the presence of hydrophobic regions in the protein sequence and the secondary structure of the protein.\n10. TM-PSSM: This tool predicts the transmembrane topology of a protein based on the presence of hydrophobic regions in the protein sequence and the secondary structure of the protein.\nIt's important to note that these tools are not perfect and may not always predict the correct topology of a protein, so it's always a good idea",
    "llama-2-7b-chat-hf_fact_raw": "1. TMHMM is a tool used for predicting transmembrane helices in proteins.\n2. Topo-TOPO predicts transmembrane topology, orientation of transmembrane helices, and the presence of glycosylation sites in a protein.\n3. Predict-TMD is used to predict transmembrane topology, orientation of transmembrane helices, and glycosylation sites in a protein.\n4. PHD-TOPO predicts transmembrane topology based on the presence of hydrophobic regions in the protein sequence.\n5. SOSUI predicts transmembrane topology of a protein by analyzing hydrophobic regions and the secondary structure of the protein.",
    "llama-2-7b-chat-hf_fact": [
      "TMHMM is a tool used for predicting transmembrane helices in proteins.",
      "Topo-TOPO predicts transmembrane topology, orientation of transmembrane helices, and the presence of glycosylation sites in a protein.",
      "Predict-TMD is used to predict transmembrane topology, orientation of transmembrane helices, and glycosylation sites in a protein.",
      "PHD-TOPO predicts transmembrane topology based on the presence of hydrophobic regions in the protein sequence.",
      "SOSUI predicts transmembrane topology of a protein by analyzing hydrophobic regions and the secondary structure of the protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Topo2 (also called TOPO2) is a tool used for the visualization of transmembrane protein orientation but it doesn't predict glycosylation sites.\n3. FALSE [correction]: Predict-TMD is used for predicting transmembrane domains (TMDs) but it does not predict glycosylation sites.\n4. TRUE [PHD-TOPO predicts transmembrane topology by identifying hydrophobic regions that potentially span the lipid bilayer.]\n5. TRUE [SOSUI is a classification and secondary structure prediction system for membrane proteins that includes analysis of hydrophobicity and secondary structure to predict transmembrane regions.]",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Galassi classification is used to classify disorders related to the function of the cerebral cortex, specifically those involving the frontal and parietal lobes. The classification system was developed by Dr. Francesco Galassi and colleagues.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro-Heller syndrome, is a rare genetic disorder characterized by a range of symptoms affecting the eyes, nervous system, and other body systems. Here are some common features of Shapiro syndrome:\n1. Retinal abnormalities: The most common feature of Shapiro syndrome is a range of retinal abnormalities, including microphthalmia (small eyes), anophthalmia (absence of one or both eyes), coloboma (a hole in the iris), and cataracts.\n2. Neurological problems: People with Shapiro syndrome may experience a range of neurological problems, including seizures, developmental delays, intellectual disability, and problems with coordination and balance.\n3. Skeletal abnormalities: Shapiro syndrome can cause various skeletal abnormalities, such as short stature, scoliosis (curvature of the spine), and other bone deformities.\n4. Cardiovascular problems: Some individuals with Shapiro syndrome may experience cardiovascular problems, including heart defects and abnormalities in the structure and function of the aorta.\n5. Genital abnormalities: Males with Shapiro syndrome may have undescended testes (cryptorchidism), while females may have irregular menstrual cycles or infertility.\n6. Ear abnormalities: Shapiro syndrome can cause various ear abnormalities, including small or malformed ears, and hearing loss.\n7. Dental abnormalities: People with Shapiro syndrome may have abnormalities in the development of their teeth, including small or missing teeth, and abnormal tooth alignment.\n8. Gastrointestinal problems: Some individuals with Shapiro syndrome may experience gastrointestinal problems, including constipation, diarrhea, and other digestive issues.\n9. Kidney problems: Shapiro syndrome can cause kidney problems, including kidney failure and other renal abnormalities.\n10. Other symptoms: Other symptoms of Shapiro syndrome can include growth delays, delayed speech and language development, and an increased risk of infections.\nIt's important",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is characterized by retinal abnormalities, including microphthalmia, anophthalmia, coloboma, and cataracts.\n2. People with Shapiro syndrome may experience neurological problems such as seizures, developmental delays, and intellectual disability.\n3. Shapiro syndrome can cause skeletal abnormalities like short stature and scoliosis.\n4. Individuals with Shapiro syndrome may have cardiovascular problems, including heart defects and aortic abnormalities.\n5. Males with Shapiro syndrome may present with undescended testes, and females may have fertility-related issues.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is characterized by retinal abnormalities, including microphthalmia, anophthalmia, coloboma, and cataracts.",
      "People with Shapiro syndrome may experience neurological problems such as seizures, developmental delays, and intellectual disability.",
      "Shapiro syndrome can cause skeletal abnormalities like short stature and scoliosis.",
      "Individuals with Shapiro syndrome may have cardiovascular problems, including heart defects and aortic abnormalities.",
      "Males with Shapiro syndrome may present with undescended testes, and females may have fertility-related issues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is characterized by the triad of recurrent hypothermia, hyperhidrosis, and agenesis of the corpus callosum, not by retinal abnormalities.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nShapiro syndrome is specifically associated with the triad mentioned above, and the other symptoms listed do not universally or typically apply to Shapiro syndrome. However, without additional context provided about specific instances or research that may associate Shapiro syndrome with the other statements mentioned, the veracity of statements about skeletal abnormalities, cardiovascular problems, and reproductive issues cannot be assessed.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "BRAG1 (BRAG1-related gene 1) is linked to a rare genetic disorder called BRAG1-related syndrome, which is characterized by a range of symptoms including developmental delays, intellectual disability, seizures, and distinctive facial features. Mutations in the BRAG1 gene can cause this syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRAG1 is linked to a condition known as BRAG1-related syndrome.\n2. BRAG1-related syndrome is characterized by developmental delays.\n3. Intellectual disability is a symptom of BRAG1-related syndrome.\n4. Seizures are among the symptoms of BRAG1-related syndrome.\n5. Distinctive facial features are associated with BRAG1-related syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "BRAG1 is linked to a condition known as BRAG1-related syndrome.",
      "BRAG1-related syndrome is characterized by developmental delays.",
      "Intellectual disability is a symptom of BRAG1-related syndrome.",
      "Seizures are among the symptoms of BRAG1-related syndrome.",
      "Distinctive facial features are associated with BRAG1-related syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is currently no known syndrome called \"BRAG1-related syndrome.\" BRAG1 is a GTPase-activating protein for the ADP ribosylation factor family. If you are referring to another condition with a similar name, please specify.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or information about a \"BRAG1-related syndrome\", I cannot accurately assess the truthfulness of statements 2 through 5. If \"BRAG1-related syndrome\" is a fictional or incorrect term for a real condition, the symptoms listed might apply to that condition, but I'd need the correct name to provide accurate information.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "The main inhibitor of protein phosphatase 1 (PP1) is the protein called PP1-specific inhibitor (PPI).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, in Bacillus subtilis involves the increased mutation rate of the genome during the stationary phase of growth, which is a period of limited nutrient availability. There are several mechanisms that underlie this process:\n1. DNA damage: The stationary phase is characterized by high levels of DNA damage, including base modifications, strand breaks, and cross-links. This damage can lead to the formation of mutagenic lesions, which can increase the mutation rate.\n2. Reactive oxygen species (ROS): ROS, such as hydrogen peroxide, can damage DNA and lead to mutations. The stationary phase is a period of increased ROS production, which can contribute to the high mutation rate during this phase.\n3. Methylation of DNA damage response proteins: In the stationary phase, the levels of DNA damage response proteins, such as the SOS response proteins, are reduced. This can lead to an accumulation of unrepaired DNA damage, which can increase the mutation rate.\n4. Chromatin structure: The stationary phase can lead to changes in chromatin structure, such as compaction and decondensation, which can affect the accessibility of DNA to repair machinery and increase the mutation rate.\n5. Transcriptional regulation: The expression of genes involved in DNA repair and mutagenesis can be regulated during the stationary phase. For example, the expression of the RecA recombinase, which is involved in DNA repair, is downregulated during the stationary phase, which can increase the mutation rate.\n6. Increased error-prone repair: During the stationary phase, the cell may use error-prone repair mechanisms, such as nucleotide excision repair, which can increase the mutation rate.\n7. Increased mutation rate in specific genes: Some genes, such as those involved in DNA repair and recombination, have a higher mutation rate during the stationary phase than other genes.\n8. Epigenetic modifications: Epigenetic modifications, such as DNA methylation and histone modifications, can also play a role in adaptive mutagenesis. For example, DNA methylation can repress the expression of genes involved in",
    "llama-2-7b-chat-hf_fact_raw": "1. Adaptive mutagenesis in Bacillus subtilis involves an increased mutation rate during the stationary phase of growth.\n2. The stationary phase is characterized by high levels of DNA damage, including base modifications, strand breaks, and cross-links, contributing to increased mutation rates.\n3. Reactive oxygen species production is increased during the stationary phase, which can lead to DNA damage and mutations.\n4. During the stationary phase, there can be a reduction in the levels of DNA damage response proteins, such as those involved in the SOS response.\n5. Changes in chromatin structure, such as compaction and decondensation, during the stationary phase can affect the accessibility of DNA to repair machinery.",
    "llama-2-7b-chat-hf_fact": [
      "Adaptive mutagenesis in Bacillus subtilis involves an increased mutation rate during the stationary phase of growth.",
      "The stationary phase is characterized by high levels of DNA damage, including base modifications, strand breaks, and cross-links, contributing to increased mutation rates.",
      "Reactive oxygen species production is increased during the stationary phase, which can lead to DNA damage and mutations.",
      "During the stationary phase, there can be a reduction in the levels of DNA damage response proteins, such as those involved in the SOS response.",
      "Changes in chromatin structure, such as compaction and decondensation, during the stationary phase can affect the accessibility of DNA to repair machinery."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Adaptive mutagenesis in Bacillus subtilis and other bacteria is a phenomenon where mutation rates can increase during stressful conditions like the stationary phase of growth to possibly generate diversity that might help some cells survive unfavorable conditions.\n\n2. FALSE [correction]: While the stationary phase can be associated with stress on bacterial cells, it is not characterized by inherently high levels of DNA damage like base modifications, strand breaks, and cross-links. These damages can occur due to various stressors, but they are not defining features of the stationary phase itself.\n\n3. TRUE: During the stationary phase, the metabolism can change and lead to increased production of reactive oxygen species, which can in turn lead to DNA damage and increase the mutation rate.\n\n4. TRUE: The expression of certain genes, including those involved in DNA repair, can be downregulated during the stationary phase, which could mean a reduction in the levels of DNA damage response proteins.\n\n5. UNKNOWN: While changes in chromatin structure can indeed affect DNA accessibility and therefore potentially influence repair, this statement is too broad and lacks specific evidence that these changes occur during the stationary phase and have the described effect in Bacillus subtilis or other bacteria. It is known that bacteria have nucleoid-associated proteins that can influence the structure and organization of their chromosome, but the relationship with stationary phase and its direct effect on mutagenesis may vary and is not well-defined in this context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism, also known as erucismatosis or erucistic dermatitis, is a rare inflammatory skin condition that is caused by an allergic reaction to the compound erucic acid, which is found in the seeds of the erucula plant (Raphanus sativus var. eruca). Erucic acid is a fatty acid that is naturally occurring in the plant and is used as a food additive in some countries.\nThe exact cause of erucism is not fully understood, but it is believed to occur when the skin comes into contact with erucic acid, which triggers an allergic response. The reaction can occur through inhalation, ingestion, or direct contact with the skin.\nSymptoms of erucism typically appear within a few hours to a few days after exposure to erucic acid and can include:\n* Redness and swelling of the skin\n* Itching and burning sensations\n* Blisters or hives\n* Pus-filled bumps or nodules\n* Skin thickening and scarring\nIn severe cases, erucism can lead to more serious complications, such as:\n* Skin infections\n* Eye irritation or vision problems\n* Respiratory problems\nIf you suspect that you have erucism, it is important to seek medical attention from a healthcare professional. They can diagnose the condition based on a physical examination and medical history, and provide appropriate treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is a rare inflammatory skin condition caused by an allergic reaction to erucic acid.\n2. Erucic acid is found in the seeds of the erucula plant, which is also known as Raphanus sativus var. eruca.\n3. Symptoms of erucism can include redness and swelling of the skin, itching and burning sensations, blisters or hives, pus-filled bumps or nodules, and skin thickening and scarring.\n4. Severe cases of erucism can lead to complications like skin infections, eye irritation or vision problems, and respiratory problems.\n5. Diagnosis of erucism can be made by a healthcare professional based on a physical examination and medical history.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is a rare inflammatory skin condition caused by an allergic reaction to erucic acid.",
      "Erucic acid is found in the seeds of the erucula plant, which is also known as Raphanus sativus var. eruca.",
      "Symptoms of erucism can include redness and swelling of the skin, itching and burning sensations, blisters or hives, pus-filled bumps or nodules, and skin thickening and scarring.",
      "Severe cases of erucism can lead to complications like skin infections, eye irritation or vision problems, and respiratory problems.",
      "Diagnosis of erucism can be made by a healthcare professional based on a physical examination and medical history."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Erucism is a condition caused by contact with the hairs of caterpillars of the family Saturniidae, not by an allergic reaction to erucic acid.\n2. FALSE [correction]: The plant referred to is more commonly known as Eruca sativa (often called arugula or rocket), not Raphanus sativus var. eruca, which is a misclassification. Raphanus sativus is the species name for the radish.\n3. UNKNOWN [correction]: While the symptoms describe a typical contact dermatitis or allergic reaction, without specific context to erucism caused by caterpillar hairs, it's difficult to confirm the accuracy of these symptoms exclusively for erucism.\n4. UNKNOWN [correction]: The complications listed could occur from severe skin reactions, but without specific context to erucism, it’s unclear if these symptoms are associated with this condition.\n5. TRUE [correction]: A healthcare professional could diagnose erucism based on a physical examination, medical history, and possibly the report of contact with caterpillars or observing the reaction.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide is a diuretic medication that is commonly used to treat a variety of medical conditions, including:\n1. Hypertension (high blood pressure): Hydrochlorothiazide is used to lower blood pressure in patients with hypertension. It works by increasing urine production, which helps to reduce the amount of fluid in the body and lower blood pressure.\n2. Heart failure: Hydrochlorothiazide can help to reduce fluid buildup in the body, which can occur in patients with heart failure.\n3. Edema (fluid retention): Hydrochlorothiazide can help to reduce fluid buildup in the body, which can occur in patients with edema.\n4. Nephrotic syndrome: Hydrochlorothiazide can help to reduce fluid buildup in the body, which can occur in patients with nephrotic syndrome.\n5. Diabetes insipidus: Hydrochlorothiazide can help to reduce fluid buildup in the body, which can occur in patients with diabetes insipidus.\n6. Kidney disease: Hydrochlorothiazide can help to reduce fluid buildup in the body, which can occur in patients with kidney disease.\n7. Liver disease: Hydrochlorothiazide can help to reduce fluid buildup in the body, which can occur in patients with liver disease.\n8. Angiotensin-converting enzyme (ACE) inhibitor-induced potassium loss: Hydrochlorothiazide can help to reduce potassium levels in the body, which can occur in patients taking ACE inhibitors.\n9. Hyperlipidemia (high cholesterol): Hydrochlorothiazide can help to reduce cholesterol levels in the blood, which can occur in patients with hyperlipidemia.\n10. Mild to moderate hypertension in children: Hydrochlorothiazide can be used to treat mild to moderate hypertension in children.\nIt is important to note that hydrochlorothiazide can have side effects, especially when taken in high doses or for a long time. Therefore, it is important to use this medic",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is used to treat hypertension by increasing urine production to lower blood pressure.\n2. The medication is indicated for reducing fluid buildup associated with heart failure.\n3. Hydrochlorothiazide is used to treat edema related to fluid retention.\n4. It is used for managing symptoms in patients with nephrotic syndrome.\n5. Hydrochlorothiazide can help treat diabetes insipidus by reducing fluid buildup in the body.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is used to treat hypertension by increasing urine production to lower blood pressure.",
      "The medication is indicated for reducing fluid buildup associated with heart failure.",
      "Hydrochlorothiazide is used to treat edema related to fluid retention.",
      "It is used for managing symptoms in patients with nephrotic syndrome.",
      "Hydrochlorothiazide can help treat diabetes insipidus by reducing fluid buildup in the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Hydrochlorothiazide is not typically used to treat diabetes insipidus; it is generally used to treat water retention. Diabetes insipidus involves a problem with the hormone vasopressin and a different approach to treatment is required.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence. Silicon-based materials have been developed and used in various forms to help manage and treat incontinence, including:\n1. Silicone gel-filled meshes: These are used to support the urethra and bladder neck, helping to prevent leakage of urine.\n2. Silicone-coated meshes: These are used to treat stress urinary incontinence by supporting the urethra and bladder neck.\n3. Silicone catheters: These are used to collect urine in individuals with urinary retention or incontinence.\n4. Silicone-based drugs: Some drugs, such as silicon-based antibiotics, have been developed to treat urinary tract infections.\nIt is important to note that the use of silicon in the treatment of incontinence is still a developing area of research, and more studies are needed to fully understand its effectiveness and safety. Additionally, silicon-based treatments may not be suitable for everyone and should be discussed with a healthcare provider.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon-based materials have been developed for use in the treatment of incontinence.\n2. Silicone gel-filled meshes are used to support the urethra and bladder neck, helping to prevent urine leakage.\n3. Silicone-coated meshes are used to treat stress urinary incontinence.\n4. Silicone catheters are used to collect urine for individuals with urinary retention or incontinence.\n5. Silicon-based antibiotics have been developed to treat urinary tract infections.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon-based materials have been developed for use in the treatment of incontinence.",
      "Silicone gel-filled meshes are used to support the urethra and bladder neck, helping to prevent urine leakage.",
      "Silicone-coated meshes are used to treat stress urinary incontinence.",
      "Silicone catheters are used to collect urine for individuals with urinary retention or incontinence.",
      "Silicon-based antibiotics have been developed to treat urinary tract infections."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: There are no silicon-based antibiotics. Antibiotics are typically organic compounds, not silicon-based.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "There is a controversial association between the moon cycle and the risk of rupture of intracranial aneurysms. Some studies have suggested that the incidence of rupture of intracranial aneurysms may be higher during the full moon, possibly due to changes in blood pressure and vessel diameter. However, other studies have found no significant correlation between the moon cycle and aneurysm rupture risk. The exact mechanism underlying this association is not well understood and requires further investigation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Some studies suggest a higher incidence of intracranial aneurysm rupture during the full moon.\n2. The association may involve changes in blood pressure and vessel diameter.\n3. Other studies have found no significant correlation between the moon cycle and aneurysm rupture risk.\n4. The exact mechanism underlying the association between the moon cycle and rupture risk of intracranial aneurysms is not well understood.\n5. Further investigation is required to understand the association between the moon cycle and rupture risk of intracranial aneurysms.",
    "llama-2-7b-chat-hf_fact": [
      "Some studies suggest a higher incidence of intracranial aneurysm rupture during the full moon.",
      "The association may involve changes in blood pressure and vessel diameter.",
      "Other studies have found no significant correlation between the moon cycle and aneurysm rupture risk.",
      "The exact mechanism underlying the association between the moon cycle and rupture risk of intracranial aneurysms is not well understood.",
      "Further investigation is required to understand the association between the moon cycle and rupture risk of intracranial aneurysms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Some studies have suggested a higher incidence of intracranial aneurysm rupture during the full moon, although this remains a controversial and debated topic due to the variances in study results.\n2. UNKNOWN: The claim regarding changes in blood pressure and vessel diameter related to the moon phase implicates a possible mechanism but is not established as a universally accepted fact. While there may be hypotheses regarding this association, without specific evidence or consensus in the scientific community, the truth of the statement is difficult to determine.\n3. TRUE: It's commonly the case that different studies yield varying results, and indeed, other studies have found no significant correlation between the moon cycle and aneurysm rupture risk, contributing to the ongoing debate.\n4. TRUE: The exact mechanism underlying the association between the moon cycle and the rupture risk of intracranial aneurysms remains unclear, and the scientific community has not reached a consensus.\n5. TRUE: Given the conflicting nature of the studies and the lack of a clear mechanism, further investigation is warranted to gain a better understanding of any association between the moon cycle and rupture risk of intracranial aneurysms.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, HuR protein (also known as ELAVL1) is known to regulate the splicing process in various cell types. HuR is an RNA-binding protein that plays a critical role in the regulation of mRNA splicing, particularly in the cytoplasm. It recognizes and binds to specific sequences in the 3' untranslated region (UTR) of target mRNAs and modulates their splicing patterns by blocking or enhancing the activity of splicing factors.\nHuR has been shown to regulate the splicing of a variety of mRNAs involved in different biological processes, including cell proliferation, differentiation, and survival. For example, HuR has been shown to promote the splicing of the Bcl-2 mRNA, leading to increased expression of the anti-apoptotic protein Bcl-2 and resistance to chemotherapy in cancer cells. HuR has also been implicated in the regulation of splicing of mRNAs involved in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.\nIn summary, HuR protein plays a critical role in regulating the splicing process in various cell types, and its dysregulation has been implicated in a variety of diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein, also known as ELAVL1, regulates the splicing process in various cell types.\n2. HuR plays a role in the regulation of mRNA splicing, particularly in the cytoplasm.\n3. HuR recognizes and binds to specific sequences in the 3' untranslated region (UTR) of target mRNAs.\n4. HuR has been shown to promote the splicing of the Bcl-2 mRNA, which can lead to increased expression of the anti-apoptotic protein Bcl-2.\n5. Dysregulation of HuR protein has been implicated in a variety of diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein, also known as ELAVL1, regulates the splicing process in various cell types.",
      "HuR plays a role in the regulation of mRNA splicing, particularly in the cytoplasm.",
      "HuR recognizes and binds to specific sequences in the 3' untranslated region (UTR) of target mRNAs.",
      "HuR has been shown to promote the splicing of the Bcl-2 mRNA, which can lead to increased expression of the anti-apoptotic protein Bcl-2.",
      "Dysregulation of HuR protein has been implicated in a variety of diseases, including cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: HuR protein, also known as ELAVL1, is primarily known for regulating mRNA stability and translation in various cell types, not the splicing process.\n2. TRUE: HuR is known for playing a role in the regulation of mRNA stability and translation, particularly in the cytoplasm.\n3. TRUE: HuR does recognize and bind to specific sequences in the 3' untranslated region (UTR) of target mRNAs.\n4. UNKNOWN: Without specific evidence or a specific scientific reference provided here, it is difficult to confirm the claim about HuR promoting the splicing of the Bcl-2 mRNA.\n5. TRUE: Dysregulation of HuR protein has been implicated in a variety of diseases, including cancer and some neurodegenerative disorders.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "The prothymosin alpha c-terminal peptide (PCT) has been shown to have a variety of functions in the body, including:\n1. Regulation of cell proliferation and differentiation: PCT has been shown to inhibit the proliferation of certain cell types, such as tumor cells, and to promote the differentiation of stem cells.\n2. Anti-inflammatory effects: PCT has been shown to have anti-inflammatory properties, and may play a role in the regulation of immune responses.\n3. Neuroprotection: PCT has been shown to have neuroprotective effects, and may play a role in the protection of neurons against damage caused by various insults, such as oxidative stress and excitotoxicity.\n4. Cardiovascular protection: PCT has been shown to have cardiovascular protective effects, and may play a role in the prevention of cardiovascular disease.\n5. Anti-aging effects: PCT has been shown to have anti-aging effects, and may play a role in the promotion of healthy aging and the prevention of age-related diseases.\n6. Regulation of circadian rhythms: PCT has been shown to regulate circadian rhythms, and may play a role in the regulation of the body's internal clock.\n7. Modulation of the immune response: PCT has been shown to modulate the immune response, and may play a role in the regulation of immune function.\n8. Anti-tumor effects: PCT has been shown to have anti-tumor effects, and may play a role in the prevention and treatment of cancer.\nIt is worth noting that the functions of PCT are not limited to the above list, and it may have other functions in the body that have not yet been fully elucidated.",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha c-terminal peptide (PCT) inhibits the proliferation of certain cell types, such as tumor cells.\n2. Prothymosin alpha c-terminal peptide (PCT) promotes the differentiation of stem cells.\n3. Prothymosin alpha c-terminal peptide (PCT) has anti-inflammatory properties.\n4. Prothymosin alpha c-terminal peptide (PCT) provides neuroprotective effects against damage such as oxidative stress and excitotoxicity.\n5. Prothymosin alpha c-terminal peptide (PCT) has cardiovascular protective effects.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha c-terminal peptide (PCT) inhibits the proliferation of certain cell types, such as tumor cells.",
      "Prothymosin alpha c-terminal peptide (PCT) promotes the differentiation of stem cells.",
      "Prothymosin alpha c-terminal peptide (PCT) has anti-inflammatory properties.",
      "Prothymosin alpha c-terminal peptide (PCT) provides neuroprotective effects against damage such as oxidative stress and excitotoxicity.",
      "Prothymosin alpha c-terminal peptide (PCT) has cardiovascular protective effects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements pertain to very specific scientific claims about Prothymosin alpha c-terminal peptide (PCT), which are outside general knowledge and would require consulting up-to-date specialized scientific literature to confirm their accuracy. Without access to the relevant studies or expert analysis, it is not possible to determine the truthfulness of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "The peptide that plays a pivotal role in human cystatin C fibrillization is the amino acid sequence RRARRR. This sequence is found in the N-terminal region of human cystatin C and is responsible for the formation of fibrils in vitro.",
    "llama-2-7b-chat-hf_fact_raw": "1. The peptide sequence RRARRR plays a pivotal role in human cystatin C fibrillization.\n2. The peptide sequence RRARRR is found in the N-terminal region of human cystatin C.\n3. The peptide sequence RRARRR is responsible for the formation of fibrils in vitro.",
    "llama-2-7b-chat-hf_fact": [
      "The peptide sequence RRARRR plays a pivotal role in human cystatin C fibrillization.",
      "The peptide sequence RRARRR is found in the N-terminal region of human cystatin C.",
      "The peptide sequence RRARRR is responsible for the formation of fibrils in vitro."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The peptide sequence RRARRR is found in the C-terminal region of human cystatin C.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Yes, the concentration of protein HIF-1α (hypoxia-inducible factor 1 alpha) increases after the administration of the cytoprotective prodrug amifostine (ethyol). Amifostine is a phosphodiesterase inhibitor that activates the protein HIF-1α by preventing the degradation of its messenger RNA (mRNA), leading to increased protein expression and activity. HIF-1α plays a critical role in adapting cellular metabolism and response to hypoxia, and its activation by amifostine can help protect cells against oxidative stress and other harmful effects of radiation and chemotherapy.",
    "llama-2-7b-chat-hf_fact_raw": "1. The concentration of the protein HIF-1α increases after the administration of the cytoprotective prodrug amifostine (ethyol).\n2. Amifostine is a phosphodiesterase inhibitor.\n3. Amifostine activates the protein HIF-1α by preventing the degradation of its mRNA.\n4. The protein HIF-1α is involved in adapting cellular metabolism and response to hypoxia.\n5. Activation of HIF-1α by amifostine can protect cells against oxidative stress and harmful effects of radiation and chemotherapy.",
    "llama-2-7b-chat-hf_fact": [
      "The concentration of the protein HIF-1α increases after the administration of the cytoprotective prodrug amifostine (ethyol).",
      "Amifostine is a phosphodiesterase inhibitor.",
      "Amifostine activates the protein HIF-1α by preventing the degradation of its mRNA.",
      "The protein HIF-1α is involved in adapting cellular metabolism and response to hypoxia.",
      "Activation of HIF-1α by amifostine can protect cells against oxidative stress and harmful effects of radiation and chemotherapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: It is established that the concentration of HIF-1α can increase after administration of certain cytoprotective agents, including amifostine, due to its protective roles under stress conditions.\n2. FALSE [correction]: Amifostine is not primarily known as a phosphodiesterase inhibitor. It is recognized as a cytoprotective prodrug that can scavenge free radicals and thereby protect normal tissues from the harmful effects of radiation and chemotherapy.\n3. UNKNOWN: Without more specific context or reference, it is difficult to determine the exact mechanism of HIF-1α activation by amifostine. It's known that HIF-1α regulation can occur at the level of protein stabilization and gene transcription, but direct evidence of amifostine acting by preventing the degradation of HIF-1α mRNA is not commonly reported or may not be the primary mechanism.\n4. TRUE: HIF-1α (hypoxia-inducible factor 1-alpha) is indeed a regulatory protein that plays a critical role in cell’s response to hypoxia by adapting cellular metabolism and other functions to low oxygen conditions.\n5. TRUE: Amifostine is known to protect cells against oxidative stress and can mitigate the harmful effects of radiation and chemotherapy. One possible mechanism for this cytoprotection is through the activation of pathways related to HIF-1α, although the exact molecular interactions may involve a range of downstream effects.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase that deposits histone H3 lysine 4 trimethylation (H3K4me3) marks on histone proteins in various cell types, including stem cells, progenitor cells, and cancer cells. H3K4me3 is a repressive mark that can silence gene expression by blocking the activation of transcription factors and recruiting histone-modifying enzymes that remove activating marks.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is a histone methyltransferase.\n2. Set7 deposits histone H3 lysine 4 trimethylation (H3K4me3) marks.\n3. H3K4me3 marks can be found on histone proteins in stem cells, progenitor cells, and cancer cells.\n4. H3K4me3 is considered a repressive mark that can silence gene expression.\n5. H3K4me3 works by blocking the activation of transcription factors and recruiting enzymes that remove activating marks.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is a histone methyltransferase.",
      "Set7 deposits histone H3 lysine 4 trimethylation (H3K4me3) marks.",
      "H3K4me3 marks can be found on histone proteins in stem cells, progenitor cells, and cancer cells.",
      "H3K4me3 is considered a repressive mark that can silence gene expression.",
      "H3K4me3 works by blocking the activation of transcription factors and recruiting enzymes that remove activating marks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Set7 specifically catalyzes the mono-methylation of histone H3 lysine 4 (H3K4me1), not trimethylation (H3K4me3).\n3. TRUE\n4. FALSE [correction]: H3K4me3 is generally considered an activating mark associated with the transcriptional start sites of actively transcribed genes, not a repressive mark.\n5. FALSE [correction]: H3K4me3 generally works by facilitating the binding of transcription factors and recruiting chromatin remodeling enzymes that promote transcription, not by blocking activation or recruiting enzymes that remove activating marks.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "The protein hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "DNAJC11 encodes a protein that is predominantly localized to the mitochondria.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is predominantly localized to the mitochondria.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is predominantly localized to the mitochondria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Yes, ultraconserved elements (UEs) are depleted among copy number variants (CNVs). UEs are short, conserved sequences that are found throughout the genome, and they are typically associated with regulatory elements such as promoters and enhancers. CNVs, on the other hand, are genetic variations that involve the gain or loss of DNA sequences, and they can affect the expression of genes and the regulation of gene expression.\nStudies have shown that UEs are enriched in regions of the genome that are not affected by CNVs, and that CNVs are often associated with the loss of UEs. This suggests that UEs are particularly important for the regulation of gene expression and that their loss can have important consequences for the proper functioning of the genome.\nOne study published in the journal Nature in 2015 found that UEs are depleted among CNVs in a variety of organisms, including humans. The study used a combination of computational and experimental approaches to identify UEs and CNVs in the human genome, and found that only a small proportion of UEs were found within CNVs.\nAnother study published in the journal Science in 2017 found that the depletion of UEs among CNVs is a general feature of mammalian genomes. The study used a combination of sequencing and computational approaches to identify UEs and CNVs in a variety of mammalian species, and found that UEs were significantly less frequent in CNVs than in non-CNV regions of the genome.\nOverall, these studies suggest that UEs are an important component of the genome that are particularly vulnerable to disruption by CNVs, and that the loss of UEs may have important consequences for the proper functioning of the genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements (UEs) are depleted among copy number variants (CNVs).\n2. Ultraconserved elements are typically associated with regulatory elements such as promoters and enhancers.\n3. Copy number variants can affect the expression of genes and the regulation of gene expression.\n4. A study published in Nature in 2015 found that ultraconserved elements are depleted among CNVs in a variety of organisms, including humans.\n5. A study published in Science in 2017 reported that the depletion of UEs among CNVs is a general feature of mammalian genomes.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements (UEs) are depleted among copy number variants (CNVs).",
      "Ultraconserved elements are typically associated with regulatory elements such as promoters and enhancers.",
      "Copy number variants can affect the expression of genes and the regulation of gene expression.",
      "A study published in Nature in 2015 found that ultraconserved elements are depleted among CNVs in a variety of organisms, including humans.",
      "A study published in Science in 2017 reported that the depletion of UEs among CNVs is a general feature of mammalian genomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Ultraconserved elements (UEs) are indeed typically depleted among copy number variants (CNVs) because of the strong purifying selection acting on these sequences due to their functional importance.\n2. TRUE: Ultraconserved elements are often found to be associated with regulatory elements, including promoters and enhancers, contributing to the control of gene expression.\n3. TRUE: Copy number variants can affect gene expression and are known to influence the regulation of gene expression by altering gene dosage or disrupting regulatory elements.\n4. TRUE: Although I do not have access to specific study references post-2023, it is plausible that a study published in a high-impact journal such as Nature could report such findings, and given that UEs are generally conserved across species, this statement is credible.\n5. UNKNOWN: As with the previous statement, specific study references cannot be verified due to my knowledge cutoff. But assuming similar research trends have continued, this statement could be true since the conservation of UEs in mammalian genomes would likely be reported in a prominent journal like Science. However, without the ability to access post-2023 publications, the existence of this exact study is unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Hasatin kinase, also known as Haspin, is a protein that plays a crucial role in regulating the progression of mitosis. The substrate of Haspin during mitosis is the histone H3. Haspin phosphorylates histone H3 on specific residues, leading to the stabilization of the chromatin structure and the proper progression of mitosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Haspin kinase is also known as Haspin.\n2. The substrate of Haspin kinase during mitosis is the histone H3.\n3. Haspin kinase phosphorylates histone H3 on specific residues.\n4. The phosphorylation of histone H3 by Haspin kinase contributes to the stabilization of chromatin structure.\n5. The proper progression of mitosis is regulated by the activity of Haspin kinase on histone H3.",
    "llama-2-7b-chat-hf_fact": [
      "Haspin kinase is also known as Haspin.",
      "The substrate of Haspin kinase during mitosis is the histone H3.",
      "Haspin kinase phosphorylates histone H3 on specific residues.",
      "The phosphorylation of histone H3 by Haspin kinase contributes to the stabilization of chromatin structure.",
      "The proper progression of mitosis is regulated by the activity of Haspin kinase on histone H3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The phosphorylation of histone H3 by Haspin kinase contributes to the regulation of chromosome segregation during mitosis by creating a binding site for the chromosomal passenger complex at the centromeres, not specifically to the stabilization of chromatin structure.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroid replication is a unique mechanism of replication that involves the RNA molecule itself, rather than a cellular machinery. Here's how it works:\nViroids are small, single-stranded RNA molecules that replicate by a process called \"self-replication.\" They are not dependent on a host cell's machinery for replication, but instead, they use their own RNA sequence to produce new copies of themselves.\nThe replication process of viroids involves the following steps:\n1. Binding: The viroid RNA binds to a specific host cell receptor, usually a transmembrane protein.\n2. Unwinding: The viroid RNA unwinds and separates into two complementary single-stranded RNA molecules.\n3. Synthesis: The two complementary RNA molecules serve as templates for the synthesis of new viroid RNA molecules by the host cell's RNA polymerase enzyme.\n4. Encapsidation: The new RNA molecules are then encapsidated (wrapped) in a protein coat, which protects them from degradation and helps them to move within the cell.\n5. Maturation: The encapsidated RNA molecules mature and become infectious, ready to be released from the host cell and infect other cells.\nIn summary, the mechanism of viroid replication involves the use of the RNA molecule itself as a template for the synthesis of new RNA molecules, which are then encapsidated and matured to become infectious. This unique mechanism of replication is what makes viroids different from other viruses that rely on a host cell's machinery for replication.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are small, single-stranded RNA molecules that replicate by a process called \"self-replication.\"\n2. Viroids do not depend on a host cell's machinery for replication, but use their own RNA sequence to produce new copies.\n3. The viroid RNA binds to a specific host cell receptor, usually a transmembrane protein, as part of its replication process.\n4. The host cell's RNA polymerase enzyme is used to synthesize new viroid RNA molecules based on the templates provided by the separated single-stranded RNA molecules.\n5. New viroid RNA molecules are encapsidated in a protein coat which helps protect them from degradation and assists in intracellular movement.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are small, single-stranded RNA molecules that replicate by a process called \"self-replication.\"",
      "Viroids do not depend on a host cell's machinery for replication, but use their own RNA sequence to produce new copies.",
      "The viroid RNA binds to a specific host cell receptor, usually a transmembrane protein, as part of its replication process.",
      "The host cell's RNA polymerase enzyme is used to synthesize new viroid RNA molecules based on the templates provided by the separated single-stranded RNA molecules.",
      "New viroid RNA molecules are encapsidated in a protein coat which helps protect them from degradation and assists in intracellular movement."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroids depend on the host cell's machinery for replication; they do not contain the necessary components to replicate by themselves.\n3. FALSE [correction]: Viroids do not bind to cell receptors like viruses; they enter the cell and take advantage of the host's machinery without the need for specific receptor-mediated entry.\n4. TRUE\n5. FALSE [correction]: Viroids do not have a protein coat (outside of plant cells); they are naked RNA molecules and are not encapsidated.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Yes, fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD). Studies have shown that levels of fibronectin in the bloodstream are significantly increased in individuals with DMD, particularly during the early stages of the disease. This increase in fibronectin is thought to be due to the excessive production of fibronectin in muscle tissue in response to the disease-causing mutations in the dystrophin gene.\nThe use of fibronectin as a biomarker for DMD has several advantages, including its simplicity and non-invasive nature, as well as its potential to detect the disease at an early stage. However, further research is needed to validate the use of fibronectin as a biomarker for DMD and to determine its clinical utility.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n2. Studies indicate that individuals with DMD have significantly increased levels of fibronectin in their bloodstream, especially during early stages of the disease.\n3. The increase in fibronectin levels in individuals with DMD may be due to excessive production in muscle tissue.\n4. This excessive production of fibronectin is thought to be a response to mutations in the dystrophin gene.\n5. The use of fibronectin as a biomarker for DMD is considered to be simple, non-invasive, and capable of early disease detection.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).",
      "Studies indicate that individuals with DMD have significantly increased levels of fibronectin in their bloodstream, especially during early stages of the disease.",
      "The increase in fibronectin levels in individuals with DMD may be due to excessive production in muscle tissue.",
      "This excessive production of fibronectin is thought to be a response to mutations in the dystrophin gene.",
      "The use of fibronectin as a biomarker for DMD is considered to be simple, non-invasive, and capable of early disease detection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - Fibronectin is a protein that has been researched as a potential serum biomarker for various conditions, including Duchenne muscular dystrophy (DMD).\n2. TRUE - Published studies do suggest that individuals with DMD have increased levels of fibronectin in their bloodstream, which indicates muscle damage.\n3. TRUE - The increase in fibronectin levels in individuals with DMD can be related to muscle fiber damage and turnover, which may lead to release or production of fibronectin by affected muscle tissue.\n4. TRUE - The mutations in the dystrophin gene are the primary cause of DMD, leading to muscle damage and subsequent cellular responses, including the possible increase of fibronectin production.\n5. UNKNOWN - While using fibronectin as a biomarker for DMD can potentially be non-invasive and helpful for early detection, the statement lacks details regarding its simplicity and the current status of its use, which requires more specific evidence or consensus within the scientific community.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects, including:\n1. The ENCODE (ENCyclopedia Of DNA Elements) project, which aims to map all the functional elements in the human genome.\n2. The Roadmap Epigenomics Project, which aims to create a comprehensive map of the epigenetic marks in various organisms, including humans.\n3. The Epigenetics Roadmap Project, which aims to create a comprehensive map of the epigenetic marks in various organisms, including humans.\n4. The Human Epigenome Project, which aims to create a comprehensive map of the epigenetic marks in human cells and tissues.\n5. The Mouse Epigenome Project, which aims to create a comprehensive map of the epigenetic marks in mouse cells and tissues.\n6. The Epigenetic Atlas of Human Disease, which aims to identify epigenetic changes associated with various diseases, including cancer and neurological disorders.\n7. The Epigenetic Regulation of Stem Cells, which aims to understand the epigenetic mechanisms that regulate stem cell function and differentiation.\n8. The Epigenetic Control of Gene Expression, which aims to understand the epigenetic mechanisms that control gene expression and their role in various diseases.\n9. The Epigenetic Modifications in Cancer, which aims to understand the epigenetic changes that occur in cancer and their role in tumor progression and treatment resistance.\n10. The Epigenetic Modifications in Neurological Disorders, which aims to understand the epigenetic changes that occur in neurological disorders, such as Alzheimer's disease and Parkinson's disease.\nThese projects have generated a large amount of epigenomic data, including data on DNA methylation, histone modifications, and other epigenetic marks, which are available for analysis through the DeepBlue data server.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE project.\n2. The Roadmap Epigenomics Project data is included in the DeepBlue epigenomic data server.\n3. The Human Epigenome Project is one of the sources of data for the DeepBlue epigenomic data server.\n4. Data from the Mouse Epigenome Project can be found in the DeepBlue epigenomic data server.\n5. The DeepBlue epigenomic data server provides data related to the Epigenetic Atlas of Human Disease.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE project.",
      "The Roadmap Epigenomics Project data is included in the DeepBlue epigenomic data server.",
      "The Human Epigenome Project is one of the sources of data for the DeepBlue epigenomic data server.",
      "Data from the Mouse Epigenome Project can be found in the DeepBlue epigenomic data server.",
      "The DeepBlue epigenomic data server provides data related to the Epigenetic Atlas of Human Disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The DeepBlue epigenomic data server contains data from various sources including the ENCODE (Encyclopedia of DNA Elements) project, providing a variety of epigenomic datasets.\n2. TRUE: The Roadmap Epigenomics Project, which is a collaborative research project that aims to map human epigenomes, is indeed one of the projects whose data is included in the DeepBlue epigenomic data server.\n3. UNKNOWN: Without specific reference to a \"Human Epigenome Project\", it is difficult to verify this statement. The term could refer to a variety of projects or initiatives dealing with human epigenomes, and it is unclear whether the data from such a project is included in the DeepBlue server unless it is explicitly stated in the context of the server's database resources.\n4. UNKNOWN: Similarly to statement 3, without more context or specific confirmation, it is unclear whether the data from a \"Mouse Epigenome Project\" is specifically included in the DeepBlue epigenomic data server.\n5. UNKNOWN: The statement regarding the Epigenetic Atlas of Human Disease is vague and lacks detail. Without further information, it is uncertain whether this specific data is provided by the DeepBlue epigenomic data server or if such an atlas exists within their offerings.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "The tool that employs self-organizing maps (SOM) for analyzing synonymous codon usage is called \"CodonMapper\".",
    "llama-2-7b-chat-hf_fact_raw": "1. Self-organizing maps (SOM) are employed for analyzing synonymous codon usage.\n2. \"CodonMapper\" is a tool that uses self-organizing maps for this purpose.",
    "llama-2-7b-chat-hf_fact": [
      "Self-organizing maps (SOM) are employed for analyzing synonymous codon usage.",
      "\"CodonMapper\" is a tool that uses self-organizing maps for this purpose."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 (Microtubule-Associated Protein Light Chain 1) is a protein that plays a critical role in the regulation of microtubule dynamics and stability in cells. It is a key component of the plus-end tracking protein complex, which helps to regulate the growth and stability of microtubules by interacting with their plus-ends. MINDY-1 is also involved in the regulation of cell division and the maintenance of genome stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a protein that is involved in the regulation of microtubule dynamics and stability.\n2. It is part of the plus-end tracking protein complex.\n3. MINDY-1 interacts with the plus-ends of microtubules.\n4. The protein plays a role in the regulation of cell division.\n5. MINDY-1 is associated with the maintenance of genome stability.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a protein that is involved in the regulation of microtubule dynamics and stability.",
      "It is part of the plus-end tracking protein complex.",
      "MINDY-1 interacts with the plus-ends of microtubules.",
      "The protein plays a role in the regulation of cell division.",
      "MINDY-1 is associated with the maintenance of genome stability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MINDY-1 is a protein, but there is no evidence suggesting that it is involved in the regulation of microtubule dynamics and stability. MINDY-1 refers to a family of enzymes known as MIU-containing novel DUB family (MINDY), which is associated with deubiquitination processes.\n2. FALSE [correction]: Given the correction above, MINDY-1 is not part of the plus-end tracking protein complex, as that relates to proteins involved with microtubules, not deubiquitination.\n3. FALSE [correction]: As MINDY-1 is part of the deubiquitination enzyme family, it does not interact with microtubules but is involved in removing ubiquitin from substrate proteins.\n4. UNKNOWN: While deubiquitination can play a role in the regulation of cell division, without further context it is not possible to definitively say MINDY-1 itself is directly involved.\n5. UNKNOWN: The maintenance of genome stability can be influenced by numerous factors, including deubiquitination. However, without specific evidence that MINDY-1 is involved in this, the claim cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, including:\n1. PhyloBLAST: This software uses a BLAST-like algorithm to identify conserved regions in multiple genomes.\n2. ConServ: This tool uses a HMM-based approach to identify conserved regions in genomic sequences.\n3. PALI (Position-Specific Scoring Matrix for Inferring Conserved Regions): This software uses a PSSM-based approach to identify conserved regions in genomic sequences.\n4. MUSCLE (Multiple Sequence Comparison by Log-Expectation): This software uses a multiple sequence alignment approach to identify conserved regions in genomic sequences.\n5. MAFFT (Multiple Alignment using Fast Fourier Transform): This software uses a multiple sequence alignment approach to identify conserved regions in genomic sequences.\n6. BLASTZ: This software uses a BLAST-like algorithm to identify conserved regions in genomic sequences.\n7. GLIMMER: This software uses a profile-based approach to identify conserved regions in genomic sequences.\n8. HMMER: This software uses a HMM-based approach to identify conserved regions in genomic sequences.\n9. Prodigal: This software uses a multiple sequence alignment approach to identify conserved regions in genomic sequences.\n10. RepeatMasker: This software uses a repeat-masking approach to identify conserved regions in genomic sequences.\nThese software packages can be used to identify conserved regions in genomic sequences, which can be useful for a variety of downstream analyses, such as functional annotation, gene prediction, and evolutionary analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. PhyloBLAST uses a BLAST-like algorithm to identify conserved regions in multiple genomes.\n2. ConServ uses a HMM-based approach to identify conserved regions in genomic sequences.\n3. MUSCLE (Multiple Sequence Comparison by Log-Expectation) uses a multiple sequence alignment approach to identify conserved regions in genomic sequences.\n4. MAFFT (Multiple Alignment using Fast Fourier Transform) also uses a multiple sequence alignment approach to identify conserved regions in genomic sequences.\n5. RepeatMasker uses a repeat-masking approach to identify conserved regions in genomic sequences.",
    "llama-2-7b-chat-hf_fact": [
      "PhyloBLAST uses a BLAST-like algorithm to identify conserved regions in multiple genomes.",
      "ConServ uses a HMM-based approach to identify conserved regions in genomic sequences.",
      "MUSCLE (Multiple Sequence Comparison by Log-Expectation) uses a multiple sequence alignment approach to identify conserved regions in genomic sequences.",
      "MAFFT (Multiple Alignment using Fast Fourier Transform) also uses a multiple sequence alignment approach to identify conserved regions in genomic sequences.",
      "RepeatMasker uses a repeat-masking approach to identify conserved regions in genomic sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PhyloBLAST is not a commonly recognized bioinformatics tool, and there may be confusion with BLAST, which locates regions of local similarity between sequences, or PhyloT which is a tool for phylogenetic tree generation.\n2. UNKNOWN: Without more context, it's difficult to validate whether \"ConServ\" refers to a specific tool that uses a Hidden Markov Model (HMM)-based approach. Typically, conservation tools named Consurf or ConSeq are well-known which use HMM or other methods to identify conserved regions.\n3. TRUE: MUSCLE is a tool that employs multiple sequence alignments to help identify conserved regions in genomic sequences.\n4. TRUE: MAFFT also utilizes multiple sequence alignment methodologies to identify conserved regions in genomic sequences.\n5. FALSE [correction]: RepeatMasker is a program that screens DNA sequences for interspersed repeats and low complexity DNA sequences. Its primary use is in identifying and masking repetitive elements, not specifically identifying conserved regions, though by masking repeats, conserved regions might become more apparent.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "The PIEZO2 gene has been associated with several diseases, including:\n1. Hypertension: Mutations in the PIEZO2 gene have been found to be associated with essential hypertension, a common cardiovascular disease.\n2. Nephrocalcinosis: PIEZO2 mutations can lead to the accumulation of calcium in the kidneys, which can cause nephrocalcinosis, a condition characterized by the presence of calcium deposits in the kidneys.\n3. Chronic kidney disease: PIEZO2 mutations have also been linked to chronic kidney disease, a condition in which the kidneys gradually lose their function over time.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the PIEZO2 gene are associated with essential hypertension.\n2. PIEZO2 mutations can cause nephrocalcinosis, which is characterized by calcium deposits in the kidneys.\n3. PIEZO2 mutations have been linked to chronic kidney disease, a condition where the kidneys gradually lose function.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the PIEZO2 gene are associated with essential hypertension.",
      "PIEZO2 mutations can cause nephrocalcinosis, which is characterized by calcium deposits in the kidneys.",
      "PIEZO2 mutations have been linked to chronic kidney disease, a condition where the kidneys gradually lose function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the PIEZO2 gene are generally associated with conditions affecting touch and proprioception, not essential hypertension.\n2. UNKNOWN\n3. UNKNOWN\n\nThe information about the PIEZO2 gene's involvement with specific conditions like nephrocalcinosis and chronic kidney disease is not well-established or may not be commonly known without specific research data. As of my knowledge cutoff date in early 2023, the PIEZO2 gene is most commonly associated with mechanosensitive ion channels involved in sensory functions.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization promotes the degradation of extracellular matrix (ECM) components, such as collagen and fibronectin, through the activation of proteases. This process is important for tissue remodeling and repair during development and in response to injury or disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the degradation of extracellular matrix (ECM) components.\n2. Collagen and fibronectin are examples of ECM components affected by ERAP1-ERAP2 dimerization.\n3. The activation of proteases is involved in the degradation of ECM components by ERAP1-ERAP2 dimerization.\n4. Tissue remodeling and repair during development are processes influenced by ERAP1-ERAP2 dimerization.\n5. ERAP1-ERAP2 dimerization plays a role in response to injury or disease.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the degradation of extracellular matrix (ECM) components.",
      "Collagen and fibronectin are examples of ECM components affected by ERAP1-ERAP2 dimerization.",
      "The activation of proteases is involved in the degradation of ECM components by ERAP1-ERAP2 dimerization.",
      "Tissue remodeling and repair during development are processes influenced by ERAP1-ERAP2 dimerization.",
      "ERAP1-ERAP2 dimerization plays a role in response to injury or disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement lacks specific context and references to confirm the accuracy of the information about ERAP1-ERAP2 dimerization roles. ERAP1 and ERAP2 are aminopeptidases involved in trimming peptides for presentation by MHC Class I molecules; whether they directly promote ECM degradation is not typically cited in standard literature without a specific study's context.\n2. UNKNOWN: Without specific context from a study or review, it is unclear if collagen and fibronectin are directly affected by ERAP1-ERAP2 dimerization. These ECM components are degraded by matrix metalloproteinases and other enzymes, however, ERAP1 and ERAP2's direct effect on these components is not widely recognized without particular evidence.\n3. UNKNOWN: While proteases are indeed involved in the degradation of ECM components, whether ERAP1-ERAP2 dimerization specifically activates such proteases is not certain without context. ERAP proteins are known more for their role in antigen processing rather than direct action on proteases involved in ECM degradation.\n4. UNKNOWN: The effect of ERAP1-ERAP2 dimerization on tissue remodeling and repair during development is not a widely established concept without specific context. ERAP proteins are primarily implicated in immune system functions.\n5. UNKNOWN: Again, while ERAP enzymes have a known role in immune function, it is not clear without specific context or references that ERAP1-ERAP2 dimerization plays a direct role in the response to injury or disease in the context of tissue remodeling.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are two proteins that play important roles in the regulation of embryonic development and tissue homeostasis. In non-damaged gallbladders, R-spondin 1 and Noggin have been shown to play the following functions:\nR-spondin 1:\n* Regulation of gallbladder morphogenesis: R-spondin 1 is expressed in the gallbladder during embryonic development and plays a crucial role in the formation and morphogenesis of the gallbladder.\n* Maintenance of gallbladder function: R-spondin 1 is also expressed in adult gallbladders and is involved in the regulation of gallbladder function, including the secretion of bile and the contraction of the gallbladder muscle.\nNoggin:\n* Regulation of cell proliferation and differentiation: Noggin is expressed in the gallbladder and regulates the proliferation and differentiation of gallbladder epithelial cells.\n* Maintenance of gallbladder tissue homeostasis: Noggin also plays a role in maintaining the tissue homeostasis of the gallbladder by regulating the expression of genes involved in cell adhesion and migration.\nOverall, R-spondin 1 and Noggin play important roles in the development and maintenance of non-damaged gallbladders, and their dysregulation can lead to gallbladder diseases such as gallstones and cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 is expressed in the gallbladder during embryonic development and plays a crucial role in gallbladder morphogenesis.\n2. R-spondin 1 is involved in the regulation of adult gallbladder function, including bile secretion and gallbladder muscle contraction.\n3. Noggin regulates the proliferation and differentiation of gallbladder epithelial cells.\n4. Noggin plays a role in maintaining gallbladder tissue homeostasis by regulating genes involved in cell adhesion and migration.\n5. Dysregulation of R-spondin 1 and Noggin can lead to gallbladder diseases such as gallstones and cancer.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 is expressed in the gallbladder during embryonic development and plays a crucial role in gallbladder morphogenesis.",
      "R-spondin 1 is involved in the regulation of adult gallbladder function, including bile secretion and gallbladder muscle contraction.",
      "Noggin regulates the proliferation and differentiation of gallbladder epithelial cells.",
      "Noggin plays a role in maintaining gallbladder tissue homeostasis by regulating genes involved in cell adhesion and migration.",
      "Dysregulation of R-spondin 1 and Noggin can lead to gallbladder diseases such as gallstones and cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - R-spondin 1 is known to be expressed during the development of various organs and tissues, including the gallbladder, and plays a role in organ patterning and morphogenesis.\n2. UNKNOWN - While R-spondin 1 is important in developmental processes, its specific role in regulating adult gallbladder function, including bile secretion and muscle contraction, is not well-established without further evidence.\n3. UNKNOWN - Noggin is known to be a developmental protein that is involved in regulating the activity of morphogens such as BMPs (bone morphogenetic proteins), which could affect the proliferation and differentiation of various cell types. However, its specific role in gallbladder epithelial cells requires more precise information.\n4. UNKNOWN - While Noggin does modulate the activity of genes involved in cell adhesion and migration by antagonizing BMP signaling, its specific role in maintaining gallbladder tissue homeostasis is not specified here without additional context or evidence.\n5. UNKNOWN - Dysregulation of developmental pathways such as those involving R-spondin 1 and Noggin can be implicated in various diseases, including cancer, but the statement does not provide specific evidence linking the dysregulation of these proteins to gallbladder diseases such as gallstones and cancer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) requires several subunits to function. The core subunits of NOX5 include:\n1. NOX5P: The catalytic subunit of NOX5 that generates ROS (reactive oxygen species) through the transfer of electrons from NADPH to oxygen.\n2. p47phox: An adaptor subunit that interacts with the plasma membrane and recruits the NOX5P subunit to the membrane.\n3. p67phox: An adaptor subunit that interacts with the p47phox subunit and plays a role in the assembly of the NOX5 complex.\n4. Rac1: A small GTPase that interacts with the NOX5 complex and regulates its activity.\n5. Nox5-interacting protein 1 (NIP1): A protein that interacts with the NOX5 complex and regulates its activity.\nTogether, these subunits work cooperatively to generate ROS, which are involved in various cellular processes such as cell signaling, migration, and proliferation.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) requires several subunits to function.\n2. NOX5P is the catalytic subunit of NOX5.\n3. p47phox is an adaptor subunit in the NOX5 complex.\n4. p67phox is an adaptor subunit that interacts with the p47phox subunit in the NOX5 complex.\n5. Rac1 is a small GTPase that interacts with the NOX5 complex and helps regulate its activity.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) requires several subunits to function.",
      "NOX5P is the catalytic subunit of NOX5.",
      "p47phox is an adaptor subunit in the NOX5 complex.",
      "p67phox is an adaptor subunit that interacts with the p47phox subunit in the NOX5 complex.",
      "Rac1 is a small GTPase that interacts with the NOX5 complex and helps regulate its activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) is unique among NOX enzymes as it doesn't require additional subunits (like p47phox or p67phox) to function.\n2. TRUE\n3. FALSE [correction]: p47phox is an adaptor subunit in the NOX2 (not NOX5) complex.\n4. FALSE [correction]: p67phox is an adaptor subunit that interacts with the p47phox subunit in the NOX2 (not NOX5) complex.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are connected in the regulation of iron metabolism. Furin is a protease that cleaves the precursor protein hepcidin to produce the active form of hepcidin, which in turn inhibits iron absorption in the duodenum and promotes iron efflux from macrophages, thereby regulating iron homeostasis in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease that cleaves the precursor protein hepcidin to produce its active form.\n2. The active form of hepcidin inhibits iron absorption in the duodenum.\n3. The active form of hepcidin promotes iron efflux from macrophages.\n4. Hepcidin is involved in the regulation of iron homeostasis in the body.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease that cleaves the precursor protein hepcidin to produce its active form.",
      "The active form of hepcidin inhibits iron absorption in the duodenum.",
      "The active form of hepcidin promotes iron efflux from macrophages.",
      "Hepcidin is involved in the regulation of iron homeostasis in the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Furin is a protease, but it does not cleave the precursor protein hepcidin. Hepcidin is produced as an active peptide hormone without the need for cleavage by furin.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolytic pathway, also known as the Embden-Meyerhof pathway. This pathway is responsible for the breakdown of glucose and produces pyruvate, which can be used to produce ATP through the electron transport chain. The glycolytic pathway is composed of 10 genes and is the most well-studied metabolic pathway in yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the glycolytic pathway.\n2. The glycolytic pathway is also known as the Embden-Meyerhof pathway.\n3. The glycolytic pathway is responsible for the breakdown of glucose.\n4. The glycolytic pathway produces pyruvate.\n5. The glycolytic pathway is composed of 10 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the glycolytic pathway.",
      "The glycolytic pathway is also known as the Embden-Meyerhof pathway.",
      "The glycolytic pathway is responsible for the breakdown of glucose.",
      "The glycolytic pathway produces pyruvate.",
      "The glycolytic pathway is composed of 10 genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The largest metabolic gene cluster in yeast is not necessarily the glycolytic pathway. Gene clusters can vary depending on the context, but terms like \"largest metabolic gene cluster\" are not typically how pathways are described in scientific literature, and the glycolytic pathway is a series of enzymatic reactions rather than a gene cluster.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The glycolytic pathway is composed of 10 enzymatic steps, not necessarily 10 genes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "LIMT (Long Non-Coding RNA in Myeloid cells Inhibits Transcription) is a long non-coding RNA (lncRNA) that has been shown to play a negative regulatory role in the expression of genes involved in myeloid cell differentiation and function. Specifically, LIMT has been shown to inhibit the expression of genes involved in the myeloid cell lineage, including genes involved in the differentiation of myeloid cells into macrophages and granulocytes.\nLIMT is known to function by binding to the promoter regions of these genes and preventing the recruitment of RNA polymerase, the enzyme responsible for transcribing DNA into RNA, to these regions. This leads to a decrease in the expression of these genes and a resulting decrease in the differentiation of myeloid cells.\nAdditionally, LIMT has been shown to play a role in the regulation of cellular processes such as cell adhesion, migration, and survival. It has also been implicated in the development and progression of certain diseases, including cancer and autoimmune disorders.\nOverall, the role of LIMT lncRNA is to negatively regulate the expression of genes involved in myeloid cell differentiation and function, and it is a promising area of research for understanding the regulation of myeloid cell biology and the development of new therapeutic strategies for diseases such as cancer and autoimmune disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT (Long Non-Coding RNA in Myeloid cells Inhibits Transcription) is a long non-coding RNA.\n2. LIMT plays a negative regulatory role in the expression of genes involved in myeloid cell differentiation and function.\n3. LIMT inhibits the expression of genes involved in the differentiation of myeloid cells into macrophages and granulocytes.\n4. LIMT functions by binding to the promoter regions of genes and preventing the recruitment of RNA polymerase.\n5. LIMT has been implicated in the development and progression of diseases such as cancer and autoimmune disorders.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT (Long Non-Coding RNA in Myeloid cells Inhibits Transcription) is a long non-coding RNA.",
      "LIMT plays a negative regulatory role in the expression of genes involved in myeloid cell differentiation and function.",
      "LIMT inhibits the expression of genes involved in the differentiation of myeloid cells into macrophages and granulocytes.",
      "LIMT functions by binding to the promoter regions of genes and preventing the recruitment of RNA polymerase.",
      "LIMT has been implicated in the development and progression of diseases such as cancer and autoimmune disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific scientific literature or data presented to validate statements 4 and 5, the mechanism of action of LIMT (such as the specific binding to promoter regions) and its role in disease (such as cancer and autoimmune disorders) cannot be confirmed as true or false within this context. These would require specific evidence from peer-reviewed research to substantiate.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "There are several R packages and bioconductor packages that can be used for performing SNP (Single Nucleotide Polymorphism) enrichment analysis. Some of the commonly used packages are:\n1. 'SNPset' package: This package provides a comprehensive set of tools for performing SNP enrichment analysis. It can be used to identify overrepresented SNPs in a set of genes or regions of interest.\n2. 'Enrichr' package: This package uses a Bayesian approach to identify overrepresented SNPs in a given dataset. It can be used to identify SNPs that are enriched in functional regions of the genome, such as gene regulatory elements.\n3. 'GSEA' package: This package uses a modified version of the Gene Set Enrichment Analysis (GSEA) method to identify overrepresented gene sets in a given dataset. It can be used to identify SNPs that are enriched in specific gene sets or pathways.\n4. 'Pathway studio' package: This package provides a comprehensive set of tools for pathway analysis. It can be used to identify overrepresented pathways in a given dataset, including those that are enriched with SNPs.\n5. 'Plink' package: This package provides a simple and efficient way to perform SNP analysis. It can be used to perform a variety of SNP analysis tasks, including enrichment analysis.\n6. 'MAST' package: This package provides a comprehensive set of tools for genome-wide association study (GWAS) analysis. It can be used to identify overrepresented SNPs in a given dataset, including those that are enriched in functional regions of the genome.\n7. 'GWASeq' package: This package provides a comprehensive set of tools for GWAS analysis, including enrichment analysis. It can be used to identify overrepresented SNPs in a given dataset, including those that are enriched in functional regions of the genome.\n8. 'GenomicRanges' package: This package provides a comprehensive set of tools for genomic range analysis. It can be used to identify overrepresented SNPs in a given dataset, including those that are enriched in functional regions of the genome.\n9. 'SNP",
    "llama-2-7b-chat-hf_fact_raw": "1. The 'SNPset' package is used for performing SNP enrichment analysis and identifies overrepresented SNPs in genes or regions of interest.\n2. The 'Enrichr' package uses a Bayesian approach to identify overrepresented SNPs in a dataset and can identify SNPs enriched in functional genomic regions.\n3. The 'GSEA' package uses a modified version of the Gene Set Enrichment Analysis method to identify overrepresented gene sets or pathways in a dataset.\n4. The 'Plink' package is used for a variety of SNP analysis tasks, including enrichment analysis.\n5. The 'MAST' package can be used for genome-wide association study analysis to identify overrepresented SNPs in a dataset.",
    "llama-2-7b-chat-hf_fact": [
      "The 'SNPset' package is used for performing SNP enrichment analysis and identifies overrepresented SNPs in genes or regions of interest.",
      "The 'Enrichr' package uses a Bayesian approach to identify overrepresented SNPs in a dataset and can identify SNPs enriched in functional genomic regions.",
      "The 'GSEA' package uses a modified version of the Gene Set Enrichment Analysis method to identify overrepresented gene sets or pathways in a dataset.",
      "The 'Plink' package is used for a variety of SNP analysis tasks, including enrichment analysis.",
      "The 'MAST' package can be used for genome-wide association study analysis to identify overrepresented SNPs in a dataset."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific documentation or context about the 'SNPset' package, it is not possible to determine the accuracy of this statement.\n2. FALSE [correction]: The 'Enrichr' package is actually an online tool that provides a comprehensive set of gene set enrichment analysis tools, not specifically for identifying overrepresented SNPs using a Bayesian approach. The package is particularly known for gene-level analysis rather than SNPs.\n3. TRUE: The 'GSEA' (Gene Set Enrichment Analysis) package indeed uses a modified version of the Gene Set Enrichment Analysis method to identify overrepresented gene sets or pathways in a dataset, typically in the context of expression data.\n4. TRUE: The 'Plink' software package is widely used for whole-genome association analysis and can perform a variety of tasks related to SNP data, potentially including enrichment analysis as part of broader analyses.\n5. FALSE [correction]: The 'MAST' package, which stands for Model-based Analysis of Single-cell Transcriptomics, is designed for analyzing single-cell RNA sequencing data instead of performing genome-wide association study (GWAS) analysis to identify overrepresented SNPs. It focuses on statistical tests, exploratory data analyses, and graphical visualizations in the context of single-cell data.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Radial glial cells are intermediate progenitors that give rise to ependymal cells in the central nervous system (CNS). The key players involved in radial glial specification to ependymal cells include:\n1. Notch signaling pathway: Notch is a transmembrane receptor that plays a crucial role in the regulation of cell fate decisions, including the specification of radial glial cells to ependymal cells.\n2. Wnt/β-catenin signaling pathway: Wnt/β-catenin signaling is involved in the regulation of radial glial cell fate decisions, including the maintenance of radial glial identity and the induction of ependymal cell fate.\n3. BMP signaling pathway: BMP (bone morphogenetic protein) signaling is involved in the regulation of radial glial cell fate decisions, including the induction of ependymal cell fate.\n4. Shh signaling pathway: Shh (sonic hedgehog) signaling is involved in the regulation of radial glial cell fate decisions, including the induction of ependymal cell fate.\n5. FGF signaling pathway: Fibroblast growth factor (FGF) signaling is involved in the regulation of radial glial cell fate decisions, including the induction of ependymal cell fate.\n6. EGFR signaling pathway: Epidermal growth factor receptor (EGFR) signaling is involved in the regulation of radial glial cell fate decisions, including the induction of ependymal cell fate.\n7. PI3K/Akt signaling pathway: Phosphatidylinositol 3-kinase (PI3K)/Akt signaling is involved in the regulation of radial glial cell fate decisions, including the maintenance of radial glial identity and the induction of ependymal cell fate.\n8. Hippo signaling pathway: Hippo signaling is involved in the regulation of radial glial cell fate decisions, including the maintenance of radial glial identity and the induction of ependymal cell fate.\n9. Yap/Tead signaling pathway: Yes-associated protein (Yap)/Tead signaling is involved in the regulation of radial glial cell fate decisions",
    "llama-2-7b-chat-hf_fact_raw": "1. The Notch signaling pathway plays a crucial role in the specification of radial glial cells to ependymal cells.\n2. The Wnt/β-catenin signaling pathway is involved in the regulation of radial glial cell fate decisions.\n3. BMP (bone morphogenetic protein) signaling is involved in the induction of ependymal cell fate from radial glial cells.\n4. Shh (sonic hedgehog) signaling regulates radial glial cell fate decisions, including the induction of ependymal cell fate.\n5. The FGF (fibroblast growth factor) signaling pathway is involved in the regulation of radial glial cell fate decisions.",
    "llama-2-7b-chat-hf_fact": [
      "The Notch signaling pathway plays a crucial role in the specification of radial glial cells to ependymal cells.",
      "The Wnt/β-catenin signaling pathway is involved in the regulation of radial glial cell fate decisions.",
      "BMP (bone morphogenetic protein) signaling is involved in the induction of ependymal cell fate from radial glial cells.",
      "Shh (sonic hedgehog) signaling regulates radial glial cell fate decisions, including the induction of ependymal cell fate.",
      "The FGF (fibroblast growth factor) signaling pathway is involved in the regulation of radial glial cell fate decisions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - The Notch signaling pathway is indeed crucial in neural development, including the specification of radial glial cells to ependymal cells.\n2. TRUE - The Wnt/β-catenin signaling pathway plays a role in regulating radial glial cell fate decisions.\n3. TRUE - BMP signaling has been implicated in the induction of ependymal cell fate from radial glial cells.\n4. FALSE [correction]: Shh (sonic hedgehog) signaling is primarily known for its role in ventral patterning of the neural tube and the regulation of motor neuron and interneuron generation. It is not predominantly recognized for the induction of ependymal cell fate from radial glial cells.\n5. TRUE - FGF signaling has been associated with the regulation of neural progenitor cells including radial glial cells and their fate decisions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are characterized by the lack of expression of specific markers, including:\n1. Tumor suppressor proteins: TP53, PTEN, and CDKN2A (also known as p16).\n2. Receptors: EGFR, HER2, and HER3.\n3. Cyclin-dependent kinase inhibitors: CDKN1A (also known as p21) and CDKN2A (also known as p16).\nThe absence of these markers distinguishes triple negative gliomas from other types of gliomas, such as glioblastoma, which are typically characterized by the presence of these markers. Triple negative gliomas are aggressive and malignant, and they are often difficult to treat. They are typically found in adults, and the prognosis for patients with these tumors is generally poor.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas lack expression of tumor suppressor proteins TP53, PTEN, and CDKN2A (p16).\n2. Triple negative gliomas lack expression of receptors such as EGFR, HER2, and HER3.\n3. Triple negative gliomas lack expression of cyclin-dependent kinase inhibitors CDKN1A (p21) and CDKN2A (p16).\n4. Triple negative gliomas are different from glioblastomas, which typically express the markers that triple negative gliomas lack.\n5. Triple negative gliomas are aggressive and malignant tumors, generally associated with a poor prognosis for patients.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas lack expression of tumor suppressor proteins TP53, PTEN, and CDKN2A (p16).",
      "Triple negative gliomas lack expression of receptors such as EGFR, HER2, and HER3.",
      "Triple negative gliomas lack expression of cyclin-dependent kinase inhibitors CDKN1A (p21) and CDKN2A (p16).",
      "Triple negative gliomas are different from glioblastomas, which typically express the markers that triple negative gliomas lack.",
      "Triple negative gliomas are aggressive and malignant tumors, generally associated with a poor prognosis for patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Triple negative gliomas lack expression of receptors such as estrogen receptor (ER), progesterone receptor (PR), and HER2/neu. The description provided is more characteristic of triple negative breast cancer.\n3. TRUE\n4. FALSE [correction]: Glioblastomas may also lack expression of the mentioned markers, so this statement is not universally accurate. The term \"triple negative\" when applied to glioblastomas can sometimes refer to the lack of expression of the same markers as in triple negative gliomas (TP53, PTEN, and CDKN2A), making the two more similar in this aspect than the statement suggests.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 (Topoisomerase 1-associated protein AZ1) is a protein that plays a role in the regulation of DNA topoisomerase I activity and is involved in various cellular processes, including DNA replication, repair, and cell division. It is a component of the DNA damage response pathway and helps to maintain genome stability by regulating the activity of topoisomerase I, which is an enzyme that relaxes DNA supercoils. TOPAZ1 is also a tumor suppressor and its loss of function has been implicated in various types of cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 stands for Topoisomerase 1-associated protein AZ1.\n2. TOPAZ1 is involved in DNA replication, repair, and cell division.\n3. The protein is a component of the DNA damage response pathway.\n4. TOPAZ1 helps maintain genome stability by regulating the activity of topoisomerase I.\n5. Loss of function of TOPAZ1 has been implicated in various types of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 stands for Topoisomerase 1-associated protein AZ1.",
      "TOPAZ1 is involved in DNA replication, repair, and cell division.",
      "The protein is a component of the DNA damage response pathway.",
      "TOPAZ1 helps maintain genome stability by regulating the activity of topoisomerase I.",
      "Loss of function of TOPAZ1 has been implicated in various types of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TOPAZ1 does not stand for Topoisomerase 1-associated protein AZ1; it is a gene that can be referred to as Testis and Ovary Specific PAZ Domain Containing 1.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe information provided is insufficient to determine the accuracy of statements 2-5 without more context or specific scientific references. Topaz1 is known to be a gene with a specific role in the body, but its functions and associations with conditions like cancer could require more detailed and specific scientific literature to confirm or refute.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "The expression of GATA-1 isoforms is controlled by the GATA-1 gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. The GATA-1 gene controls the expression of GATA-1 isoforms.",
    "llama-2-7b-chat-hf_fact": [
      "The GATA-1 gene controls the expression of GATA-1 isoforms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a sequencing-based method used to identify and characterize the full-length RNA transcripts in a cell or tissue. It stands for \"Mature Isolate of RNA-seq\" and is a type of RNA sequencing (RNA-seq) method that is designed to capture the full-length transcripts of RNA molecules, including those that are not polyadenylated or have a shortened 3' end. MIRA-seq is particularly useful for studying the expression of long non-coding RNAs (lncRNAs) and other RNA molecules that are difficult to detect using traditional RNA-seq methods.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is used to identify and characterize the full-length RNA transcripts in a cell or tissue.\n2. MIRA-seq stands for \"Mature Isolate of RNA-seq.\"\n3. MIRA-seq is a type of RNA sequencing (RNA-seq) method.\n4. This method is designed to capture the full-length transcripts of RNA molecules, including those that are not polyadenylated or have a shortened 3' end.\n5. MIRA-seq is useful for studying the expression of long non-coding RNAs (lncRNAs) and other RNA molecules that traditional RNA-seq methods may struggle to detect.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is used to identify and characterize the full-length RNA transcripts in a cell or tissue.",
      "MIRA-seq stands for \"Mature Isolate of RNA-seq.\"",
      "MIRA-seq is a type of RNA sequencing (RNA-seq) method.",
      "This method is designed to capture the full-length transcripts of RNA molecules, including those that are not polyadenylated or have a shortened 3' end.",
      "MIRA-seq is useful for studying the expression of long non-coding RNAs (lncRNAs) and other RNA molecules that traditional RNA-seq methods may struggle to detect."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: MIRA-seq does not stand for \"Mature Isolate of RNA-seq.\" It stands for \"Methylation Interaction-Resistant Amplification Sequencing.\"\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST (rilonacept) is a prescription medication used to treat cryopyrin-associated periodic syndrome (CAPS) in adults and children aged 12 years and older, and to treat gout flares in adults. CAPS is a group of rare genetic disorders that cause recurring episodes of fever, pain, and inflammation, while gout is a type of arthritis that causes joint pain and swelling.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST (rilonacept) is a prescription medication.\n2. ARCALYST is used to treat cryopyrin-associated periodic syndrome (CAPS) in adults and children aged 12 years and older.\n3. ARCALYST is also used to treat gout flares in adults.\n4. CAPS is a group of rare genetic disorders characterized by recurring episodes of fever, pain, and inflammation.\n5. Gout is a type of arthritis associated with joint pain and swelling.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST (rilonacept) is a prescription medication.",
      "ARCALYST is used to treat cryopyrin-associated periodic syndrome (CAPS) in adults and children aged 12 years and older.",
      "ARCALYST is also used to treat gout flares in adults.",
      "CAPS is a group of rare genetic disorders characterized by recurring episodes of fever, pain, and inflammation.",
      "Gout is a type of arthritis associated with joint pain and swelling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "The human acrocentric chromosomes involved in Robertsonian translocation are:\n1. Chromosome 13 (t(13;14)(q10;q32))\n2. Chromosome 14 (t(14;15)(q32;q21))\n3. Chromosome 21 (t(21;22)(q22;q11))\n4. Chromosome 22 (t(22;15)(q11;q32))\nNote: Robertsonian translocations are reciprocal translocations, meaning that the genetic material is exchanged between two chromosomes in a reciprocal manner. The above list shows the acrocentric chromosomes involved in these translocations.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromosome 13 is involved in Robertsonian translocation.\n2. Chromosome 14 is involved in Robertsonian translocation.\n3. Chromosome 21 is involved in Robertsonian translocation.\n4. Chromosome 22 is involved in Robertsonian translocation.\n5. Robertsonian translocations are reciprocal translocations involving exchanges of genetic material between chromosomes.",
    "llama-2-7b-chat-hf_fact": [
      "Chromosome 13 is involved in Robertsonian translocation.",
      "Chromosome 14 is involved in Robertsonian translocation.",
      "Chromosome 21 is involved in Robertsonian translocation.",
      "Chromosome 22 is involved in Robertsonian translocation.",
      "Robertsonian translocations are reciprocal translocations involving exchanges of genetic material between chromosomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Robertsonian translocations are not reciprocal; they typically involve the fusion of two acrocentric chromosomes at the centromere, resulting in one large chromosome and one very small chromosome that often gets lost in the cell.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "There are several R packages that can be used for the identification of pediatric brain tumors, including:\n1. \"brainTumor\": This package provides a set of tools for the analysis of brain tumor genomics data, including mutation and copy number analysis.\n2. \"pediatricTumor\": This package is specifically designed for the analysis of pediatric tumors, including brain tumors, and provides functions for the analysis of genomic and transcriptomic data.\n3. \"cBioPortal\": This package is a web-based tool for the analysis of cancer genomics data, including brain tumors, and provides functions for the analysis of mutation, copy number, and mRNA expression data.\n4. \"mutationTumor\": This package provides functions for the analysis of mutation data in cancer genomics data, including brain tumors.\n5. \"genomicTumor\": This package provides functions for the analysis of genomic data in cancer, including brain tumors, and includes tools for the analysis of mutation, copy number, and mRNA expression data.\n6. \"brainTumorGenome\": This package provides functions for the analysis of brain tumor genomics data, including mutation, copy number, and mRNA expression data.\n7. \"pediatricTumorGenome\": This package is specifically designed for the analysis of pediatric tumors, including brain tumors, and provides functions for the analysis of genomic and transcriptomic data.\n8. \"TumorGenome\": This package provides functions for the analysis of tumor genomics data, including brain tumors, and includes tools for the analysis of mutation, copy number, and mRNA expression data.\n9. \"CancerGenome\": This package provides functions for the analysis of cancer genomics data, including brain tumors, and includes tools for the analysis of mutation, copy number, and mRNA expression data.\n10. \"GDC_BrainTumor\": This package provides functions for the analysis of brain tumor genomics data, including mutation, copy number, and mRNA expression data, from The Cancer Genome Atlas (TCGA).\nPlease note that these packages are for research purposes only and are not intended to be used for clinical diagnosis or treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"brainTumor\" R package provides tools for mutation and copy number analysis of brain tumor genomics data.\n2. The \"pediatricTumor\" R package is designed for the analysis of genomic and transcriptomic data of pediatric tumors, including brain tumors.\n3. The \"cBioPortal\" R package is a web-based tool for analyzing cancer genomics data, including brain tumors, with functions for mutation, copy number, and mRNA expression data analysis.\n4. The \"GDC_BrainTumor\" R package provides functions for the analysis of brain tumor genomics data from The Cancer Genome Atlas (TCGA).\n5. The R packages mentioned are intended for research purposes and not for clinical diagnosis or treatment.",
    "llama-2-7b-chat-hf_fact": [
      "The \"brainTumor\" R package provides tools for mutation and copy number analysis of brain tumor genomics data.",
      "The \"pediatricTumor\" R package is designed for the analysis of genomic and transcriptomic data of pediatric tumors, including brain tumors.",
      "The \"cBioPortal\" R package is a web-based tool for analyzing cancer genomics data, including brain tumors, with functions for mutation, copy number, and mRNA expression data analysis.",
      "The \"GDC_BrainTumor\" R package provides functions for the analysis of brain tumor genomics data from The Cancer Genome Atlas (TCGA).",
      "The R packages mentioned are intended for research purposes and not for clinical diagnosis or treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information about the \"brainTumor\" R package, it is not possible to confirm or correct the statement. This requires checking the documentation or description of the package itself.\n2. UNKNOWN: Similar to the previous statement, it is not possible to confirm whether the \"pediatricTumor\" R package is designed for the analysis mentioned without further information.\n3. TRUE: The cBioPortal is indeed a web-based tool for cancer genomics data analysis. It does include functions for analyzing various types of data including mutation, copy number, and mRNA expression. However, it's important to note that \"cBioPortal\" itself is a web-based portal, and there are R packages available (such as \"cgdsr\") that interface with cBioPortal, rather than \"cBioPortal\" being an R package itself.\n4. UNKNOWN: There is no specific R package called \"GDC_BrainTumor\" that can be confirmed without additional information. However, there are R packages designed for analyzing data from The Cancer Genome Atlas (TCGA), so a package with a name like that might exist.\n5. TRUE: R packages mentioned and similar packages typically come with disclaimers stating that they are intended for research purposes only and should not be used for clinical diagnosis or treatment without validation and regulatory approval.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "No, NEMO (NF-κB essential modulator) is not a zinc finger protein. NEMO is a protein that plays a critical role in the regulation of NF-κB (nuclear factor kappa B), a transcription factor that regulates inflammation and immune responses. While NEMO does contain a zinc finger domain, it is not the primary structural component of the protein. Instead, NEMO is a adaptor protein that interacts with multiple signaling molecules, including IKKs (IκB kinases), IKKβ, and p105/p50, to modulate NF-κB activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO stands for NF-κB essential modulator.\n2. NEMO is not classified as a zinc finger protein.\n3. NEMO contains a zinc finger domain.\n4. NEMO is an adaptor protein that interacts with signaling molecules.\n5. NF-κB, which NEMO regulates, is a transcription factor that regulates inflammation and immune responses.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO stands for NF-κB essential modulator.",
      "NEMO is not classified as a zinc finger protein.",
      "NEMO contains a zinc finger domain.",
      "NEMO is an adaptor protein that interacts with signaling molecules.",
      "NF-κB, which NEMO regulates, is a transcription factor that regulates inflammation and immune responses."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: NEMO does contain a zinc finger domain, which is involved in protein-protein interactions.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Yes, TFIIS (transcription factor IIS) can affect nucleosome positioning during transcription elongation. TFIIS is a transcriptional elongation factor that plays a critical role in the initiation and elongation of transcription by RNA polymerase II (RNAPII). It helps to position the RNAPII complex in the correct position on the DNA template and can also influence the positioning of nucleosomes along the DNA strand, which can in turn affect the transcriptional process.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS can affect nucleosome positioning during transcription elongation.\n2. TFIIS is a transcription elongation factor.\n3. TFIIS plays a critical role in the initiation and elongation of transcription by RNA polymerase II.\n4. TFIIS helps to position the RNA polymerase II complex on the DNA template.\n5. The positioning of nucleosomes along the DNA strand can affect the transcriptional process.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS can affect nucleosome positioning during transcription elongation.",
      "TFIIS is a transcription elongation factor.",
      "TFIIS plays a critical role in the initiation and elongation of transcription by RNA polymerase II.",
      "TFIIS helps to position the RNA polymerase II complex on the DNA template.",
      "The positioning of nucleosomes along the DNA strand can affect the transcriptional process."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: TFIIS plays a critical role in transcription elongation, particularly in aiding RNA polymerase II in overcoming transcriptional arrest, rather than in the initiation of transcription.\n4. FALSE [correction]: TFIIS does not position the RNA polymerase II complex on the DNA template; it is involved in the process of transcription elongation by aiding RNA polymerase II in resuming transcription when it becomes stalled.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "In yeast, origins of replication close to centromeres fire late.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences (Glycine-Arginine) are a type of non-coding RNA sequences that are found in the introns of mammalian genes. Some of the properties of mammalian GA-sequences include:\n1. Long-range intron-exon structure: Mammalian GA-sequences are located in the introns of genes and can be hundreds of nucleotides long, spanning multiple exons.\n2. Adenine-rich: GA-sequences are rich in adenine nucleotides, which is unusual for non-coding RNA sequences.\n3. High stability: GA-sequences are more stable than other non-coding RNA sequences, such as circular RNAs (circRNAs), and are less prone to degradation.\n4. Regulation of splicing: GA-sequences can regulate the splicing of nearby exons, and their presence can influence the inclusion or exclusion of specific exons in the final mature RNA transcript.\n5. Regulation of gene expression: GA-sequences can also regulate gene expression by binding to transcription factors or other regulatory proteins, and altering their activity.\n6. Tissue-specific expression: GA-sequences are tissue-specific, with different sequences found in different tissues and cell types.\n7. Evolutionary conservation: GA-sequences are highly conserved across different species, indicating their importance in the regulation of gene expression.\n8. Interaction with other RNA molecules: GA-sequences can interact with other RNA molecules, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), and play a role in the regulation of gene expression.\n9. Involvement in disease: GA-sequences have been implicated in a number of diseases, including cancer, neurological disorders, and metabolic disorders.\n10. Potential as therapeutic targets: GA-sequences are a promising target for the development of new therapies, as they play a critical role in the regulation of gene expression and are implicated in a number of diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences are located in the introns of genes and can span multiple exons.\n2. GA-sequences are rich in adenine nucleotides, differing from typical non-coding RNA sequences.\n3. GA-sequences have greater stability and are less prone to degradation compared to other non-coding RNA sequences like circular RNAs.\n4. GA-sequences can regulate the splicing of nearby exons, influencing the inclusion or exclusion of specific exons in the mature RNA transcript.\n5. GA-sequences are involved in the regulation of gene expression by interacting with regulatory proteins and transcription factors.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences are located in the introns of genes and can span multiple exons.",
      "GA-sequences are rich in adenine nucleotides, differing from typical non-coding RNA sequences.",
      "GA-sequences have greater stability and are less prone to degradation compared to other non-coding RNA sequences like circular RNAs.",
      "GA-sequences can regulate the splicing of nearby exons, influencing the inclusion or exclusion of specific exons in the mature RNA transcript.",
      "GA-sequences are involved in the regulation of gene expression by interacting with regulatory proteins and transcription factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mammalian GA-sequences, typically referred to as GA-rich sequences or G-rich regions, are not specifically located in introns and do not span multiple exons by default. They could be found in various regions of the genome, including both genic and intergenic areas. Their exact location can vary, and they are not characterized by their span across exons.\n\n2. UNKNOWN: Without a clear definition of GA-sequences in this context, it is difficult to determine whether they are particularly rich in adenine nucleotides. Generally, a sequence described as \"GA-rich\" might suggest an abundance of guanine (G) and adenine (A) nucleotides, but without more specifics, this statement can't be accurately assessed.\n\n3. FALSE [correction]: This statement is broad and would depend on the specific characteristics of the GA-sequences in question. In general, it is not possible to say that GA-sequences, or any sequence type, have greater stability compared to other non-coding RNA sequences like circular RNAs without specific empirical evidence. Circular RNAs are known for their stability, which is one of their distinguishing features.\n\n4. UNKNOWN: While certain sequences within or near introns can indeed impact splicing, the statement is too vague without specific information concerning GA-sequences. It's not possible to confirm the role of GA-sequences in regulating splicing without additional context or a clear definition of these sequences.\n\n5. FALSE [correction]: The statement makes a broad claim about GA-sequences being involved in the regulation of gene expression by interacting with regulatory proteins and transcription factors. While certain sequences and non-coding RNAs can influence gene expression by such mechanisms, without specific information on GA-sequences and their interactions, we cannot confirm this statement is true for GA-sequences as described here.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "The mouse genome contains 10 Groucho-related genes (GRGs), also known as Groucho-like genes (GLGs). These genes are:\n1. Groucho (Gro)\n2. Groucho-like 1 (Gl1)\n3. Groucho-like 2 (Gl2)\n4. Groucho-like 3 (Gl3)\n5. Groucho-like 4 (Gl4)\n6. Groucho-like 5 (Gl5)\n7. Groucho-like 6 (Gl6)\n8. Groucho-like 7 (Gl7)\n9. Groucho-like 8 (Gl8)\n10. Groucho-like 9 (Gl9)\nNote: The number of GRGs may vary slightly depending on the source and method of annotation.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS\n",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "RNA polymerase II (RNAPII) is composed of several subunits, including RNA polymerase core subunits (RPB1, RPB2, and RPB3) and additional subunits that are associated with the enzyme during transcription elongation. Of these subunits, the RPB1 subunit carries the RNA cleavage activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II is composed of several subunits.\n2. The subunits of RNA polymerase II include the RNA polymerase core subunits RPB1, RPB2, and RPB3.\n3. The RPB1 subunit of RNA polymerase II carries the RNA cleavage activity.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II is composed of several subunits.",
      "The subunits of RNA polymerase II include the RNA polymerase core subunits RPB1, RPB2, and RPB3.",
      "The RPB1 subunit of RNA polymerase II carries the RNA cleavage activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The RPB1 subunit of RNA polymerase II does not carry the RNA cleavage activity. It is the largest subunit essential for catalytic activity and includes the carboxy-terminal domain (CTD), which is important for transcription regulation. RNA cleavage activity associated with transcription is typically assigned to specific RNA processing enzymes, not to RNA polymerase II itself.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome is a rare genetic disorder caused by mutations in the PHLPP1 gene. The PHLPP1 gene provides instructions for making a protein called pleckstrin homology domain-containing protein 1 (PHLPP1), which is involved in the regulation of signaling pathways that are important for cell growth and division. Mutations in the PHLPP1 gene can lead to the development of Ohdo syndrome, which is characterized by a range of symptoms including growth retardation, intellectual disability, distinctive facial features, and an increased risk of developing certain cancers.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is a genetic disorder caused by mutations in the PHLPP1 gene.\n2. The PHLPP1 gene is responsible for making a protein called pleckstrin homology domain-containing protein 1.\n3. The PHLPP1 protein is involved in the regulation of signaling pathways related to cell growth and division.\n4. Mutations in the PHLPP1 gene can lead to the development of Ohdo syndrome.\n5. Ohdo syndrome is characterized by symptoms such as growth retardation, intellectual disability, distinctive facial features, and an increased risk of certain cancers.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is a genetic disorder caused by mutations in the PHLPP1 gene.",
      "The PHLPP1 gene is responsible for making a protein called pleckstrin homology domain-containing protein 1.",
      "The PHLPP1 protein is involved in the regulation of signaling pathways related to cell growth and division.",
      "Mutations in the PHLPP1 gene can lead to the development of Ohdo syndrome.",
      "Ohdo syndrome is characterized by symptoms such as growth retardation, intellectual disability, distinctive facial features, and an increased risk of certain cancers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ohdo syndrome is a genetic disorder, but it is not typically caused by mutations in the PHLPP1 gene. It can be caused by mutations in several different genes, including SALL1 and MED12.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: While the PHLPP1 protein is involved in the regulation of signaling pathways, mutations in the PHLPP1 gene are not known to be directly associated with the development of Ohdo syndrome.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "The R/Bioconductor package \"psychgene\" has been developed for the analysis of psychiatric disease genes. This package provides tools for the analysis of genetic data in the context of psychiatric disorders, including gene-level association analysis, pathway analysis, and gene-gene interaction analysis. It also includes tools for visualizing and interpreting the results of these analyses.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package developed for analyzing psychiatric disease genes is called \"psychgene.\"\n2. The \"psychgene\" package includes tools for gene-level association analysis.\n3. The \"psychgene\" package includes tools for pathway analysis.\n4. The \"psychgene\" package includes tools for gene-gene interaction analysis.\n5. The \"psychgene\" package provides tools for visualizing and interpreting the results of analyses.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package developed for analyzing psychiatric disease genes is called \"psychgene.\"",
      "The \"psychgene\" package includes tools for gene-level association analysis.",
      "The \"psychgene\" package includes tools for pathway analysis.",
      "The \"psychgene\" package includes tools for gene-gene interaction analysis.",
      "The \"psychgene\" package provides tools for visualizing and interpreting the results of analyses."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific details about the \"psychgene\" R/Bioconductor package, I cannot verify or correct these statements. R/Bioconductor packages are numerous, and their functionalities vary widely, so confirming these statements requires either knowledge of this specific package or information provided in a passage that has not been included here.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "The \"swirl\" sign is a clinical sign that can be observed in patients with intracerebral hemorrhage (ICH). It is characterized by a spiral or swirling pattern of brain tissue that is visible on a computed tomography (CT) scan or magnetic resonance imaging (MRI) scan of the brain.\nThe swirl sign is caused by the movement of blood in the affected area of the brain, which can occur as a result of the hemorrhage. The blood can create a \"whirlpool\" or \"swirl\" pattern in the surrounding brain tissue, which can be seen on imaging studies. The swirl sign is often more prominent on CT scans than on MRI scans.\nThe swirl sign can be an important diagnostic marker for ICH, as it can help doctors identify the location and extent of the hemorrhage. It can also be used to monitor the progression of the hemorrhage over time. However, the swirl sign is not specific to ICH and can also be seen in other conditions, such as subarachnoid hemorrhage and cerebral edema.\nIn summary, the swirl sign is a clinical sign that can be observed on imaging studies in patients with intracerebral hemorrhage. It is caused by the movement of blood in the affected area of the brain and can help doctors diagnose and monitor the progression of the hemorrhage.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"swirl\" sign is visible on a CT or MRI scan of the brain in patients with intracerebral hemorrhage (ICH).\n2. This sign is characterized by a spiral or swirling pattern of brain tissue.\n3. The swirl sign is caused by the movement of blood in the affected area of the brain due to the hemorrhage.\n4. It is used to help identify the location and extent of the hemorrhage and monitor its progression.\n5. The swirl sign is not specific to ICH and can be seen in other conditions such as subarachnoid hemorrhage and cerebral edema.",
    "llama-2-7b-chat-hf_fact": [
      "The \"swirl\" sign is visible on a CT or MRI scan of the brain in patients with intracerebral hemorrhage (ICH).",
      "This sign is characterized by a spiral or swirling pattern of brain tissue.",
      "The swirl sign is caused by the movement of blood in the affected area of the brain due to the hemorrhage.",
      "It is used to help identify the location and extent of the hemorrhage and monitor its progression.",
      "The swirl sign is not specific to ICH and can be seen in other conditions such as subarachnoid hemorrhage and cerebral edema."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The \"swirl\" sign does not refer to a spiral or swirling pattern of brain tissue, but rather to the presence of a heterogeneous area of low attenuation within a hematoma on a CT scan, indicative of active bleeding within the brain.\n3. FALSE [correction]: The swirl sign is caused not by the movement of blood but by the mix of different densities within the hematoma, often indicating ongoing bleeding or rebleeding in the context of ICH.\n4. TRUE\n5. FALSE [correction]: The swirl sign is relatively specific to intracerebral hemorrhage and is not typically associated with other conditions like subarachnoid hemorrhage or cerebral edema, where different imaging features would be observed.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Arabidopsis ROF1 (RNA polymerase II-associated factor 1) expression is induced by various environmental and developmental signals, including:\n1. Light: ROF1 is light-induced and plays a role in the regulation of light-responsive genes.\n2. Temperature: ROF1 expression is temperature-sensitive and is involved in the regulation of cold-inducible genes.\n3. Water availability: ROF1 is involved in the regulation of drought-responsive genes.\n4. Hormones: ROF1 is involved in the regulation of abscisic acid (ABA) and ethylene signaling.\n5. Defense against pathogens: ROF1 is involved in the regulation of pathogen-responsive genes, such as those involved in the defense against bacterial and fungal infections.\n6. Developmental processes: ROF1 is involved in the regulation of genes involved in various developmental processes, such as flower development and leaf morphogenesis.\n7. Nutrient availability: ROF1 is involved in the regulation of genes involved in the response to nutrient availability, such as nitrogen and phosphorus availability.\n8. Aging: ROF1 is involved in the regulation of genes involved in the aging process.\nPlease let me know if you need more information on any of these inducers.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by light.\n2. Temperature changes can induce the expression of Arabidopsis ROF1.\n3. Arabidopsis ROF1 is involved in the regulation of drought-responsive genes, implying its expression is induced by water availability.\n4. The regulation of abscisic acid (ABA) and ethylene signaling in Arabidopsis involves ROF1 expression.\n5. Arabidopsis ROF1 expression is related to the defense against bacterial and fungal infections, indicating its involvement in pathogen response.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by light.",
      "Temperature changes can induce the expression of Arabidopsis ROF1.",
      "Arabidopsis ROF1 is involved in the regulation of drought-responsive genes, implying its expression is induced by water availability.",
      "The regulation of abscisic acid (ABA) and ethylene signaling in Arabidopsis involves ROF1 expression.",
      "Arabidopsis ROF1 expression is related to the defense against bacterial and fungal infections, indicating its involvement in pathogen response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Arabidopsis ROF1 expression is not induced by light; it is actually repressed by light and induced in dark conditions.\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "The most common cause of hereditary renal amyloidosis is the protein alpha-2-macroglobulin (A2M).",
    "llama-2-7b-chat-hf_fact_raw": "1. Alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis.",
    "llama-2-7b-chat-hf_fact": [
      "Alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Alpha-2-macroglobulin (A2M) is not the most common cause of hereditary renal amyloidosis. The most common form of hereditary renal amyloidosis is attributed to mutations in the gene encoding for transthyretin (TTR).",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed using various proteomic techniques such as two-dimensional gel electrophoresis (2DGE), mass spectrometry (MS), and label-free quantification. These studies have identified thousands of proteins that are present in the hippocampus and have provided insights into the molecular mechanisms underlying various hippocampal functions, including learning and memory, neurotransmission, and synaptic plasticity.\nSome of the key findings from these studies include:\n1. The hippocampus contains a large number of proteins involved in synaptic transmission and plasticity, such as N-methyl-D-aspartate (NMDA) receptors, AMPA receptors, and glutamate decarboxylase.\n2. The hippocampus also contains a variety of proteins involved in neuroprotection and neuronal survival, such as brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and the neuroprotective protein, neuronal pentraxin 1 (Nptx1).\n3. The hippocampus is rich in proteins involved in the regulation of gene expression, including transcription factors, chromatin remodeling complexes, and histone-modifying enzymes.\n4. The hippocampus contains proteins involved in the regulation of inflammation and immune response, such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α).\n5. The hippocampus is also rich in proteins involved in the regulation of energy metabolism, including proteins involved in glycolysis, the citric acid cycle, and oxidative phosphorylation.\nThese studies have provided a comprehensive view of the proteins present in the hippocampus and have identified many potential targets for the development of new therapeutic strategies for the treatment of hippocampal-related disorders, such as Alzheimer's disease and epilepsy.",
    "llama-2-7b-chat-hf_fact_raw": "1. Various proteomic techniques, including two-dimensional gel electrophoresis (2DGE), mass spectrometry (MS), and label-free quantification, have been used to analyze the proteome of the mouse hippocampus.\n2. These proteomic studies have identified thousands of proteins present in the mouse hippocampus.\n3. Proteins involved in synaptic transmission and plasticity, such as N-methyl-D-aspartate (NMDA) receptors and AMPA receptors, are present in the mouse hippocampus.\n4. The mouse hippocampus contains proteins associated with neuroprotection and neuronal survival, such as brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3).\n5. Proteins involved in the regulation of energy metabolism, including those in glycolysis and the citric acid cycle, are found in the mouse hippocampus.",
    "llama-2-7b-chat-hf_fact": [
      "Various proteomic techniques, including two-dimensional gel electrophoresis (2DGE), mass spectrometry (MS), and label-free quantification, have been used to analyze the proteome of the mouse hippocampus.",
      "These proteomic studies have identified thousands of proteins present in the mouse hippocampus.",
      "Proteins involved in synaptic transmission and plasticity, such as N-methyl-D-aspartate (NMDA) receptors and AMPA receptors, are present in the mouse hippocampus.",
      "The mouse hippocampus contains proteins associated with neuroprotection and neuronal survival, such as brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3).",
      "Proteins involved in the regulation of energy metabolism, including those in glycolysis and the citric acid cycle, are found in the mouse hippocampus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nProteomic techniques such as 2DGE, MS, and label-free quantification are commonly used methods for analyzing the proteome, and it is plausible that these methods have been applied to the study of the mouse hippocampus. Given the complexity of the mouse hippocampus and its functions, it is reasonable to expect that thousands of proteins could be identified. Some of these proteins would be related to synaptic transmission and plasticity—which NMDA and AMPA receptors are a part of. The presence of neuroprotective proteins like BDNF and NT-3 in the mouse hippocampus is also consistent with the known biology of this brain region. Lastly, the hippocampus requires energy to function, thus the presence of proteins involved in energy regulation, such as those in glycolysis and the citric acid cycle, is accurate. Without access to specific scientific literature or studies contradicting these statements, they are accepted as true based on existing knowledge of the mouse hippocampus and proteomics.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "No, mouse chromosomes are not acrocentric. Acrocentric chromosomes are characterized by a large centromere and a short arm (p arm), while the mouse chromosomes have a more typical karyotype with a smaller centromere and longer arms (q and r arms).",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are not acrocentric.\n2. Acrocentric chromosomes have a large centromere and a short p arm.\n3. Mouse chromosomes have a smaller centromere and longer arms.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are not acrocentric.",
      "Acrocentric chromosomes have a large centromere and a short p arm.",
      "Mouse chromosomes have a smaller centromere and longer arms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mouse chromosomes are indeed acrocentric.\n2. FALSE [correction]: Acrocentric chromosomes have a centromere near one end, creating a long q arm and a very short p arm, but not necessarily a large centromere.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "There are several siRNA-based drugs in clinical trials for the treatment of pancreatic cancer, including:\n1. ONX 0801: This is an investigational RNA interference (RNAi) therapeutic that targets and silences multiple cancer-promoting genes, including KRAS, in pancreatic cancer cells. ONX 0801 is being developed by Onxolate Therapeutics and is currently in Phase 2 clinical trials for the treatment of pancreatic cancer.\n2. RX-0201: This is an investigational RNAi therapeutic that targets and silences the KRAS gene in pancreatic cancer cells. RX-0201 is being developed by Rexahn Pharmaceuticals and is currently in Phase 2 clinical trials for the treatment of pancreatic cancer.\n3. AP-102: This is an investigational RNAi therapeutic that targets and silences the PD-L1 gene in pancreatic cancer cells. AP-102 is being developed by Apogenix and is currently in Phase 2 clinical trials for the treatment of pancreatic cancer.\nIt's important to note that these drugs are still in the experimental stage, and more research is needed to determine their safety and effectiveness in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. ONX 0801 is an investigational RNAi therapeutic targeting multiple cancer-promoting genes, including KRAS, for pancreatic cancer treatment.\n2. ONX 0801 is in Phase 2 clinical trials.\n3. RX-0201 is an investigational RNAi therapeutic that targets the KRAS gene in pancreatic cancer cells.\n4. RX-0201 is in Phase 2 clinical trials.\n5. AP-102 is an investigational RNAi therapeutic that targets the PD-L1 gene in pancreatic cancer cells and is in Phase 2 clinical trials.",
    "llama-2-7b-chat-hf_fact": [
      "ONX 0801 is an investigational RNAi therapeutic targeting multiple cancer-promoting genes, including KRAS, for pancreatic cancer treatment.",
      "ONX 0801 is in Phase 2 clinical trials.",
      "RX-0201 is an investigational RNAi therapeutic that targets the KRAS gene in pancreatic cancer cells.",
      "RX-0201 is in Phase 2 clinical trials.",
      "AP-102 is an investigational RNAi therapeutic that targets the PD-L1 gene in pancreatic cancer cells and is in Phase 2 clinical trials."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation: Without having specific and current information about investigational RNAi therapeutics including ONX 0801, RX-0201, and AP-102, as well as their respective trial phases, it is not possible to determine the truth of these statements. Such information is usually specific to ongoing medical research and would require up-to-date knowledge from clinical trial registries or recent scientific publications.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG (Hexamethylene Glycine) pore is a type of ion channel that is found in the nuclear envelope of eukaryotic cells. It is composed of a hexamethylene glycine (HMG) sequence of amino acids and forms a porous structure that spans the nuclear envelope, allowing the passage of certain ions and small molecules. The HPG pore plays a critical role in regulating the transport of molecules between the nucleus and cytoplasm, and is involved in various cellular processes such as gene expression, cell signaling, and cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore is found in the nuclear envelope of eukaryotic cells.\n2. It consists of a sequence of amino acids known as hexamethylene glycine (HMG).\n3. The HPG pore forms a structure that allows the passage of certain ions and small molecules through the nuclear envelope.\n4. The HPG pore is involved in the regulation of transport between the nucleus and cytoplasm.\n5. The HPG pore plays a role in cellular processes including gene expression, cell signaling, and cell division.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore is found in the nuclear envelope of eukaryotic cells.",
      "It consists of a sequence of amino acids known as hexamethylene glycine (HMG).",
      "The HPG pore forms a structure that allows the passage of certain ions and small molecules through the nuclear envelope.",
      "The HPG pore is involved in the regulation of transport between the nucleus and cytoplasm.",
      "The HPG pore plays a role in cellular processes including gene expression, cell signaling, and cell division."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The nuclear pore complex (NPC) is found in the nuclear envelope of eukaryotic cells, not the HPG pore.\n2. FALSE [correction]: Hexamethylene glycine (HMG) refers to a specific chemical compound and does not constitute a component of the nuclear pore complex. The nuclear pore complex is made up of multiple proteins known as nucleoporins.\n3. TRUE: The nuclear pore complex does form a structure that allows the passage of ions and small molecules, along with large molecules like RNA and proteins, through the nuclear envelope.\n4. TRUE: The nuclear pore complex is involved in the regulation of transport between the nucleus and the cytoplasm.\n5. TRUE: The nuclear pore complex plays a role in cellular processes including gene expression, cell signaling, and cell division by regulating the transport of molecules necessary for these processes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a research project aimed at sequencing and analyzing the genomes of 959 species of nematode worms, which are a group of microscopic worms that are found in a wide range of environments, including soil, plants, and animals. The initiative is led by the University of California, Berkeley and involves a collaboration of researchers from around the world.\nThe goal of the 959 Nematode Genomes initiative is to generate a comprehensive understanding of the evolution, diversity, and biology of nematodes, which are important model organisms in biology and medicine. By sequencing the genomes of such a large number of nematode species, researchers hope to identify new genes and genetic pathways that are involved in a wide range of biological processes, including development, reproduction, and disease resistance.\nThe initiative is also focused on developing new computational tools and methods for analyzing large-scale genomic data, which will be useful for analyzing the genomes of other organisms as well.\nOverall, the 959 Nematode Genomes initiative is a major undertaking that will provide new insights into the biology of nematodes and will have important implications for fields such as agriculture, medicine, and evolutionary biology.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematode worms.\n2. The initiative is led by the University of California, Berkeley.\n3. The project involves a collaboration of researchers from around the world.\n4. One goal of the project is to understand the evolution, diversity, and biology of nematodes.\n5. The initiative is developing new computational tools and methods for analyzing large-scale genomic data.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematode worms.",
      "The initiative is led by the University of California, Berkeley.",
      "The project involves a collaboration of researchers from around the world.",
      "One goal of the project is to understand the evolution, diversity, and biology of nematodes.",
      "The initiative is developing new computational tools and methods for analyzing large-scale genomic data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN (without specific information regarding the initiative's leadership; such initiatives may be led or collaborated on by multiple institutions or organizations)\n3. TRUE (such initiatives usually involve international collaboration)\n4. TRUE (genome projects often aim to understand evolution, diversity, and biology of the organisms they study)\n5. TRUE (genome initiatives typically involve the development of new computational tools for managing and analyzing large-scale genomic data)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data, including:\n1. NIPTkit: This package provides a comprehensive set of tools for the analysis of NIPT data, including quality control, sample classification, and variant calling.\n2. PrenatalTest: This package is specifically designed for the analysis of NIPT data and provides functions for data cleaning, filtering, and visualization.\n3. Prenatals: This package provides a set of functions for the analysis of NIPT data, including sample classification, variant calling, and risk assessment.\n4. NIPT-Analysis: This package provides a comprehensive set of tools for the analysis of NIPT data, including quality control, sample classification, and variant calling.\n5. PrenatalGenetics: This package provides a set of functions for the analysis of NIPT data, including sample classification, variant calling, and risk assessment.\n6. NIPT-Tools: This package provides a set of functions for the analysis of NIPT data, including quality control, sample classification, and variant calling.\n7. PrenatalTesting: This package provides a set of functions for the analysis of NIPT data, including sample classification, variant calling, and risk assessment.\n8. NIPT-Workflow: This package provides a set of functions for the analysis of NIPT data, including quality control, sample classification, and variant calling.\n9. Prenatals-pipeline: This package provides a set of functions for the analysis of NIPT data, including sample classification, variant calling, and risk assessment.\n10. NIPT-Analysis-pipeline: This package provides a set of functions for the analysis of NIPT data, including quality control, sample classification, and variant calling.\nPlease note that the availability and functionality of these packages may change over time, and it is recommended to consult the documentation and the authors of the packages for the most up-to-date information.",
    "llama-2-7b-chat-hf_fact_raw": "1. NIPTkit is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. PrenatalTest is an R package designed specifically for analysis of NIPT data.\n3. NIPT-Analysis is an R package that offers tools for NIPT data analysis.\n4. PrenatalGenetics is an R package that provides functions for NIPT data analysis.\n5. NIPT-Tools is an R package that includes functions for analyzing NIPT data.",
    "llama-2-7b-chat-hf_fact": [
      "NIPTkit is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "PrenatalTest is an R package designed specifically for analysis of NIPT data.",
      "NIPT-Analysis is an R package that offers tools for NIPT data analysis.",
      "PrenatalGenetics is an R package that provides functions for NIPT data analysis.",
      "NIPT-Tools is an R package that includes functions for analyzing NIPT data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nSince the authenticity of R package names such as PrenatalTest, NIPT-Analysis, PrenatalGenetics, and NIPT-Tools cannot be determined without additional context or verification from a reliable source such as CRAN (Comprehensive R Archive Network) or GitHub, the statements regarding these packages are unknown. The statement about NIPTkit is true provided there is a documented R package named NIPTkit developed for NIPT data analysis. Without specific evidence of the existence of the other R packages mentioned, we cannot determine the truthfulness of the statements about them.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome is a rare genetic disorder characterized by a variety of symptoms affecting the brain and nervous system. It is caused by mutations in the ACHENBACH gene, which is located on chromosome 16. The symptoms of Achenbach's syndrome can vary in severity and may include:\n1. Intellectual disability: Individuals with Achenbach's syndrome often have mild to moderate intellectual disability, which can range from mild cognitive impairment to more severe cognitive deficits.\n2. Autism spectrum disorder: Many individuals with Achenbach's syndrome have symptoms of autism spectrum disorder (ASD), such as difficulty with social interactions, communication, and repetitive behaviors.\n3. Seizures: Achenbach's syndrome can cause seizures, which can range from mild to severe and may be a sign of the disorder.\n4. Cerebellar ataxia: The cerebellum is a part of the brain that plays a role in coordination, balance, and movement. Individuals with Achenbach's syndrome may experience cerebellar ataxia, which can cause problems with coordination, balance, and movement.\n5. Spasticity: Spasticity is a condition characterized by stiffness and rigidity of the muscles, which can make movement difficult. Individuals with Achenbach's syndrome may experience spasticity, particularly in the legs and lower back.\n6. Scoliosis: Achenbach's syndrome can cause scoliosis, which is a curvature of the spine.\n7. Vision problems: Some individuals with Achenbach's syndrome may experience vision problems, such as blurred vision, double vision, or difficulty with depth perception.\n8. Hearing loss: Hearing loss is a common feature of Achenbach's syndrome, and can range from mild to severe.\n9. Sleep disturbances: Individuals with Achenbach's syndrome may experience sleep disturbances, such as insomnia or difficulty falling asleep.\n10. Other features: Achenbach's syndrome can also cause a range of other symptoms, including delayed",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is a rare genetic disorder.\n2. It is caused by mutations in the ACHENBACH gene.\n3. The ACHENBACH gene is located on chromosome 16.\n4. Individuals with Achenbach's syndrome often have symptoms of autism spectrum disorder.\n5. Seizures can be a symptom of Achenbach's syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is a rare genetic disorder.",
      "It is caused by mutations in the ACHENBACH gene.",
      "The ACHENBACH gene is located on chromosome 16.",
      "Individuals with Achenbach's syndrome often have symptoms of autism spectrum disorder.",
      "Seizures can be a symptom of Achenbach's syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is not a genetic disorder; it is a condition involving spontaneous bruising, primarily of the hands.\n2. FALSE [correction]: Achenbach's syndrome is not caused by mutations in a gene called ACHENBACH; the cause of the syndrome is not well understood.\n3. UNKNOWN: Since Achenbach's syndrome is not caused by a gene called ACHENBACH, there’s no information on its location on a chromosome.\n4. UNKNOWN: There is no well-established link between Achenbach's syndrome and autism spectrum disorders. Achenbach's syndrome primarily involves bruising without other systematically identified symptoms like those of autism spectrum disorder.\n5. UNKNOWN: Typically, Achenbach's syndrome is characterized by bruising, and seizures are not a commonly reported symptom. However, without more specific information, it's not possible to definitively include or exclude seizures as a symptom.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "There are several algorithms used for the detection of long repeat expansions in genomic DNA, including:\n1. RepeatMasker: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repetitive elements in a genome.\n2. GCG-PSI-BLAST: This algorithm uses a modified version of the BLAST algorithm to identify repetitive elements in a genome by comparing the query sequence to a database of known repetitive elements.\n3. LTR-REPEAT: This algorithm uses a combination of sequence similarity and k-mer frequency to identify long repeat elements in a genome.\n4. GATK-REPEAT: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repetitive elements in a genome, and also includes a Bayesian framework for estimating the probability of each repeat being a true positive.\n5. REPEAT-FINDER: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repetitive elements in a genome, and also includes a feature for identifying the type of repeat (e.g. L1, Alu, etc.).\n6. Sscrooge: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repetitive elements in a genome, and also includes a feature for identifying the type of repeat (e.g. L1, Alu, etc.).\n7. RNA-seq based methods: Some methods use RNA-seq data to identify long repeat expansions by comparing the expression levels of genes in different samples.\n8. DeepSEA: This algorithm uses a combination of sequence similarity and k-mer frequency to identify repetitive elements in a genome, and also includes a feature for identifying the type of repeat (e.g. L1, Alu, etc.).\nPlease note that these are some of the commonly used algorithms, and there are many other methods available for detecting long repeat expansions. The choice of algorithm will depend on the specific research question, the type of data available, and the computational resources required.",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker is an algorithm used to identify repetitive elements in a genome through sequence similarity and k-mer frequency.\n2. GCG-PSI-BLAST is an algorithm that uses a modified version of the BLAST algorithm to identify repetitive elements by comparing a query sequence to a database of known repeats.\n3. LTR-REPEAT is an algorithm designed to identify long repeat elements in a genome.\n4. GATK-REPEAT includes a Bayesian framework to estimate the probability of repeats being true positives.\n5. RNA-seq based methods can be used to identify long repeat expansions by comparing gene expression levels across different samples.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker is an algorithm used to identify repetitive elements in a genome through sequence similarity and k-mer frequency.",
      "GCG-PSI-BLAST is an algorithm that uses a modified version of the BLAST algorithm to identify repetitive elements by comparing a query sequence to a database of known repeats.",
      "LTR-REPEAT is an algorithm designed to identify long repeat elements in a genome.",
      "GATK-REPEAT includes a Bayesian framework to estimate the probability of repeats being true positives.",
      "RNA-seq based methods can be used to identify long repeat expansions by comparing gene expression levels across different samples."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GCG-PSI-BLAST is not an algorithm; rather, PSI-BLAST (Position-Specific Iterated BLAST) is an extension of the BLAST algorithm that allows for the comparison of a query sequence to a database of sequences with the goal of finding distant evolutionary relationships. GCG (Genetics Computer Group) refers to a package of bioinformatics programs.\n3. FALSE [correction]: The statement is vague and possibly incorrect because there is no well-known algorithm named LTR-REPEAT for identifying long repeat elements specifically. There are algorithms for identifying long terminal repeats (LTRs), such as LTR_FINDER or RepeatMasker, but LTR-REPEAT is not a recognized tool.\n4. FALSE [correction]: GATK-REPEAT does not exist as an algorithm; \"GATK\" refers to the Genome Analysis Toolkit, which is a software package for analyzing next-generation sequencing data, but not specifically for identifying repeats with a Bayesian framework. Corrections cannot fully be made due to a lack of detail for what \"GATK-REPEAT\" is intended to mean.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 has been shown to promote the growth and progression of certain types of brain tumors, including:\n* Medulloblastoma: A type of pediatric brain cancer that originates in the cerebellum.\n* Glioblastoma: The most common and aggressive type of adult brain cancer.\n* Astrocytoma: A type of brain cancer that originates in the star-shaped glial cells called astrocytes.\n* Oligodendroglioma: A type of brain cancer that originates in the oligodendrocytes, which are the cells that produce the fatty insulating substance called myelin in the brain.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 promotes the growth and progression of medulloblastoma, a pediatric brain cancer that originates in the cerebellum.\n2. Neuroligin-3 promotes the growth and progression of glioblastoma, which is the most common and aggressive type of adult brain cancer.\n3. Neuroligin-3 is associated with the promotion of astrocytoma, a brain cancer originating in the glial cells known as astrocytes.\n4. Neuroligin-3 is linked to the promotion of oligodendroglioma, a brain cancer that originates in the oligodendrocytes.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 promotes the growth and progression of medulloblastoma, a pediatric brain cancer that originates in the cerebellum.",
      "Neuroligin-3 promotes the growth and progression of glioblastoma, which is the most common and aggressive type of adult brain cancer.",
      "Neuroligin-3 is associated with the promotion of astrocytoma, a brain cancer originating in the glial cells known as astrocytes.",
      "Neuroligin-3 is linked to the promotion of oligodendroglioma, a brain cancer that originates in the oligodendrocytes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n\nRationale:\n1. The statement regarding the specifics of neuroligin-3's role in medulloblastoma would require specific scientific research to confirm or deny. Without the research source or current scientific consensus, I cannot accurately confirm or deny the statement.\n2. Some studies have shown that neuroligin-3 can promote the growth and progression of glioblastoma; therefore, this statement appears to be true based on specific scientific findings.\n3. Similar to statement 1, a claim on neuroligin-3's association with astrocytoma would require validation from scientific sources. As it stands, without additional information, the truth of this statement is unknown.\n4. As with statements 1 and 3, the link between neuroligin-3 and oligodendroglioma needs to be supported by specific scientific literature; hence, the accuracy of this statement is unknown without further context.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Gas vesicles in bacteria can vary in size, but they are typically around 10-100 nanometers (nm) in diameter. However, some gas vesicles can be larger, reaching sizes of up to 1-2 micrometers (μm) in some species.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles in bacteria can vary in size.\n2. Gas vesicles are typically around 10-100 nanometers in diameter.\n3. Some gas vesicles can reach sizes of up to 1-2 micrometers in some species.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles in bacteria can vary in size.",
      "Gas vesicles are typically around 10-100 nanometers in diameter.",
      "Some gas vesicles can reach sizes of up to 1-2 micrometers in some species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Gas vesicles are typically around 45-200 nanometers in diameter.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "BET (Bromodomain and Extra-Terminal) proteins are a family of proteins that play a crucial role in regulating gene expression by modifying chromatin structure. Here are some of the known BET proteins:\n1. BRD2 (Bromodomain-Containing Protein 2)\n2. BRD3 (Bromodomain-Containing Protein 3)\n3. BRDT (Bromodomain-Containing Protein T)\n4. BET1 (Bromodomain-Containing Protein 1)\n5. BETA (Bromodomain-Containing Protein Alpha)\n6. BRGA (Bromodomain-Containing Protein Gamma)\n7. BRGGA (Bromodomain-Containing Protein Gamma-Like)\n8. BRGKL (Bromodomain-Containing Protein Kinase-Like)\n9. BRGK (Bromodomain-Containing Protein Kinase)\n10. BETL (Bromodomain-Containing Protein Like)\nIt's worth noting that this list is not exhaustive and there may be additional BET proteins that have been identified in recent research.",
    "llama-2-7b-chat-hf_fact_raw": "1. BET proteins are known to regulate gene expression by modifying chromatin structure.\n2. BRD2 is a BET protein identified as Bromodomain-Containing Protein 2.\n3. BRD3 is a BET protein identified as Bromodomain-Containing Protein 3.\n4. BRDT is a BET protein identified as Bromodomain-Containing Protein T.\n5. The list of BET proteins is not exhaustive and additional BET proteins may have been identified in recent research.",
    "llama-2-7b-chat-hf_fact": [
      "BET proteins are known to regulate gene expression by modifying chromatin structure.",
      "BRD2 is a BET protein identified as Bromodomain-Containing Protein 2.",
      "BRD3 is a BET protein identified as Bromodomain-Containing Protein 3.",
      "BRDT is a BET protein identified as Bromodomain-Containing Protein T.",
      "The list of BET proteins is not exhaustive and additional BET proteins may have been identified in recent research."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: BRDT is a BET protein identified as Bromodomain, Testis-Specific.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "One algorithm that has been developed for prediction of protein subcellular localization using deep learning is the \"DeepLoc\" algorithm. It was proposed by the group of Dr. Arshad Desai at the University of California, San Diego, and was first published in 2018.\nDeepLoc uses a deep learning model to predict the subcellular localization of a protein based on its amino acid sequence. The model is trained on a large dataset of known protein localizations, and it learns to predict the localization of a new protein by analyzing its sequence features. The algorithm has been shown to be highly accurate and outperforms traditional machine learning methods in predicting protein localization.\nThe basic idea of DeepLoc is to use a deep neural network to learn a mapping between the amino acid sequence of a protein and its subcellular localization. The network takes the protein sequence as input and outputs a probability distribution over the different subcellular locations, such as the nucleus, cytoplasm, or membrane. The network is trained on a large dataset of protein sequences and their corresponding localizations, and it learns to recognize the features of the sequence that are important for predicting localization.\nDeepLoc has been shown to be effective in predicting the localization of proteins in various organisms, including bacteria, yeast, and humans. It has also been used to predict the localization of proteins in different cellular compartments, such as the endoplasmic reticulum and the mitochondria.\nOverall, DeepLoc is a powerful tool for predicting protein subcellular localization using deep learning, and it has the potential to be used in a wide range of applications, including drug discovery and personalized medicine.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"DeepLoc\" algorithm for prediction of protein subcellular localization using deep learning was proposed by the group of Dr. Arshad Desai at the University of California, San Diego.\n2. The DeepLoc algorithm was first published in 2018.\n3. DeepLoc uses a deep learning model to predict subcellular localization based on a protein's amino acid sequence.\n4. The model employed by DeepLoc is trained on a large dataset of known protein localizations.\n5. DeepLoc has been shown to outperform traditional machine learning methods in predicting protein localization.",
    "llama-2-7b-chat-hf_fact": [
      "The \"DeepLoc\" algorithm for prediction of protein subcellular localization using deep learning was proposed by the group of Dr. Arshad Desai at the University of California, San Diego.",
      "The DeepLoc algorithm was first published in 2018.",
      "DeepLoc uses a deep learning model to predict subcellular localization based on a protein's amino acid sequence.",
      "The model employed by DeepLoc is trained on a large dataset of known protein localizations.",
      "DeepLoc has been shown to outperform traditional machine learning methods in predicting protein localization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information about the creation of the \"DeepLoc\" algorithm and the group responsible for it, the truth of this statement cannot be determined.\n2. FALSE [correction]: The DeepLoc algorithm was first published in 2017, as detailed in the paper \"DeepLoc: Prediction of Protein Subcellular Localization Using Deep Learning\" by Almagro Armenteros et al.\n3. TRUE: The DeepLoc algorithm indeed uses a deep learning model to predict the subcellular localization of proteins based on their amino acid sequences.\n4. TRUE: Machine learning models, including deep learning models like DeepLoc, are generally trained on large datasets of known information, in this case, known protein localizations.\n5. TRUE: The publication introducing DeepLoc has reported that it outperforms traditional machine learning methods in the specific task of predicting protein subcellular localization.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "MULTOVL is a protein that is involved in the regulation of gene expression, specifically in the context of DNA damage response. It is a multi-functional protein that can act as a transcriptional coactivator, a DNA-binding protein, and a regulator of chromatin structure. MULTOVL is composed of multiple domains, including an N-terminal transcriptional activation domain, a central DNA-binding domain, and a C-terminal chromatin-modifying domain. It is involved in the regulation of various cellular processes, including cell cycle progression, DNA repair, and apoptosis, and is implicated in various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. MULTOVL is involved in the regulation of gene expression related to DNA damage response.\n2. MULTOVL acts as a transcriptional coactivator.\n3. MULTOVL has a DNA-binding function.\n4. MULTOVL is composed of multiple domains, such as an N-terminal transcriptional activation domain, a central DNA-binding domain, and a C-terminal chromatin-modifying domain.\n5. MULTOVL is implicated in various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "MULTOVL is involved in the regulation of gene expression related to DNA damage response.",
      "MULTOVL acts as a transcriptional coactivator.",
      "MULTOVL has a DNA-binding function.",
      "MULTOVL is composed of multiple domains, such as an N-terminal transcriptional activation domain, a central DNA-binding domain, and a C-terminal chromatin-modifying domain.",
      "MULTOVL is implicated in various diseases, including cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no known protein or gene named MULTOVL. The statements appear to be describing characteristics typically associated with certain transcription factors or proteins involved in gene regulation, but since MULTOVL is not recognized in the scientific community, the statement is false.\n2. FALSE [correction]: As there is no known protein or gene named MULTOVL, it does not act as a transcriptional coactivator.\n3. FALSE [correction]: Since MULTOVL is not a recognized protein or gene, it does not have a DNA-binding function.\n4. FALSE [correction]: MULTOVL, not being a known protein or gene, is not composed of any domains including an N-terminal transcriptional activation domain, a central DNA-binding domain, or a C-terminal chromatin-modifying domain.\n5. FALSE [correction]: Without being a recognized protein or gene, MULTOVL cannot be implicated in any diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Yes, GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment. Studies have shown that GDF15 levels are increased in response to metformin treatment in patients with type 2 diabetes, and that high levels of GDF15 are associated with improved insulin sensitivity and glucose metabolism. Therefore, measuring GDF15 levels in the blood may be a useful way to monitor the effectiveness of metformin treatment and to identify patients who are likely to benefit from this medication.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 stands for Growth Differentiation Factor 15.\n2. GDF15 levels are increased in response to metformin treatment in patients with type 2 diabetes.\n3. High levels of GDF15 are associated with improved insulin sensitivity and glucose metabolism.\n4. Measuring GDF15 levels in the blood may be used to monitor the effectiveness of metformin treatment.\n5. GDF15 can potentially identify patients who are likely to benefit from metformin medication.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 stands for Growth Differentiation Factor 15.",
      "GDF15 levels are increased in response to metformin treatment in patients with type 2 diabetes.",
      "High levels of GDF15 are associated with improved insulin sensitivity and glucose metabolism.",
      "Measuring GDF15 levels in the blood may be used to monitor the effectiveness of metformin treatment.",
      "GDF15 can potentially identify patients who are likely to benefit from metformin medication."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: High levels of GDF15 have been implicated in various pathological conditions, including inflammation and cancer, and it's not directly associated with improved insulin sensitivity and glucose metabolism.\n4. UNKNOWN: While there has been research suggesting that metformin treatment increases GDF15 levels, it is unclear without specific context if GDF15 levels are commonly used in clinical practice to monitor the effectiveness of metformin treatment for type 2 diabetes.\n5. UNKNOWN: As of my knowledge cutoff in 2023, it's unclear if GDF15 can consistently and accurately identify patients who are likely to benefit from metformin as this requires more research for validation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Yes, recursive splicing is more common in short introns. Recursive splicing, also known as intron circular splicing, occurs when the same intron is spliced back into the RNA transcript after it has been excised, resulting in the formation of a circular splicing pattern. This type of splicing is more likely to occur in short introns, as the distance between the intron and the exon is shorter, making it easier for the splicing machinery to recognize and re-splice the intron. In contrast, longer introns are less likely to undergo recursive splicing due to the longer distance between the intron and the exon, which makes it more difficult for the splicing machinery to recognize and re-splice the intron.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns compared to long introns.\n2. Recursive splicing, also known as intron circular splicing, involves the same intron being spliced back into the RNA transcript after excision.\n3. The likelihood of recursive splicing occurring in short introns is higher because the distance between the intron and the exon is shorter.\n4. This shorter distance makes it easier for the splicing machinery to recognize and re-splice the intron in short introns.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns compared to long introns.",
      "Recursive splicing, also known as intron circular splicing, involves the same intron being spliced back into the RNA transcript after excision.",
      "The likelihood of recursive splicing occurring in short introns is higher because the distance between the intron and the exon is shorter.",
      "This shorter distance makes it easier for the splicing machinery to recognize and re-splice the intron in short introns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Recursive splicing is more common in long introns compared to short introns.\n2. FALSE [correction]: Recursive splicing is not the same as intron circular splicing. Recursive splicing involves the use of a downstream 5' splice site within an intron to join to an upstream 3' splice site, effectively excising the intron in multiple steps.\n3. FALSE [correction]: The likelihood of recursive splicing occurring in long introns is higher because it helps in the removal of long introns that cannot be spliced in a single step.\n4. FALSE [correction]: The shorter distance in short introns does not make it easier for the splicing machinery to re-splice the intron; recursive splicing actually helps in the splicing of long introns where the distance might be too long for the conventional splicing machinery to handle efficiently in one event.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "TALE-iD is a method used for identifying the functional genomics of non-coding RNAs, specifically long non-coding RNAs (lncRNAs). It is a computational approach that uses TALE (transcriptional activator-like effector) nucleases to knockout or knockdown specific lncRNAs in cells and then measures the changes in gene expression to identify the functional effects of the lncRNA. The method allows researchers to identify the functional effects of lncRNAs on gene expression and cellular processes, and can be used to better understand the role of lncRNAs in various biological processes and diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. TALE-iD is used for identifying the functional genomics of non-coding RNAs, specifically long non-coding RNAs (lncRNAs).\n2. TALE-iD is a computational approach.\n3. TALE (transcriptional activator-like effector) nucleases are used in TALE-iD to knockout or knockdown specific lncRNAs in cells.\n4. TALE-iD measures changes in gene expression to identify the functional effects of the lncRNA.\n5. TALE-iD helps researchers understand the role of long non-coding RNAs in various biological processes and diseases.",
    "llama-2-7b-chat-hf_fact": [
      "TALE-iD is used for identifying the functional genomics of non-coding RNAs, specifically long non-coding RNAs (lncRNAs).",
      "TALE-iD is a computational approach.",
      "TALE (transcriptional activator-like effector) nucleases are used in TALE-iD to knockout or knockdown specific lncRNAs in cells.",
      "TALE-iD measures changes in gene expression to identify the functional effects of the lncRNA.",
      "TALE-iD helps researchers understand the role of long non-coding RNAs in various biological processes and diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: TALE-iD does not necessarily use TALE nucleases to knockout or knockdown specific lncRNAs; it's a computational method, and the acronym's meaning does not imply the use of TALE nucleases for such purposes within this context.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing, including:\n1. CL-Image: A Lisp library for image processing, providing functions for image manipulation, filtering, and analysis.\n2. ImageTk: A Lisp interface to the Tk image processing toolkit, providing a wide range of image processing functions.\n3. Lisp-Image: A Lisp library for image processing, providing functions for image manipulation, filtering, and analysis, as well as support for multiple image formats.\n4. LispyImage: A Lisp image processing framework that provides a simple and intuitive API for image manipulation and analysis.\n5. Image-Lisp: A Lisp library for image processing, providing functions for image manipulation, filtering, and analysis, as well as support for multiple image formats.\n6. Lisp-Image-Tools: A collection of Lisp functions for image processing, including filtering, resizing, and thresholding.\n7. Image-processing-Lisp: A Lisp library for image processing, providing a wide range of functions for image manipulation and analysis, as well as support for multiple image formats.\n8. Lisp-Image-Processing: A Lisp library for image processing, providing functions for image manipulation, filtering, and analysis, as well as support for multiple image formats.\n9. Image-Lisp-Toolkit: A Lisp toolkit for image processing, providing a set of functions for image manipulation, filtering, and analysis, as well as support for multiple image formats.\n10. Lisp-Image-Workbench: A Lisp environment for image processing, providing a comprehensive set of functions for image manipulation, filtering, and analysis, as well as support for multiple image formats.\nPlease note that this is not an exhaustive list and there may be other Lisp frameworks available for image processing.",
    "llama-2-7b-chat-hf_fact_raw": "1. CL-Image is a Lisp library designed for image processing tasks.\n2. ImageTk is a Lisp interface to the Tk image processing toolkit.\n3. Lisp-Image-Tools is a collection of Lisp functions specifically created for image processing.\n4. Image-processing-Lisp is a Lisp library that supports a wide range of image formats for processing.\n5. Lisp-Image-Workbench is a Lisp environment that offers a comprehensive set of functions for image manipulation and analysis.",
    "llama-2-7b-chat-hf_fact": [
      "CL-Image is a Lisp library designed for image processing tasks.",
      "ImageTk is a Lisp interface to the Tk image processing toolkit.",
      "Lisp-Image-Tools is a collection of Lisp functions specifically created for image processing.",
      "Image-processing-Lisp is a Lisp library that supports a wide range of image formats for processing.",
      "Lisp-Image-Workbench is a Lisp environment that offers a comprehensive set of functions for image manipulation and analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: ImageTk is a Python module that provides a Tkinter-compatible photo image object, not a Lisp interface.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nUnfortunately, without specific knowledge or information about the Lisp libraries or tools mentioned, it is not possible to confidently verify the accuracy of statements 1, 3, 4, and 5. They could be real Lisp libraries or made-up names. The verification would require access to a repository of Lisp libraries or documentation to confirm their existence and purpose.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "The number of genes in Saccharomyces cerevisiae (baker's yeast) that are the result of an ancient whole genome duplication is estimated to be around 100-200. This is a result of a single whole genome duplication event that occurred in the yeast lineage around 1,000-2,000 million years ago. This event, known as the \"yeast whole genome duplication\" (WGD), resulted in the duplication of approximately 50-60% of the yeast genome, including many genes involved in various cellular processes. Since then, there have been multiple rounds of gene loss and gene family expansion, leading to the current gene content of the yeast genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. An estimated 100-200 genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.\n2. The whole genome duplication event in the yeast lineage happened around 1,000-2,000 million years ago.\n3. Approximately 50-60% of the Saccharomyces cerevisiae genome was duplicated during the yeast whole genome duplication event.",
    "llama-2-7b-chat-hf_fact": [
      "An estimated 100-200 genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.",
      "The whole genome duplication event in the yeast lineage happened around 1,000-2,000 million years ago.",
      "Approximately 50-60% of the Saccharomyces cerevisiae genome was duplicated during the yeast whole genome duplication event."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The whole genome duplication event in the yeast lineage happened around 100-150 million years ago.\n3. FALSE [correction]: Approximately 90% or more of the Saccharomyces cerevisiae genome was initially duplicated during the yeast whole genome duplication event, though not all of these duplications have been retained.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor β (Esrrb) is a nuclear receptor that binds to the complex formed by the estrogen response element (EREs) and the DNA. EREs are located in the promoter region of target genes and are recognized by Esrrb, leading to the regulation of gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor β (Esrrb) is a nuclear receptor.\n2. Esrrb binds to the complex formed by the estrogen response element (EREs) and DNA.\n3. The estrogen response elements (EREs) are located in the promoter region of target genes.\n4. Esrrb's binding to EREs leads to the regulation of gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor β (Esrrb) is a nuclear receptor.",
      "Esrrb binds to the complex formed by the estrogen response element (EREs) and DNA.",
      "The estrogen response elements (EREs) are located in the promoter region of target genes.",
      "Esrrb's binding to EREs leads to the regulation of gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Estrogen-related receptor β (Esrrb) does not bind to estrogens or the estrogen response element (EREs) but to other response elements in DNA.\n3. TRUE\n4. FALSE [correction]: While Esrrb does regulate gene expression, it does not bind to estrogen response elements (EREs); instead, it binds to other response elements in DNA.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 is a zinc finger CCHC-type histone triad-containing protein that plays a role in regulating gene expression by modulating the structure of chromatin, the complex of DNA and proteins that make up the chromosomes. Specifically, ZCCHC17 has been shown to be involved in the regulation of stem cell pluripotency, cell fate determination, and cell proliferation, and is implicated in various diseases such as cancer and developmental disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is a zinc finger CCHC-type histone triad-containing protein.\n2. ZCCHC17 plays a role in regulating gene expression by modulating chromatin structure.\n3. ZCCHC17 has been shown to be involved in the regulation of stem cell pluripotency.\n4. ZCCHC17 is implicated in various diseases, including cancer and developmental disorders.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is a zinc finger CCHC-type histone triad-containing protein.",
      "ZCCHC17 plays a role in regulating gene expression by modulating chromatin structure.",
      "ZCCHC17 has been shown to be involved in the regulation of stem cell pluripotency.",
      "ZCCHC17 is implicated in various diseases, including cancer and developmental disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n\nThe first two statements are true based on the conventional knowledge about proteins with zinc finger domains, as they often have roles in DNA binding and regulating gene expression by interacting with chromatin. However, without specific reference to scientific research, statements 3 and 4 about the involvement of ZCCHC17 in stem cell pluripotency or diseases such as cancer and developmental disorders are difficult to confirm and thus are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is composed of several proteins in human cells. The main proteins that form the NPC are:\n1. Nucleoporin 1 (NUP1): Also known as NPM1, this protein is the most abundant component of the NPC and forms the central channel of the structure.\n2. Nucleoporin 2 (NUP2): Also known as NP2, this protein is involved in the formation of the nuclear pore basket and is essential for nuclear transport.\n3. Nucleoporin 3 (NUP3): Also known as NP3, this protein is involved in the formation of the nuclear pore basket and is essential for nuclear transport.\n4. Nucleoporin 4 (NUP4): Also known as NP4, this protein is involved in the formation of the nuclear pore basket and is essential for nuclear transport.\n5. Nucleoporin 5 (NUP5): Also known as NP5, this protein is involved in the formation of the nuclear pore basket and is essential for nuclear transport.\n6. Nucleoporin 6 (NUP6): Also known as NP6, this protein is involved in the formation of the nuclear pore basket and is essential for nuclear transport.\n7. Nucleoporin 7 (NUP7): Also known as NP7, this protein is involved in the formation of the nuclear pore basket and is essential for nuclear transport.\n8. Nucleoporin 8 (NUP8): Also known as NP8, this protein is involved in the formation of the nuclear pore basket and is essential for nuclear transport.\n9. Nucleoporin 9 (NUP9): Also known as NP9, this protein is involved in the formation of the nuclear pore basket and is essential for nuclear transport.\n10. Nucleoporin 10 (NUP10): Also known as NP10, this protein is involved in the formation of the nuclear pore basket and is essential for nuclear transport.\nThese proteins work together to form a complex that spans the nuclear envelope and regulates the transport of molecules between the nucleus and the cytoplasm.",
    "llama-2-7b-chat-hf_fact_raw": "1. The nuclear pore complex (NPC) is composed of several proteins in human cells.\n2. Nucleoporin 1 (NUP1), also known as NPM1, forms the central channel of the NPC structure.\n3. Nucleoporins, including NUP2 and NUP3, are involved in the formation of the nuclear pore basket and are essential for nuclear transport.\n4. The nuclear pore complex regulates the transport of molecules between the nucleus and the cytoplasm.\n5. The NPC spans the nuclear envelope in human cells.",
    "llama-2-7b-chat-hf_fact": [
      "The nuclear pore complex (NPC) is composed of several proteins in human cells.",
      "Nucleoporin 1 (NUP1), also known as NPM1, forms the central channel of the NPC structure.",
      "Nucleoporins, including NUP2 and NUP3, are involved in the formation of the nuclear pore basket and are essential for nuclear transport.",
      "The nuclear pore complex regulates the transport of molecules between the nucleus and the cytoplasm.",
      "The NPC spans the nuclear envelope in human cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Nucleoporin 1 (NUP1) is a protein component associated with the nuclear pore complex, but NPM1 (nucleophosmin) is not equivalent to NUP1 and does not form the central channel of the NPC structure. NUP62 is known to be one of the proteins forming the central channel.\n3. TRUE - Nucleoporins, including NUP153 and NUP50 (rather than NUP2 and NUP3), contribute to the nuclear basket structure and are involved in nuclear transport. However, NUP2 also plays roles in nuclear-cytoplasmic transport, although not necessarily in forming the nuclear basket.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a topoisomerase II inhibitor. Specifically, it is a topotecan analog that selectively binds to and inhibits the activity of topoisomerase II alpha (Topo IIα), which is involved in DNA replication and repair.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase II inhibitor.\n2. Gepotidacin selectively binds to and inhibits the activity of topoisomerase II alpha (Topo IIα).\n3. Topoisomerase II alpha (Topo IIα) is involved in DNA replication and repair.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase II inhibitor.",
      "Gepotidacin selectively binds to and inhibits the activity of topoisomerase II alpha (Topo IIα).",
      "Topoisomerase II alpha (Topo IIα) is involved in DNA replication and repair."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is not a topoisomerase II inhibitor; it is a novel antibiotic that inhibits bacterial topoisomerase II enzymes, specifically DNA gyrase and topoisomerase IV.\n2. FALSE [correction]: Gepotidacin does not selectively bind to and inhibit the activity of topoisomerase II alpha (Topo IIα) in humans; it targets bacterial enzymes DNA gyrase and topoisomerase IV.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW (Spatially-aware Processing Workbench) is a software platform designed to enable the development and execution of spatially-aware applications in various domains, including biology, physics, and computer vision. It provides a set of tools and libraries for processing and analyzing spatial data, as well as a programming environment for creating and executing spatially-aware algorithms.\nHere are some key features of Canvas SPW:\n1. Spatial Data Processing: Canvas SPW provides a range of tools for processing and analyzing spatial data, including filtering, transforming, and visualizing data.\n2. Spatial Operations: The platform includes a set of spatial operations, such as distance calculations, spatial matching, and spatial join, that can be used to perform complex spatial analysis.\n3. Programming Environment: Canvas SPW provides a programming environment for creating and executing spatially-aware algorithms. Developers can write code in a variety of programming languages, including Python, Java, and C++, and use the platform's spatial libraries to perform spatial operations.\n4. Integration with Other Tools: Canvas SPW can be integrated with other tools and platforms, such as Jupyter Notebook, Matplotlib, and R, allowing developers to use the platform in conjunction with their existing workflows.\n5. Scalability: Canvas SPW is designed to be scalable, allowing it to handle large datasets and complex spatial analysis tasks.\n6. Flexibility: The platform provides a flexible and modular architecture, allowing developers to customize the platform to meet their specific needs.\n7. Documentation: Canvas SPW provides detailed documentation and tutorials, making it easy for developers to get started with the platform and understand its capabilities.\nIn summary, Canvas SPW is a powerful platform for developing and executing spatially-aware applications in a variety of domains. Its ability to process and analyze spatial data, combined with its programming environment and integration with other tools, make it a valuable tool for researchers and developers working in the field of spatial analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is a software platform designed for developing and executing spatially-aware applications in domains like biology, physics, and computer vision.\n2. The platform offers tools for processing and analyzing spatial data, including functions like filtering, transforming, and data visualization.\n3. Canvas SPW provides a programming environment that supports writing code in Python, Java, and C++.\n4. It allows integration with tools such as Jupyter Notebook, Matplotlib, and R for enhanced workflow.\n5. Canvas SPW is built to be scalable to manage large datasets and complex spatial analysis tasks.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is a software platform designed for developing and executing spatially-aware applications in domains like biology, physics, and computer vision.",
      "The platform offers tools for processing and analyzing spatial data, including functions like filtering, transforming, and data visualization.",
      "Canvas SPW provides a programming environment that supports writing code in Python, Java, and C++.",
      "It allows integration with tools such as Jupyter Notebook, Matplotlib, and R for enhanced workflow.",
      "Canvas SPW is built to be scalable to manage large datasets and complex spatial analysis tasks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific knowledge about \"Canvas SPW\" or a reliable source of information to verify these statements, I am not able to determine their truthfulness. Therefore, the response to all the statements is \"UNKNOWN\".",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "STING (Stimulator of Interferon Genes) is a protein that plays a crucial role in the innate immune response to viral infections. STING agonists are substances that activate the STING protein and trigger an immune response. Here are some examples of STING agonists:\n1. CpG DNA: CpG dinucleotides are found in the genomes of many bacteria and viruses, and they are recognized by STING as a sign of infection. CpG DNA is a common STING agonist used in cancer immunotherapy.\n2. Poly(dA:dT) oligonucleotides: Poly(dA:dT) oligonucleotides are synthetic oligonucleotides that contain repeating sequences of adenine and thymine. They are also recognized by STING and can stimulate an immune response.\n3. Small molecule agonists: Several small molecules have been identified as STING agonists, including the drugs cyclic dinucleotides (CDNs) and imidazoquinoline derivatives. These molecules can activate STING and stimulate an immune response.\n4. Viral proteins: Some viral proteins, such as the poxvirus protein K3L, can inhibit the activity of STING and prevent it from stimulating an immune response.\n5. DNA damage: DNA damage can also activate STING and stimulate an immune response. This is because STING is involved in the response to DNA damage, and it can recognize and respond to breaks in DNA.\nIt's worth noting that STING agonists can have different effects on different cell types and tissues, and their effects can vary depending on the context in which they are used.",
    "llama-2-7b-chat-hf_fact_raw": "1. CpG DNA is recognized by the STING protein as a sign of infection and is used as a STING agonist in cancer immunotherapy.\n2. Poly(dA:dT) oligonucleotides are synthetic oligonucleotides that can stimulate an immune response by activating STING.\n3. Small molecules, including cyclic dinucleotides and imidazoquinoline derivatives, have been identified as STING agonists.\n4. The poxvirus protein K3L can inhibit the activity of STING.\n5. DNA damage can activate STING and stimulate an immune response.",
    "llama-2-7b-chat-hf_fact": [
      "CpG DNA is recognized by the STING protein as a sign of infection and is used as a STING agonist in cancer immunotherapy.",
      "Poly(dA:dT) oligonucleotides are synthetic oligonucleotides that can stimulate an immune response by activating STING.",
      "Small molecules, including cyclic dinucleotides and imidazoquinoline derivatives, have been identified as STING agonists.",
      "The poxvirus protein K3L can inhibit the activity of STING.",
      "DNA damage can activate STING and stimulate an immune response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: CpG DNA is recognized by Toll-like receptor 9 (TLR9), not STING. CpG oligonucleotides can be used as adjuvants in cancer immunotherapy because of their ability to stimulate TLR9.\n2. FALSE [correction]: Poly(dA:dT) oligonucleotides do not activate STING directly. They are sensed by other DNA sensors which can activate the STING pathway indirectly, but STING itself is best known for binding cyclic dinucleotides.\n3. TRUE\n4. FALSE [correction]: The poxvirus protein K3L does not inhibit the activity of STING; it is an inhibitor of the host protein kinase R (PKR). Another poxvirus protein, A46, which acts to inhibit Toll-like and IL-1 receptors, could be confused with affecting STING among the web of interactions in the immune response.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Slicing-based Chromatin Accessibility and Genome Editing) is a genome engineering technology that combines two main components:\n1. Slicing: SLIC-CAGE uses the CRISPR-Cas13 system to cleave specific genomic regions, creating a \"sliced\" chromatin structure. This slicing event is specific to the targeted genomic region and does not affect the rest of the genome.\n2. CAGE: After slicing, the SLIC-CAGE system introduces a CAGE (Chromatin Accessibility and Genome Editing) domain, which is a specific DNA-binding protein that recognizes and binds to the sliced chromatin. This binding event opens up the chromatin structure, allowing for the recruitment of other proteins that can modify or repair the DNA.\nBy combining these two components, SLIC-CAGE enables precise and efficient editing of specific genomic regions, with minimal off-target effects. This technology has the potential to revolutionize the field of genome engineering and has already shown promising results in various applications, including gene therapy and gene editing.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE uses the CRISPR-Cas13 system for cleaving specific genomic regions.\n2. The CRISPR-Cas13 system in SLIC-CAGE specifically targets and does not affect the rest of the genome.\n3. A CAGE domain in SLIC-CAGE is a specific DNA-binding protein.\n4. The CAGE domain recognizes and binds specifically to the sliced chromatin.\n5. SLIC-CAGE is a technology designed for precise and efficient editing of specific genomic regions.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE uses the CRISPR-Cas13 system for cleaving specific genomic regions.",
      "The CRISPR-Cas13 system in SLIC-CAGE specifically targets and does not affect the rest of the genome.",
      "A CAGE domain in SLIC-CAGE is a specific DNA-binding protein.",
      "The CAGE domain recognizes and binds specifically to the sliced chromatin.",
      "SLIC-CAGE is a technology designed for precise and efficient editing of specific genomic regions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The term \"CAGE\" in the context of SLIC-CAGE is more commonly associated with 'Cleavage Under Targets and Release Using Nuclease (CUT&RUN)' technology and is not a specific DNA-binding protein.\n4. FALSE [correction]: Although the term \"CAGE domain\" is not accurate, in SLIC-CAGE, the targeting mechanism involves the guide RNA directing the Cas13 to specific RNA molecules, not chromatin which is associated with DNA.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (LEM-motif protein 3) is a protein that plays several roles in the cell, including:\n1. Chromatin remodeling: LEM-3 is involved in the remodeling of chromatin structure, particularly in the regulation of gene expression during cell differentiation and development.\n2. Transcriptional elongation: LEM-3 interacts with the transcriptional elongation complex and regulates the processivity of RNA polymerase II.\n3. DNA repair: LEM-3 is involved in the repair of DNA double-strand breaks, particularly through its interaction with the DNA repair protein, 53BP1.\n4. Cell cycle regulation: LEM-3 regulates the G1/S checkpoint and the progression of the cell cycle, particularly through its interaction with the retinoblastoma protein (Rb).\n5. Apoptosis: LEM-3 has been shown to promote apoptosis (programmed cell death) in response to DNA damage and other stimuli.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is involved in the remodeling of chromatin structure.\n2. LEM-3 interacts with the transcriptional elongation complex to regulate RNA polymerase II.\n3. LEM-3 is involved in the repair of DNA double-strand breaks through interaction with the DNA repair protein, 53BP1.\n4. LEM-3 regulates the G1/S checkpoint in the cell cycle and the progression of the cell cycle through interaction with the retinoblastoma protein (Rb).\n5. LEM-3 promotes apoptosis in response to DNA damage and other stimuli.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is involved in the remodeling of chromatin structure.",
      "LEM-3 interacts with the transcriptional elongation complex to regulate RNA polymerase II.",
      "LEM-3 is involved in the repair of DNA double-strand breaks through interaction with the DNA repair protein, 53BP1.",
      "LEM-3 regulates the G1/S checkpoint in the cell cycle and the progression of the cell cycle through interaction with the retinoblastoma protein (Rb).",
      "LEM-3 promotes apoptosis in response to DNA damage and other stimuli."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: LEM-3, also known as LEM domain containing 3, has been implicated in chromatin organization processes, which can include remodeling of chromatin structure.\n2. UNKNOWN: The statement is highly specific and requires detailed knowledge of LEM-3 interactions. Without specific literature evidence, it's unclear whether LEM-3 interacts directly with the transcriptional elongation complex to regulate RNA polymerase II.\n3. TRUE: LEM-3 has been found to participate in DNA repair mechanisms, including the repair of DNA double-strand breaks, and interacts with various DNA repair proteins. However, the specific interaction with 53BP1 would need to be confirmed by the current literature as these interactions can be species and context-specific.\n4. UNKNOWN: The role of LEM-3 in regulating the G1/S checkpoint and interaction with retinoblastoma protein (Rb) is specific and requires detailed scientific evidence to confirm its validity.\n5. TRUE: Proteins involved in the response to DNA damage, like LEM-3, often play a role in promoting apoptosis to prevent the propagation of damaged DNA, although the exact mechanisms and stimuli may vary.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm happy to provide you with the releases of the tmVar tool:\n1. tmVar 1.0: This was the initial release of the tool, which provided a basic implementation of the variaent calling pipeline.\n2. tmVar 1.2: This release added support for multiple reference genomes and improved the accuracy of the variant calling process.\n3. tmVar 2.0: This major release introduced a new algorithm for calling variants that incorporated additional information about the genome and the sample being analyzed. This release also improved the speed and scalability of the tool.\n4. tmVar 2.1: This release added support for calling variants in non-coding regions of the genome and improved the accuracy of the variant calling process.\n5. tmVar 3.0: This major release introduced a new, more accurate variant calling algorithm that incorporated advanced methods for identifying and filtering variants. This release also improved the speed and scalability of the tool.\n6. tmVar 3.1: This release added support for calling variants in complex genomes and improved the accuracy of the variant calling process.\n7. tmVar 4.0: This major release introduced a new, more accurate variant calling algorithm that incorporated advanced methods for identifying and filtering variants. This release also improved the speed and scalability of the tool.\n8. tmVar 4.1: This release added support for calling variants in non-coding regions of the genome and improved the accuracy of the variant calling process.\n9. tmVar 5.0: This major release introduced a new, more accurate variant calling algorithm that incorporated advanced methods for identifying and filtering variants. This release also improved the speed and scalability of the tool.\n10. tmVar 5.1: This release added support for calling variants in complex genomes and improved the accuracy of the variant calling process.\nThese are the major releases of the tmVar tool, but there may be other updates and bug fixes that have been made to the tool over time.",
    "llama-2-7b-chat-hf_fact_raw": "1. tmVar 1.0 was the initial release of the tool.\n2. tmVar 1.2 added support for multiple reference genomes.\n3. tmVar 2.0 introduced a new algorithm for calling variants.\n4. tmVar 3.0 incorporated advanced methods for identifying and filtering variants.\n5. tmVar 4.0 and tmVar 5.0 each introduced a new, more accurate variant calling algorithm that improved the speed and scalability of the tool.",
    "llama-2-7b-chat-hf_fact": [
      "tmVar 1.0 was the initial release of the tool.",
      "tmVar 1.2 added support for multiple reference genomes.",
      "tmVar 2.0 introduced a new algorithm for calling variants.",
      "tmVar 3.0 incorporated advanced methods for identifying and filtering variants.",
      "tmVar 4.0 and tmVar 5.0 each introduced a new, more accurate variant calling algorithm that improved the speed and scalability of the tool."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Explanation]: Without specific knowledge about the version history and features of the tool tmVar, we cannot accurately determine the veracity of these statements. The statements would require verification against the release notes or documentation for tmVar, which are not provided here.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "There are several databases of somatic mutations in normal cells, including:\n1. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. TCGA has generated comprehensive datasets of somatic mutations in normal tissues, including those from the brain, breast, colon, lung, and other organs.\n2. The 1000 Genomes Project: The 1000 Genomes Project is an international collaboration that aimed to generate a detailed catalogue of genetic variation in the human population. The project included whole-genome sequencing of thousands of individuals, including samples from normal tissues.\n3. The ExAC (Expert Analysis of Genetic Variation) database: ExAC is a comprehensive database of genetic variation in the human population, including both common and rare variants. The database includes data from a variety of sources, including whole-genome sequencing, exome sequencing, and genotyping arrays.\n4. The GTEx (Genotype-Tissue Expression) database: GTEx is a database of genetic and gene expression data from a large number of human tissues, including normal tissues. The database includes whole-genome sequencing and gene expression data from over 500 individuals, as well as detailed information on the tissue sources and processing methods used.\n5. The Roadmap Epigenomics Project: The Roadmap Epigenomics Project is a large-scale effort to map the epigenetic landscape of the human genome. The project includes comprehensive datasets of DNA methylation and histone modification in a wide range of tissues, including normal tissues.\nThese databases provide valuable resources for understanding the somatic mutations that occur in normal cells and how they may contribute to the development of disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to catalogue genomic changes in cancer.\n2. The 1000 Genomes Project was an international collaboration that aimed to create a detailed catalogue of human genetic variation through whole-genome sequencing.\n3. The ExAC database is a comprehensive repository of genetic variation in the human population derived from whole-genome sequencing, exome sequencing, and genotyping arrays.\n4. The GTEx database contains genetic and gene expression data from a large number of human tissues, including data from over 500 individuals.\n5. The Roadmap Epigenomics Project aims to map the epigenetic landscape of the human genome, including DNA methylation and histone modification datasets for a variety of tissues.",
    "llama-2-7b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to catalogue genomic changes in cancer.",
      "The 1000 Genomes Project was an international collaboration that aimed to create a detailed catalogue of human genetic variation through whole-genome sequencing.",
      "The ExAC database is a comprehensive repository of genetic variation in the human population derived from whole-genome sequencing, exome sequencing, and genotyping arrays.",
      "The GTEx database contains genetic and gene expression data from a large number of human tissues, including data from over 500 individuals.",
      "The Roadmap Epigenomics Project aims to map the epigenetic landscape of the human genome, including DNA methylation and histone modification datasets for a variety of tissues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The ExAC (Exome Aggregation Consortium) database is primarily a repository of genetic variation from exome sequencing, not whole-genome sequencing or genotyping arrays.\n4. FALSE [correction]: While the GTEx (Genotype-Tissue Expression) database does contain genetic and gene expression data from a very large number of human tissues, the number of individuals included in the database exceeds 500, reaching into the thousands.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available that are implemented in Java. Here are a few examples:\n1. JGraphT: JGraphT is a Java library for graph theory that provides a simple and efficient way to create, manipulate, and analyze graphs. It supports a wide range of graph algorithms and is highly extensible.\n2. Graphiti: Graphiti is a Java library for graph theory that provides a simple and intuitive API for creating, manipulating, and visualizing graphs. It supports a wide range of graph algorithms and is highly customizable.\n3. Gephi: Gephi is a Java library for network data analysis that provides a powerful and flexible platform for working with large-scale graph data. It supports a wide range of graph algorithms and is highly extensible.\n4. Weka: Weka is a Java library for data mining that includes a number of graph-related tools and algorithms. It provides a simple and intuitive API for working with graph data and is highly extensible.\n5. GraphCrunch: GraphCrunch is a Java library for graph processing that provides a simple and efficient way to create, manipulate, and analyze graphs. It supports a wide range of graph algorithms and is highly extensible.\n6. JGraph: JGraph is a Java library for graph theory that provides a simple and efficient way to create, manipulate, and analyze graphs. It supports a wide range of graph algorithms and is highly extensible.\n7. GraphMol: GraphMol is a Java library for molecular graph theory that provides a simple and efficient way to create, manipulate, and analyze molecular graphs. It supports a wide range of graph algorithms and is highly extensible.\n8. JGrapht: JGrapht is a Java library for graph theory that provides a simple and efficient way to create, manipulate, and analyze graphs. It supports a wide range of graph algorithms and is highly extensible.\nThese libraries can be used for a wide range of applications, such as social network analysis, recommendation systems, fraud detection, and more.",
    "llama-2-7b-chat-hf_fact_raw": "1. JGraphT is a Java library for graph theory that provides capabilities for creating, manipulating, and analyzing graphs.\n2. Graphiti is a Java library that offers an API for creating, manipulating, and visualizing graphs.\n3. Gephi is a network data analysis Java library for working with large-scale graph data.\n4. Weka is a Java library for data mining that includes graph-related tools and algorithms.\n5. GraphCrunch is a Java library for graph processing that supports the creation, manipulation, and analysis of graphs.",
    "llama-2-7b-chat-hf_fact": [
      "JGraphT is a Java library for graph theory that provides capabilities for creating, manipulating, and analyzing graphs.",
      "Graphiti is a Java library that offers an API for creating, manipulating, and visualizing graphs.",
      "Gephi is a network data analysis Java library for working with large-scale graph data.",
      "Weka is a Java library for data mining that includes graph-related tools and algorithms.",
      "GraphCrunch is a Java library for graph processing that supports the creation, manipulation, and analysis of graphs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Gephi is an open-source network analysis and visualization software tool, not a Java library.\n4. TRUE\n5. FALSE [correction]: GraphCrunch is not specifically a Java library; it is a software tool for comparing graph data, not for general-purpose graph processing.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "The four advances integrated into the SHERLOCKv2 platform are:\n1. Single-molecule sensitivity: SHERLOCKv2 can detect single molecules of the target nucleic acid, significantly improving the sensitivity of the assay compared to previous versions.\n2. Multiplexing: SHERLOCKv2 allows for the detection of multiple targets in a single reaction, enabling the analysis of multiple genomic regions or the detection of multiple viruses or bacteria in a single assay.\n3. Portability: The SHERLOCKv2 platform is designed to be portable and easy to use, making it possible to perform the assay in a variety of settings, including in the field or in resource-limited environments.\n4. Speed: The SHERLOCKv2 platform can perform the assay in a matter of hours, rather than days or weeks, making it possible to quickly identify and respond to genomic threats.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 can detect single molecules of the target nucleic acid.\n2. SHERLOCKv2 allows for the detection of multiple targets in a single reaction.\n3. SHERLOCKv2 is designed to be portable.\n4. The SHERLOCKv2 platform can perform assays in a matter of hours.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 can detect single molecules of the target nucleic acid.",
      "SHERLOCKv2 allows for the detection of multiple targets in a single reaction.",
      "SHERLOCKv2 is designed to be portable.",
      "The SHERLOCKv2 platform can perform assays in a matter of hours."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nExplanation:\n1. SHERLOCK (Specific High Sensitivity Enzymatic Reporter unLOCKing) is a technology that can detect single molecules of the target nucleic acid, hence the statement is true.\n2. SHERLOCKv2, an updated version of the original technology, does allow for multiplex detection, which means it can detect multiple targets in a single reaction.\n3. One of the advantages of the SHERLOCK technology is its design for portability, enabling field-based or point-of-care diagnostics.\n4. SHERLOCK platforms, including versions like SHERLOCKv2, are able to perform assays relatively quickly, often within a few hours, which makes this statement true.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The Bartender algorithm is a heuristic algorithm used in bioinformatics to predict the secondary structure of RNA molecules. It was developed by David Baker and colleagues in 1994.\nThe algorithm works by considering the following factors:\n1. Base pairing: The algorithm uses a set of heuristics to predict the most stable base pairings between nucleotides in the RNA molecule.\n2. Hydrogen bonding: The algorithm takes into account the hydrogen bonding interactions between nucleotides, which can also influence the stability of the RNA structure.\n3. Stacking interactions: The algorithm considers the stacking interactions between the RNA molecule and the surrounding solvent, which can also affect the stability of the structure.\n4. Electrostatic interactions: The algorithm accounts for the electrostatic interactions between the RNA molecule and the surrounding solvent, which can also influence the stability of the structure.\n5. Solvation free energy: The algorithm calculates the solvation free energy of the RNA molecule, which can also affect the stability of the structure.\n6. RNA structure prediction: The algorithm uses a combination of these factors to predict the most stable secondary structure for the RNA molecule.\nThe Bartender algorithm is a simplified version of the more complex and computationally expensive Monte Carlo simulations used to model RNA structure. It is faster and more efficient than Monte Carlo simulations, making it a useful tool for large-scale RNA structure prediction. However, it is not as accurate as Monte Carlo simulations and may not capture all of the subtleties of RNA structure.\nIn summary, the Bartender algorithm is a heuristic algorithm used to predict the secondary structure of RNA molecules based on a set of heuristics that take into account base pairing, hydrogen bonding, stacking interactions, electrostatic interactions, solvation free energy, and RNA structure prediction. It is a useful tool for large-scale RNA structure prediction but may not be as accurate as more complex simulations.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender algorithm is used in bioinformatics to predict the secondary structure of RNA molecules.\n2. David Baker and colleagues developed the Bartender algorithm in 1994.\n3. The algorithm considers base pairing, hydrogen bonding, stacking interactions, electrostatic interactions, and solvation free energy to predict RNA structure.\n4. The Bartender algorithm is faster and more efficient but less accurate than Monte Carlo simulations for RNA structure prediction.\n5. It is used for large-scale RNA structure prediction.",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender algorithm is used in bioinformatics to predict the secondary structure of RNA molecules.",
      "David Baker and colleagues developed the Bartender algorithm in 1994.",
      "The algorithm considers base pairing, hydrogen bonding, stacking interactions, electrostatic interactions, and solvation free energy to predict RNA structure.",
      "The Bartender algorithm is faster and more efficient but less accurate than Monte Carlo simulations for RNA structure prediction.",
      "It is used for large-scale RNA structure prediction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Bartender algorithm is not used to predict the secondary structure of RNA molecules; it is actually a tool used for clustering barcoded reads from multiplexed DNA sequencing data.\n2. FALSE [correction]: The Bartender algorithm was not developed by David Baker and colleagues, nor was it developed in 1994. It was developed by different researchers and is not related to RNA structure prediction.\n3. FALSE [correction]: This statement is not applicable to the Bartender algorithm since it refers to RNA structure prediction characteristics, which is not the algorithm's purpose.\n4. FALSE [correction]: Since the Bartender algorithm is not used for RNA structure prediction, any comparison to Monte Carlo simulations in this context is not accurate.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "There are several web-based pedigree editors available, including:\n1. Pedigree Online: This is a popular web-based platform that allows users to create and edit family trees, as well as connect with other researchers and share information.\n2. MyHeritage: MyHeritage is a genealogy research platform that offers a web-based pedigree editor, as well as access to historical records and family tree building tools.\n3. FamilySearch: FamilySearch is a free genealogy research platform provided by The Church of Jesus Christ of Latter-day Saints. It offers a web-based pedigree editor, as well as access to historical records and family tree building tools.\n4. GenoPro: GenoPro is a professional genealogy software that offers a web-based pedigree editor, as well as advanced features such as custom reports and charts.\n5. Legacy Family Tree: Legacy Family Tree is a genealogy research platform that offers a web-based pedigree editor, as well as access to historical records and family tree building tools.\n6. FamilyTreeWebinars: FamilyTreeWebinars is a platform that offers web-based genealogy courses and training, as well as a web-based pedigree editor.\n7. GenealogyBank: GenealogyBank is a genealogy research platform that offers a web-based pedigree editor, as well as access to historical records and family tree building tools.\n8. Findmypast: Findmypast is a genealogy research platform that offers a web-based pedigree editor, as well as access to historical records and family tree building tools.\n9. Ancestry: Ancestry is a genealogy research platform that offers a web-based pedigree editor, as well as access to historical records and family tree building tools.\n10. WeRelate: WeRelate is a free and open-source genealogy platform that offers a web-based pedigree editor, as well as access to historical records and family tree building tools.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigree Online is a web-based platform for creating, editing, and sharing family trees.\n2. MyHeritage provides a web-based pedigree editor and access to historical records and family tree building tools.\n3. FamilySearch is a free genealogy research platform run by The Church of Jesus Christ of Latter-day Saints, which includes a web-based pedigree editor.\n4. GenoPro offers a web-based pedigree editor with features such as custom reports and charts.\n5. Ancestry offers a web-based pedigree editor and access to historical records and family tree building tools.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigree Online is a web-based platform for creating, editing, and sharing family trees.",
      "MyHeritage provides a web-based pedigree editor and access to historical records and family tree building tools.",
      "FamilySearch is a free genealogy research platform run by The Church of Jesus Christ of Latter-day Saints, which includes a web-based pedigree editor.",
      "GenoPro offers a web-based pedigree editor with features such as custom reports and charts.",
      "Ancestry offers a web-based pedigree editor and access to historical records and family tree building tools."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GenoPro offers a pedigree editor software that requires installation; it is not web-based.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases available for spider-venom toxins, including:\n1. ToxinDB: A comprehensive database of toxins from various sources, including spider venoms. It contains information on the structure, function, and pharmacological activities of toxins.\n2. Spider Toxin Database (SpTox): A database of spider venom peptides and proteins, including their sequences, structures, and functional properties.\n3. Venom-DB: A database of venom peptides and proteins from various organisms, including spiders, snakes, and scorpions. It includes information on the molecular properties, biological activities, and evolution of these peptides and proteins.\n4. Natural Products Dictionary (NPD): A database of natural products, including spider venom peptides and proteins, with information on their structures, spectra, and biological activities.\n5. Toxin Ontology (TOX): A database of toxins from various sources, including spider venoms, with information on their structures, functions, and pharmacological activities.\n6. Spider Toxin Information System (STIS): A database of spider venom toxins, including their sequences, structures, and functional properties. It also includes information on the venomous spiders that produce these toxins.\n7. Venomous Animal Toxin Database (VAT): A database of toxins from venomous animals, including spiders, snakes, and scorpions. It includes information on the structure, function, and pharmacological activities of these toxins.\n8. Toxin Central: A database of toxins from various sources, including spider venoms, with information on their structures, functions, and pharmacological activities.\n9. Venom-Tox: A database of venom peptides and proteins from various organisms, including spiders, with information on their structures, functions, and pharmacological activities.\n10. Toxin DataBase (ToxDB): A database of toxins from various sources, including spider venoms, with information on their structures, functions, and pharmacological activities.\nThese databases provide valuable information on the structures, functions, and pharmacological activities of spider-",
    "llama-2-7b-chat-hf_fact_raw": "1. ToxinDB is a comprehensive database that includes information on toxins from various sources, such as spider venoms.\n2. Spider Toxin Database (SpTox) provides data on spider venom peptides and proteins, including sequences, structures, and functional properties.\n3. Venom-DB is a database offering information on venom peptides and proteins from various organisms, including spiders.\n4. Natural Products Dictionary (NPD) contains data on natural products, including spider venom peptides and proteins, with information on their structures and biological activities.\n5. Toxin Ontology (TOX) catalogues toxins from various sources, including spider venoms, with details on their structures and pharmacological activities.",
    "llama-2-7b-chat-hf_fact": [
      "ToxinDB is a comprehensive database that includes information on toxins from various sources, such as spider venoms.",
      "Spider Toxin Database (SpTox) provides data on spider venom peptides and proteins, including sequences, structures, and functional properties.",
      "Venom-DB is a database offering information on venom peptides and proteins from various organisms, including spiders.",
      "Natural Products Dictionary (NPD) contains data on natural products, including spider venom peptides and proteins, with information on their structures and biological activities.",
      "Toxin Ontology (TOX) catalogues toxins from various sources, including spider venoms, with details on their structures and pharmacological activities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Yes, Axitinib has been shown to prolong survival in patients with pancreatic cancer. Axitinib is a tyrosine kinase inhibitor that targets the VEGF receptor 2 (VEGFR2), which is involved in angiogenesis, the process of forming new blood vessels that feed tumor growth. By inhibiting VEGFR2, Axitinib can reduce the formation of new blood vessels in the tumor, leading to a decrease in tumor growth and progression.\nSeveral clinical trials have demonstrated the efficacy and safety of Axitinib in the treatment of pancreatic cancer. For example, a phase III clinical trial published in the New England Journal of Medicine in 2018 found that Axitinib plus gemcitabine improved overall survival compared to gemcitabine alone in patients with metastatic pancreatic cancer. The median overall survival was 11.1 months in the Axitinib arm versus 9.1 months in the gemcitabine arm, representing a 20% improvement in survival.\nAdditionally, a phase II clinical trial published in the Journal of Clinical Oncology in 2017 found that Axitinib monotherapy was effective in patients with advanced pancreatic cancer, with an overall response rate of 11.4% and a median progression-free survival of 4.6 months.\nWhile these results are promising, it is important to note that Axitinib is not a cure for pancreatic cancer, and more research is needed to determine its long-term efficacy and optimal use in clinical practice.",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor that targets the VEGF receptor 2 (VEGFR2).\n2. Inhibition of VEGFR2 by Axitinib can lead to a reduction in tumor growth and progression in pancreatic cancer.\n3. A phase III clinical trial published in the New England Journal of Medicine in 2018 found that Axitinib plus gemcitabine improved overall survival in patients with metastatic pancreatic cancer compared to gemcitabine alone.\n4. The median overall survival was 11.1 months for the Axitinib arm versus 9.1 months for the gemcitabine arm according to the aforementioned clinical trial.\n5. A phase II clinical trial published in the Journal of Clinical Oncology in 2017 reported an overall response rate of 11.4% and a median progression-free survival of 4.6 months for Axitinib monotherapy in patients with advanced pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor that targets the VEGF receptor 2 (VEGFR2).",
      "Inhibition of VEGFR2 by Axitinib can lead to a reduction in tumor growth and progression in pancreatic cancer.",
      "A phase III clinical trial published in the New England Journal of Medicine in 2018 found that Axitinib plus gemcitabine improved overall survival in patients with metastatic pancreatic cancer compared to gemcitabine alone.",
      "The median overall survival was 11.1 months for the Axitinib arm versus 9.1 months for the gemcitabine arm according to the aforementioned clinical trial.",
      "A phase II clinical trial published in the Journal of Clinical Oncology in 2017 reported an overall response rate of 11.4% and a median progression-free survival of 4.6 months for Axitinib monotherapy in patients with advanced pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE (This assumes the mechanism of action indicated in statement 1 is correct, as inhibition of VEGFR2 can generally lead to reduced angiogenesis and tumor growth, which could be applicable to various types of cancer, including pancreatic cancer.)\n3. UNKNOWN (There's no way to verify the accuracy of this statement without access to the actual publication or additional specific information about clinical trials concerning Axitinib for pancreatic cancer. The statement is highly specific, and clinical trial outcomes must be confirmed against the original published data.)\n4. UNKNOWN (Similar to statement 3, this information would need to be confirmed by the actual publication or data from the clinical trial—without it, the statement's accuracy cannot be determined.)\n5. UNKNOWN (Statement 5, like statements 3 and 4, is specific and would require access to the original publication or trial data to verify its accuracy. The figures cannot be evaluated without the proper source.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Microtubule-associated protein) regulates F-actin dynamics through its interaction with actin-related protein 2/3 complex (ARP2/3 complex). The MLP protein binds to the ARP2/3 complex and inhibits its activity, thereby regulating the dynamics of F-actin.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP (Microtubule-associated protein) regulates F-actin dynamics.\n2. MLP interacts with the actin-related protein 2/3 complex (ARP2/3 complex).\n3. The MLP protein inhibits the activity of the ARP2/3 complex.",
    "llama-2-7b-chat-hf_fact": [
      "MLP (Microtubule-associated protein) regulates F-actin dynamics.",
      "MLP interacts with the actin-related protein 2/3 complex (ARP2/3 complex).",
      "The MLP protein inhibits the activity of the ARP2/3 complex."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MAPs (Microtubule-associated proteins) regulate microtubule dynamics. However, some proteins, like Muscle LIM protein (also known as MLP), may have a role in crosslinking actin filaments, they are generally not referred to as MAPs for F-actin. If MLP is intended to refer to Muscle LIM protein, the statement should clarify its role in actin dynamics.\n2. UNKNOWN\n3. UNKNOWN\n\nNote: Since MLP could refer to multiple proteins (including Muscle LIM protein), and the role of such a protein in regulating F-actin dynamics or interacting with the ARP2/3 complex can be quite specific and require a detailed understanding of cellular biology, definitive statements without context are difficult to assess. More research would be needed to confirm these specific interactions.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "The number of pseudokinases in the human kinome is not a fixed number and can vary depending on the source and method of classification. However, according to a recent study published in the journal Nature Communications, there are approximately 100-150 pseudokinases in the human kinome. These pseudokinases are proteins that have some of the structural features of kinases but do not have the ability to transfer phosphate groups to other proteins. They are thought to play a role in various cellular processes, including cell signaling and regulation of protein activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. The exact number of pseudokinases in the human kinome is variable and subject to classification methods.\n2. A recent study published in Nature Communications reported that there are approximately 100-150 pseudokinases in the human kinome.\n3. Pseudokinases are proteins with structural features of kinases but lack the ability to transfer phosphate groups to other proteins.\n4. Pseudokinases are believed to be involved in cellular processes such as cell signaling and protein activity regulation.",
    "llama-2-7b-chat-hf_fact": [
      "The exact number of pseudokinases in the human kinome is variable and subject to classification methods.",
      "A recent study published in Nature Communications reported that there are approximately 100-150 pseudokinases in the human kinome.",
      "Pseudokinases are proteins with structural features of kinases but lack the ability to transfer phosphate groups to other proteins.",
      "Pseudokinases are believed to be involved in cellular processes such as cell signaling and protein activity regulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "ApoE mimetics are compounds that mimic the structure and function of apolipoprotein E (apoE), a protein involved in lipid metabolism and cholesterol transport. Here are three examples of apoE mimetics:\n1. ApoEMimetic-101: This is a small molecule apoE mimetic that has been shown to increase HDL (high-density lipoprotein) cholesterol levels and improve insulin sensitivity in animal models.\n2. CERC-001: This is a synthetic peptide-based apoE mimetic that has been shown to reduce liver triglyceride levels and improve glucose tolerance in animal models of non-alcoholic fatty liver disease (NAFLD).\n3. Glybera: This is a recombinant apoE mimetic that has been approved for use in humans as a gene therapy for the treatment of familial chylomicronemia syndrome, a rare genetic disorder characterized by abnormally high levels of triglycerides in the blood.",
    "llama-2-7b-chat-hf_fact_raw": "1. ApoEMimetic-101 is a small molecule apoE mimetic designed to increase HDL cholesterol and improve insulin sensitivity.\n2. CERC-001 is a synthetic peptide-based apoE mimetic that aims to reduce liver triglyceride levels and improve glucose tolerance.\n3. Glybera is a recombinant apoE mimetic approved as a gene therapy for treating familial chylomicronemia syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "ApoEMimetic-101 is a small molecule apoE mimetic designed to increase HDL cholesterol and improve insulin sensitivity.",
      "CERC-001 is a synthetic peptide-based apoE mimetic that aims to reduce liver triglyceride levels and improve glucose tolerance.",
      "Glybera is a recombinant apoE mimetic approved as a gene therapy for treating familial chylomicronemia syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: Glybera is a gene therapy approved for treating lipoprotein lipase deficiency (LPLD), not familial chylomicronemia syndrome, and it is not an apoE mimetic.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 (Same Deoxyribonuclease 1) is an enzyme that plays a crucial role in regulating the innate immune response to viral infections. There are sex differences in SAMHD1 activity, with studies suggesting that females have higher levels of SAMHD1 activity compared to males.\nFor example, one study found that female mice have higher levels of SAMHD1 activity in their peripheral blood mononuclear cells compared to males, which may contribute to their increased resistance to viral infections. Another study found that female human cells have higher levels of SAMHD1 activity compared to male cells, which may also contribute to their increased resistance to viral infections.\nThese sex differences in SAMHD1 activity may be due to a variety of factors, including differences in the expression of genes involved in the SAMHD1 pathway, differences in the activity of hormones that regulate the SAMHD1 pathway, or differences in the metabolism of SAMHD1 itself.\nOverall, these sex differences in SAMHD1 activity may have important implications for our understanding of the immune response to viral infections and may help to explain why females tend to be less susceptible to certain viral infections than males.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAMHD1 is an enzyme involved in regulating the innate immune response to viral infections.\n2. Studies suggest females have higher levels of SAMHD1 activity compared to males.\n3. A study found that female mice have higher levels of SAMHD1 in their peripheral blood mononuclear cells than male mice.\n4. A study observed that female human cells have higher levels of SAMHD1 activity compared to male cells.\n5. The difference in SAMHD1 activity between sexes may contribute to females' increased resistance to viral infections.",
    "llama-2-7b-chat-hf_fact": [
      "SAMHD1 is an enzyme involved in regulating the innate immune response to viral infections.",
      "Studies suggest females have higher levels of SAMHD1 activity compared to males.",
      "A study found that female mice have higher levels of SAMHD1 in their peripheral blood mononuclear cells than male mice.",
      "A study observed that female human cells have higher levels of SAMHD1 activity compared to male cells.",
      "The difference in SAMHD1 activity between sexes may contribute to females' increased resistance to viral infections."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first statement regarding the role of SAMHD1 as an enzyme involved in regulating the innate immune response to viral infections is correct. However, the subsequent statements about sex-specific differences in SAMHD1 levels and activity, as well as the potential implications for resistance to viral infections, require specific and recent scientific evidence which has not been provided in this context. Without citations or more detailed information from recent studies that support these claims, I cannot accurately verify these statements.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Yes, RUNX2 (Runt-related transcription factor 2) has been shown to inhibit the differentiation of astrocytes. RUNX2 is a transcription factor that plays a crucial role in the regulation of cell fate decisions, including the differentiation of neural progenitor cells into astrocytes. Studies have shown that RUNX2 inhibits the expression of genes involved in astrocyte differentiation and functions, leading to a decrease in the number of astrocytes in the brain.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 stands for Runt-related transcription factor 2.\n2. RUNX2 inhibits the differentiation of astrocytes.\n3. RUNX2 is involved in the regulation of cell fate decisions.\n4. RUNX2 inhibits the expression of genes involved in astrocyte differentiation and functions.\n5. Studies have indicated that the presence of RUNX2 leads to a decrease in the number of astrocytes in the brain.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 stands for Runt-related transcription factor 2.",
      "RUNX2 inhibits the differentiation of astrocytes.",
      "RUNX2 is involved in the regulation of cell fate decisions.",
      "RUNX2 inhibits the expression of genes involved in astrocyte differentiation and functions.",
      "Studies have indicated that the presence of RUNX2 leads to a decrease in the number of astrocytes in the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: RUNX2 promotes the differentiation of osteoblasts, not astrocytes.\n3. TRUE\n4. UNKNOWN: Without specific information from the provided passage, it's unclear whether RUNX2 inhibits or promotes the expression of genes involved in astrocyte differentiation and function.\n5. UNKNOWN: The specific effects of RUNX2 on the number of astrocytes in the brain would need to be confirmed by relevant studies, and such information is not provided here.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "The Cobb-Stansby excision arthroplasty is a surgical procedure that is typically performed in the knee joint. Specifically, it is an excision arthroplasty of the medial femoral condyle (MFC) of the knee joint. The procedure involves removing a portion of the damaged or arthritic bone on the inside of the knee joint, and replacing it with an implant or prosthesis. The goal of the procedure is to relieve pain and improve knee function in patients with advanced knee osteoarthritis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.\n2. It involves an excision arthroplasty of the medial femoral condyle (MFC) of the knee joint.\n3. The procedure includes removing a portion of the damaged or arthritic bone on the inside of the knee joint.\n4. An implant or prosthesis replaces the removed portion of bone during the Cobb-Stainsby excision arthroplasty.\n5. The goal of the Cobb-Stainsby excision arthroplasty is to relieve pain and improve knee function in patients with advanced knee osteoarthritis.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.",
      "It involves an excision arthroplasty of the medial femoral condyle (MFC) of the knee joint.",
      "The procedure includes removing a portion of the damaged or arthritic bone on the inside of the knee joint.",
      "An implant or prosthesis replaces the removed portion of bone during the Cobb-Stainsby excision arthroplasty.",
      "The goal of the Cobb-Stainsby excision arthroplasty is to relieve pain and improve knee function in patients with advanced knee osteoarthritis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure primarily performed on the hip joint, not the knee joint.\n2. FALSE [correction]: Since this procedure is primarily for the hip, it does not involve excision arthroplasty of the medial femoral condyle (MFC) of the knee joint.\n3. UNKNOWN: Without specific context for the Cobb-Stainsby procedure referring to the knee, this statement is difficult to verify. However, generally in excision arthroplasties, a portion of damaged or arthritic bone is removed.\n4. TRUE: Typically in a Cobb-Stainsby excision arthroplasty, after the portion of bone is removed, an implant or prosthesis is used to maintain stability and function of the joint. However, this is true for the hip joint.\n5. TRUE: The goal of the Cobb-Stainsby excision arthroplasty, when performed on the hip, is to relieve pain and improve joint function, often in patients with arthritis or other joint issues.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Yes, over-expression of GRHL2 has been shown to promote epithelial-to-mesenchymal transition (EMT) in various cell types, including cancer cells. EMT is a process by which epithelial cells lose their cell-cell adhesion and gain mesenchymal characteristics, such as increased migration and invasiveness. Over-expression of GRHL2 has been shown to activate key transcription factors involved in EMT, such as ZEB1 and Snail, and to promote the expression of mesenchymal genes, such as vimentin and N-cadherin. Therefore, GRHL2 over-expression can contribute to the development of a more aggressive and invasive tumor phenotype.",
    "llama-2-7b-chat-hf_fact_raw": "1. Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT) in various cell types.\n2. Epithelial-to-mesenchymal transition (EMT) is characterized by the loss of cell-cell adhesion and the acquisition of mesenchymal characteristics, including increased migration and invasiveness.\n3. GRHL2 over-expression activates key transcription factors involved in EMT, such as ZEB1 and Snail.\n4. Over-expression of GRHL2 promotes the expression of mesenchymal genes, such as vimentin and N-cadherin.\n5. GRHL2 over-expression can contribute to the development of a more aggressive and invasive tumor phenotype.",
    "llama-2-7b-chat-hf_fact": [
      "Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT) in various cell types.",
      "Epithelial-to-mesenchymal transition (EMT) is characterized by the loss of cell-cell adhesion and the acquisition of mesenchymal characteristics, including increased migration and invasiveness.",
      "GRHL2 over-expression activates key transcription factors involved in EMT, such as ZEB1 and Snail.",
      "Over-expression of GRHL2 promotes the expression of mesenchymal genes, such as vimentin and N-cadherin.",
      "GRHL2 over-expression can contribute to the development of a more aggressive and invasive tumor phenotype."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Over-expression of GRHL2 is typically associated with the suppression of epithelial-to-mesenchymal transition (EMT) in various cell types, rather than promoting it.\n2. TRUE\n3. FALSE [correction]: Since GRHL2 usually acts to suppress EMT, it would not typically activate key transcription factors involved in EMT, such as ZEB1 and Snail, which promote the process.\n4. FALSE [correction]: Over-expression of GRHL2 would not promote the expression of mesenchymal genes, such as vimentin and N-cadherin, as these are indicative of EMT which GRHL2 suppresses.\n5. FALSE [correction]: Over-expression of GRHL2 would generally be expected to suppress the development of a more aggressive and invasive tumor phenotype by inhibiting EMT.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "T-UCRs (tumor-associated circular RNAs) have been implicated in lung cancer, including:\n1. circRNA000001: This circular RNA is overexpressed in lung cancer tissues and promotes the proliferation and migration of lung cancer cells.\n2. circRNA000002: This circular RNA is also overexpressed in lung cancer tissues and enhances the epithelial-mesenchymal transition (EMT) of lung cancer cells.\n3. circRNA000003: This circular RNA is downregulated in lung cancer tissues and inhibits the proliferation and migration of lung cancer cells.\n4. circRNA000004: This circular RNA is overexpressed in lung cancer tissues and promotes the EMT of lung cancer cells.\n5. circRNA000005: This circular RNA is downregulated in lung cancer tissues and inhibits the proliferation and migration of lung cancer cells.\n6. circRNA000006: This circular RNA is overexpressed in lung cancer tissues and promotes the EMT of lung cancer cells.\n7. circRNA000007: This circular RNA is downregulated in lung cancer tissues and inhibits the proliferation and migration of lung cancer cells.\n8. circRNA000008: This circular RNA is overexpressed in lung cancer tissues and promotes the EMT of lung cancer cells.\n9. circRNA000009: This circular RNA is downregulated in lung cancer tissues and inhibits the proliferation and migration of lung cancer cells.\n10. circRNA000010: This circular RNA is overexpressed in lung cancer tissues and promotes the EMT of lung cancer cells.\nIt's important to note that these are just a few examples of T-UCRs that have been implicated in lung cancer, and further research is needed to fully understand the role of these circular RNAs in lung cancer development and progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. circRNA000001 is overexpressed in lung cancer tissues and promotes the proliferation and migration of lung cancer cells.\n2. circRNA000002 is also overexpressed in lung cancer tissues and enhances the epithelial-mesenchymal transition (EMT) of lung cancer cells.\n3. circRNA000003 is downregulated in lung cancer tissues and inhibits the proliferation and migration of lung cancer cells.\n4. circRNA000004 is overexpressed in lung cancer tissues and promotes the EMT of lung cancer cells.\n5. circRNA000005 is downregulated in lung cancer tissues and inhibits the proliferation and migration of lung cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "circRNA000001 is overexpressed in lung cancer tissues and promotes the proliferation and migration of lung cancer cells.",
      "circRNA000002 is also overexpressed in lung cancer tissues and enhances the epithelial-mesenchymal transition (EMT) of lung cancer cells.",
      "circRNA000003 is downregulated in lung cancer tissues and inhibits the proliferation and migration of lung cancer cells.",
      "circRNA000004 is overexpressed in lung cancer tissues and promotes the EMT of lung cancer cells.",
      "circRNA000005 is downregulated in lung cancer tissues and inhibits the proliferation and migration of lung cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN \n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe truthfulness of the statements about the specific circRNAs (circular RNAs) can only be confirmed through scientific studies that assess their expression levels and functional roles in lung cancer tissues. Without specific references to research that supports these claims, it's not possible to determine the truth value of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151 (G protein-coupled receptor 151) is an orphan receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function. However, recent studies have shed light on its potential role in various biological processes. Here are some key findings:\n1. GPR151 is a seven-transmembrane receptor that is primarily expressed in the brain, specifically in regions involved in regulating energy homeostasis, such as the hypothalamus and brainstem.\n2. GPR151 has been shown to play a role in the regulation of glucose metabolism. Studies have shown that GPR151 activation increases glucose uptake in adipocytes and skeletal muscle cells, while GPR151 inhibition leads to impaired glucose tolerance and insulin sensitivity.\n3. GPR151 has also been implicated in the regulation of body weight and energy balance. Studies have shown that GPR151 activation leads to decreased food intake and body weight, while GPR151 inhibition leads to increased food intake and body weight gain.\n4. GPR151 has been linked to the regulation of inflammation and immune response. Studies have shown that GPR151 activation inhibits the production of pro-inflammatory cytokines, while GPR151 inhibition leads to increased inflammation.\n5. GPR151 has been shown to play a role in the regulation of neurotransmission and synaptic plasticity. Studies have shown that GPR151 activation enhances synaptic transmission and learning, while GPR151 inhibition leads to impaired synaptic plasticity and cognitive function.\nOverall, while GPR151 was once considered an orphan receptor with no clear function, recent studies have shown that it plays a complex and multifaceted role in various physiological processes, including glucose metabolism, energy homeostasis, inflammation, immune response, and neurotransmission. Further research is needed to fully understand the mechanisms of GPR151 and its potential as a therapeut",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 (G protein-coupled receptor 151) is an orphan receptor primarily expressed in the brain.\n2. GPR151 is implicated in regulating glucose metabolism, as its activation increases glucose uptake in adipocytes and skeletal muscle cells.\n3. Activation of GPR151 leads to decreased food intake and body weight, while its inhibition results in an increase in food intake and body weight.\n4. GPR151 has been linked to the regulation of inflammation and immune response, with its activation inhibiting the production of pro-inflammatory cytokines.\n5. GPR151 plays a role in the regulation of neurotransmission and synaptic plasticity, where its activation enhances synaptic transmission and learning.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 (G protein-coupled receptor 151) is an orphan receptor primarily expressed in the brain.",
      "GPR151 is implicated in regulating glucose metabolism, as its activation increases glucose uptake in adipocytes and skeletal muscle cells.",
      "Activation of GPR151 leads to decreased food intake and body weight, while its inhibition results in an increase in food intake and body weight.",
      "GPR151 has been linked to the regulation of inflammation and immune response, with its activation inhibiting the production of pro-inflammatory cytokines.",
      "GPR151 plays a role in the regulation of neurotransmission and synaptic plasticity, where its activation enhances synaptic transmission and learning."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GPR151 is not known to be directly implicated in regulating glucose metabolism. This role is more commonly associated with other receptors and proteins.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about the specific functions of GPR151, other than its expression in the brain, are not commonly established knowledge. Unless there is specific, recently published scientific research to support statements 2, 3, 4, and 5, they remain uncertain without specific context or references. Since the knowledge cutoff date is 2023, and there is no additional context provided for these statements, accurate corrections cannot be made if updates in research have indeed linked GPR151 to these functions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "The Fluzone intradermal quadrivalent vaccine contains the following attenuated live viruses:\n* FluA: A/H1N1 (Pandemrix)\n* FluB: B/Victoria\n* FluA: A/H3N2 (Severe Florida)\n* FluB: B/Brisbane\nPlease note that the specific viruses contained in each vaccine may vary depending on the manufacturer and the year of production. It's always best to consult the vaccine's package insert or the manufacturer's website for the most up-to-date information.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "The TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE) in the promoter region. Specifically, a genetic variation in the -174G>C polymorphism in the promoter region of the TNFR2 gene has been found to be associated with an increased risk of developing SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).\n2. The promoter region of the TNFR2 gene is where the genetic association with SLE is located.\n3. A genetic variation in the -174G>C polymorphism in the promoter region of the TNFR2 gene is linked with an increased risk of developing SLE.",
    "llama-2-7b-chat-hf_fact": [
      "The TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).",
      "The promoter region of the TNFR2 gene is where the genetic association with SLE is located.",
      "A genetic variation in the -174G>C polymorphism in the promoter region of the TNFR2 gene is linked with an increased risk of developing SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n\nThe first statement holds as there is scientific evidence suggesting an association between TNFR2 (Tumor Necrosis Factor Receptor 2) and autoimmune diseases, including Systemic Lupus Erythematosus. However, for the second and third statements, without specific scientific references, it's challenging to confirm or deny the location of the genetic association within the TNFR2 gene or the specific risk linked with the -174G>C polymorphism in the TNFR2 gene promoter region. These details require precise literature or study references to determine their accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "There is currently no licensed vaccine available for the prevention of peanut allergy. However, researchers are actively working on developing a peanut allergy vaccine, and several clinical trials are underway to evaluate its safety and efficacy.\nOne of the most promising approaches is to use a modified form of the peanut protein, called Peanut Allergen Powder (PAP), as a vaccine. PAP is made by grinding peanuts into a fine powder and removing the allergenic proteins using a process called protein purification. The resulting powder is then formulated with adjuvants, such as aluminum salts, to enhance the immune response.\nSeveral clinical trials have shown that PAP can stimulate an immune response in individuals with peanut allergy, and some have reported significant improvements in symptoms and tolerance to peanut exposure. However, it is important to note that these trials have been small and had limited follow-up periods, so more research is needed to confirm the long-term safety and efficacy of the vaccine.\nOther approaches to developing a peanut allergy vaccine include using peanut extracts or recombinant peanut proteins, as well as targeting different immune cells or mechanisms to enhance the immune response. However, these approaches are still in the early stages of development and have not yet been tested in humans.\nOverall, while there is currently no licensed vaccine available for peanut allergy, researchers are actively working on developing new treatments to help manage this common and potentially life-threatening condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no licensed vaccine available for the prevention of peanut allergy as of the knowledge cutoff.\n2. Researchers are conducting clinical trials to evaluate the safety and efficacy of a potential peanut allergy vaccine.\n3. Peanut Allergen Powder (PAP) is being developed as a peanut allergy vaccine that involves a protein purification process to remove allergenic proteins.\n4. Clinical trials have investigated the immune response and improvements in symptoms and tolerance to peanut exposure using PAP.\n5. Other potential vaccine approaches for peanut allergy include using peanut extracts or recombinant peanut proteins and are in the early stages of development.",
    "llama-2-7b-chat-hf_fact": [
      "There is no licensed vaccine available for the prevention of peanut allergy as of the knowledge cutoff.",
      "Researchers are conducting clinical trials to evaluate the safety and efficacy of a potential peanut allergy vaccine.",
      "Peanut Allergen Powder (PAP) is being developed as a peanut allergy vaccine that involves a protein purification process to remove allergenic proteins.",
      "Clinical trials have investigated the immune response and improvements in symptoms and tolerance to peanut exposure using PAP.",
      "Other potential vaccine approaches for peanut allergy include using peanut extracts or recombinant peanut proteins and are in the early stages of development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The mouse Fxy gene is located on the X chromosome at position Xp11.2.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on the X chromosome.\n2. The specific chromosomal position of the mouse Fxy gene is Xp11.2.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene is located on the X chromosome.",
      "The specific chromosomal position of the mouse Fxy gene is Xp11.2."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The specific chromosomal position of the mouse Fxy gene is not Xp11.2; it is generally denoted as being found on the X chromosome, but the precise cytogenetic location for the mouse Fxy gene is not provided here. Xp11.2 is a more commonly used notation for human chromosomal positions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "The basis of the MPE-seq method is the use of a reagent called methidiumpropyl-EDTA (methidium-EDTA) to selectively label and capture RNA molecules in a sample. The method is based on the reaction of methidium-EDTA with RNA, which results in the formation of a stable, fluorescently labeled complex that can be separated from other molecules in the sample using a variety of methods, such as gel electrophoresis or mass spectrometry.\nThe MPE-seq method is a form of RNA sequencing that allows for the simultaneous analysis of multiple RNA molecules in a single reaction, without the need for prior knowledge of the RNA transcripts present in the sample. It has been used to study a wide range of biological processes, including gene expression, RNA splicing, and RNA editing.\nThe basic steps of the MPE-seq method are as follows:\n1. Sample preparation: The sample is prepared by treating it with methidium-EDTA, which selectively labels and captures RNA molecules.\n2. Separation: The labeled RNA molecules are separated from other molecules in the sample using a variety of methods, such as gel electrophoresis or mass spectrometry.\n3. Detection: The labeled RNA molecules are detected using a variety of methods, such as fluorescence microscopy or high-resolution melting analysis.\n4. Data analysis: The resulting data is analyzed to identify and quantify the RNA molecules present in the sample.\nThe MPE-seq method has several advantages over other RNA sequencing methods, including its simplicity, sensitivity, and ability to analyze multiple RNA molecules in a single reaction. It is also relatively inexpensive and can be performed using standard laboratory equipment, making it a valuable tool for researchers in a variety of fields.",
    "llama-2-7b-chat-hf_fact_raw": "1. Methidiumpropyl-EDTA (methidium-EDTA) is used in MPE-seq to selectively label and capture RNA molecules in a sample.\n2. The reaction of methidium-EDTA with RNA results in the formation of a stable, fluorescently labeled complex.\n3. MPE-seq allows for the simultaneous analysis of multiple RNA molecules in a single reaction without prior knowledge of the RNA transcripts.\n4. The labeled RNA molecules can be separated from other molecules in the sample using methods such as gel electrophoresis or mass spectrometry.\n5. The MPE-seq method includes steps of sample preparation, separation, detection, and data analysis.",
    "llama-2-7b-chat-hf_fact": [
      "Methidiumpropyl-EDTA (methidium-EDTA) is used in MPE-seq to selectively label and capture RNA molecules in a sample.",
      "The reaction of methidium-EDTA with RNA results in the formation of a stable, fluorescently labeled complex.",
      "MPE-seq allows for the simultaneous analysis of multiple RNA molecules in a single reaction without prior knowledge of the RNA transcripts.",
      "The labeled RNA molecules can be separated from other molecules in the sample using methods such as gel electrophoresis or mass spectrometry.",
      "The MPE-seq method includes steps of sample preparation, separation, detection, and data analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement provides specific information about the use of Methidiumpropyl-EDTA (methidium-EDTA) in MPE-seq, but without additional context or reference, it's difficult to verify if it's used for selective labeling and capture of RNA molecules.\n2. UNKNOWN: Similar to statement 1, the claim about methidium-EDTA forming a stable, fluorescently labeled complex with RNA is specific and requires reference to scientific literature or detailed methodology to verify.\n3. TRUE: MPE-seq, as with many sequencing technologies, is designed to allow for the analysis of multiple RNA molecules simultaneously without prior knowledge of the transcripts, in line with the goal of high-throughput sequencing methods.\n4. TRUE: After labeling the RNA molecules, separation methods such as gel electrophoresis or mass spectrometry are commonly used in nucleic acid analysis, including sequencing technologies, to separate labeled molecules from others in a sample.\n5. TRUE: The described steps of sample preparation, separation, detection, and data analysis are typical in sequencing methods such as MPE-seq.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR (Genome-Wide Association Study) is typically implemented using a variety of programming languages depending on the specific requirements and the preferences of the researcher. However, some popular programming languages used for GWAS analysis include:\n1. R: R is a popular programming language for statistical computing and graphics, and is widely used in the bioinformatics community for GWAS analysis. R packages such as PLINK, GCTA, and SNPTEST provide functions for conducting GWAS.\n2. Python: Python is a versatile language that is widely used in bioinformatics and genomics. Libraries such as scikit-learn, scipy, and pandas provide functions for data manipulation and analysis, while libraries such as GWASpy and PySnp provide functions specifically for GWAS.\n3. MATLAB: MATLAB is a programming language and environment specifically designed for scientific computing and data analysis. It is commonly used for GWAS analysis due to its ability to handle large datasets and perform complex statistical analyses.\n4. SAS: SAS (Statistical Analysis System) is a software suite that is widely used in the statistics and bioinformatics communities for data analysis. It provides a range of tools for GWAS analysis, including the GENABEL and PLINK procedures.\nUltimately, the choice of programming language will depend on the specific requirements of the analysis and the researcher's familiarity with the language.",
    "llama-2-7b-chat-hf_fact_raw": "1. R is used for GWAS analysis and includes packages like PLINK, GCTA, and SNPTEST.\n2. Python is utilized in bioinformatics for GWAS, with libraries such as scikit-learn, scipy, and pandas for data manipulation and analysis.\n3. MATLAB is used in GWAS analysis for handling large datasets and performing complex statistical analyses.\n4. SAS is used by statistics and bioinformatics communities for GWAS analysis and includes tools such as the GENABEL and PLINK procedures.",
    "llama-2-7b-chat-hf_fact": [
      "R is used for GWAS analysis and includes packages like PLINK, GCTA, and SNPTEST.",
      "Python is utilized in bioinformatics for GWAS, with libraries such as scikit-learn, scipy, and pandas for data manipulation and analysis.",
      "MATLAB is used in GWAS analysis for handling large datasets and performing complex statistical analyses.",
      "SAS is used by statistics and bioinformatics communities for GWAS analysis and includes tools such as the GENABEL and PLINK procedures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: R is used for GWAS analysis and includes packages like GWASTools, GenABEL, and SNPassoc. PLINK is not an R package, but a standalone program that can be used in conjunction with R.\n2. TRUE\n3. TRUE - MATLAB can be used in GWAS analysis, although it is less common than R or Python; MATLAB has capabilities for handling large datasets and performing complex statistical analyses.\n4. PARTIALLY TRUE [correction]: SAS is used by the statistics and bioinformatics communities for GWAS analysis, and it includes tools such as PROC GENETICS for genetic analysis. However, the GENABEL and PLINK procedures are not part of SAS; GENABEL is an R package, and PLINK is a standalone program.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Xaliproden (also known as verubecestat) is a drug that has been investigated for the treatment of amyotrophic lateral sclerosis (ALS), but its effect on the prognosis of the disease is still unknown.\nThere have been some clinical trials conducted to evaluate the safety and efficacy of xaliproden in ALS patients, but the results have been mixed and inconclusive.\nA phase II clinical trial published in 2019 found that xaliproden did not meet the primary endpoint of slowing the progression of ALS compared to placebo. However, the study did show that xaliproden was associated with a slower decline in cognitive function compared to placebo.\nAnother phase III clinical trial, also published in 2019, found that xaliproden did not meet the primary endpoint of slowing the progression of ALS compared to the drug riluzole, which is the current standard of care for ALS. However, the study did show that xaliproden was associated with a slower decline in motor function compared to riluzole in some subgroups of patients.\nOverall, while the evidence is still emerging and inconclusive, some studies suggest that xaliproden may have a potential therapeutic effect on the progression of ALS, particularly in certain subgroups of patients. However, more research is needed to confirm these findings and establish the safety and efficacy of xaliproden for the treatment of ALS.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden is a drug that has been investigated for the treatment of amyotrophic lateral sclerosis (ALS).\n2. A phase II clinical trial published in 2019 found that xaliproden did not meet the primary endpoint of slowing the progression of ALS compared to placebo.\n3. The same phase II clinical trial indicated that xaliproden was associated with a slower decline in cognitive function compared to placebo.\n4. Another phase III clinical trial published in 2019 found that xaliproden did not meet the primary endpoint when compared to the drug riluzole for slowing the progression of ALS.\n5. The phase III clinical trial suggested that xaliproden was associated with a slower decline in motor function compared to riluzole in some subgroups of patients.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden is a drug that has been investigated for the treatment of amyotrophic lateral sclerosis (ALS).",
      "A phase II clinical trial published in 2019 found that xaliproden did not meet the primary endpoint of slowing the progression of ALS compared to placebo.",
      "The same phase II clinical trial indicated that xaliproden was associated with a slower decline in cognitive function compared to placebo.",
      "Another phase III clinical trial published in 2019 found that xaliproden did not meet the primary endpoint when compared to the drug riluzole for slowing the progression of ALS.",
      "The phase III clinical trial suggested that xaliproden was associated with a slower decline in motor function compared to riluzole in some subgroups of patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The statement cannot be verified as true or false without specific information about a phase II clinical trial published in 2019. As of my last update, the details of clinical trials including their findings specific to 2019 are not available to me, so I can't confirm or deny the results of this trial.\n3. UNKNOWN: Without specific information about the phase II clinical trial and its published results, it is not possible to validate this statement.\n4. UNKNOWN: Similar to the second statement, without access to specific information about a phase III clinical trial published in 2019 comparing xaliproden to riluzole, the results mentioned cannot be confirmed or denied.\n5. UNKNOWN: Again, without specific details of the phase III clinical trial’s findings, it is not possible to validate the mentioned outcomes related to motor function in subgroups of patients.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "The LiPS-A3S line is a transgenic line in which the transgene is inserted into chromosome 16.",
    "llama-2-7b-chat-hf_fact_raw": "1. The transgene in the LiPS-A3S line is inserted into chromosome 16.",
    "llama-2-7b-chat-hf_fact": [
      "The transgene in the LiPS-A3S line is inserted into chromosome 16."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nWithout additional context or specific information about the genetics involved with the \"LiPS-A3S line,\" it's impossible to verify the accuracy of the statement regarding the transgene's insertion into chromosome 16.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning tools and models that can be used for predicting drug synergy, including:\n1. DeepDrug: This is a deep learning model that predicts drug synergy by analyzing the protein-protein interaction networks of drugs and their targets.\n2. DrugSynth: This model uses a deep learning architecture to predict drug synergy by analyzing the chemical structures of drugs and their targets.\n3. DrugNet: This model predicts drug synergy by analyzing the protein-protein interaction networks of drugs and their targets, as well as the drug's chemical structure.\n4. DeepChem: This is a deep learning model that predicts drug synergy by analyzing the chemical structure of drugs and their targets.\n5. DrugBank: This is a comprehensive database of drugs and their targets, which can be used to predict drug synergy using deep learning models.\n6. ChEA-2017: This is a deep learning model that predicts drug synergy by analyzing the chemical structure of drugs and their targets, as well as the gene expression profiles of cancer cells.\n7. DrugDiscovery: This is a deep learning model that predicts drug synergy by analyzing the chemical structure of drugs and their targets, as well as the protein-protein interaction networks of drugs and their targets.\n8. DrugTarget: This is a deep learning model that predicts drug synergy by analyzing the protein-protein interaction networks of drugs and their targets, as well as the drug's chemical structure.\n9. DrugCombination: This is a deep learning model that predicts drug synergy by analyzing the chemical structure of drugs and their targets, as well as the protein-protein interaction networks of drugs and their targets.\n10. DrugTox: This is a deep learning model that predicts drug synergy by analyzing the chemical structure of drugs and their targets, as well as the toxicity profiles of drugs.\nIt's worth noting that these are just a few examples of the many deep learning models and tools available for predicting drug synergy, and the choice of which one to use will depend on the specific research question and data available.",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepDrug is a deep learning model designed to predict drug synergy by analyzing protein-protein interaction networks of drugs and their targets.\n2. DrugSynth utilizes a deep learning architecture to predict drug synergy through analysis of chemical structures of drugs and their targets.\n3. DrugNet predicts drug synergy by considering protein-protein interaction networks and the chemical structure of drugs and their targets.\n4. DeepChem is a deep learning model that predicts drug synergy by analyzing the chemical structure of drugs and their targets.\n5. DrugBank is a comprehensive database that can be used in conjunction with deep learning models to predict drug synergy.",
    "llama-2-7b-chat-hf_fact": [
      "DeepDrug is a deep learning model designed to predict drug synergy by analyzing protein-protein interaction networks of drugs and their targets.",
      "DrugSynth utilizes a deep learning architecture to predict drug synergy through analysis of chemical structures of drugs and their targets.",
      "DrugNet predicts drug synergy by considering protein-protein interaction networks and the chemical structure of drugs and their targets.",
      "DeepChem is a deep learning model that predicts drug synergy by analyzing the chemical structure of drugs and their targets.",
      "DrugBank is a comprehensive database that can be used in conjunction with deep learning models to predict drug synergy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: There is no readily available information to confirm or deny the specific purpose of \"DeepDrug\", which may be a hypothetical or proprietary model.\n2. UNKNOWN: As with \"DeepDrug\", the specific purpose of \"DrugSynth\" is not provided, so the truth of the statement cannot be confirmed or denied.\n3. UNKNOWN: Since \"DrugNet\" is not described in the provided context or widely known, the accuracy of this statement cannot be determined without additional information.\n4. FALSE [correction]: DeepChem is not exclusively a model for predicting drug synergy; it is an open-source platform to infuse deep learning into drug discovery, materials science, quantum chemistry, biology, and more, though it could potentially be used for such a task.\n5. TRUE: DrugBank is indeed a comprehensive database that contains detailed drug data including chemical, pharmacological, and pharmaceutical data that can be used alongside deep learning models to predict drug synergy or for other purposes related to drug discovery and research.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "The cloud-based platform that has been developed for comparing GWAS is called \"GWAScloud\". GWAScloud is an open-source platform that allows researchers to compare genetic association signals across different GWAS datasets, and to identify shared signals and patterns of association. It was developed by the University of California, San Diego, and is available for use by researchers worldwide.",
    "llama-2-7b-chat-hf_fact_raw": "1. GWAScloud is a cloud-based platform developed for comparing GWAS (genome-wide association studies).\n2. GWAScloud allows researchers to compare genetic association signals across different GWAS datasets.\n3. Using GWAScloud, researchers can identify shared signals and patterns of association.\n4. GWAScloud was developed by the University of California, San Diego.\n5. GWAScloud is open-source and available for use by researchers worldwide.",
    "llama-2-7b-chat-hf_fact": [
      "GWAScloud is a cloud-based platform developed for comparing GWAS (genome-wide association studies).",
      "GWAScloud allows researchers to compare genetic association signals across different GWAS datasets.",
      "Using GWAScloud, researchers can identify shared signals and patterns of association.",
      "GWAScloud was developed by the University of California, San Diego.",
      "GWAScloud is open-source and available for use by researchers worldwide."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific contextual information or a reliable source that describes GWAScloud and its details, it is not possible to determine the veracity of the statements. The statements themselves are neither widely known facts nor common knowledge about a well-known subject, such as historical events or geographic locations. Therefore, I cannot provide accurate corrections or confirmations for these statements without additional information.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "Yes, CMB305 has been shown to be effective against sarcomas in preclinical studies. CMB305 is a bispecific antibody that targets both CD3 and CD138, which are expressed on the surface of multiple myeloma cells, including some sarcomas. The antibody is designed to recruit T cells to the site of the tumor and stimulate an immune response against the cancer cells. In preclinical studies, CMB305 has shown activity against various types of sarcomas, including osteosarcoma and chondrosarcoma.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 has been shown to be effective against sarcomas in preclinical studies.\n2. CMB305 is a bispecific antibody that targets CD3 and CD138.\n3. CD138 and CD3 are expressed on the surface of multiple myeloma cells and some sarcomas.\n4. The design of CMB305 is to recruit T cells to the tumor site and stimulate an immune response against the cancer cells.\n5. Preclinical studies have indicated CMB305's activity against various types of sarcomas, including osteosarcoma and chondrosarcoma.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 has been shown to be effective against sarcomas in preclinical studies.",
      "CMB305 is a bispecific antibody that targets CD3 and CD138.",
      "CD138 and CD3 are expressed on the surface of multiple myeloma cells and some sarcomas.",
      "The design of CMB305 is to recruit T cells to the tumor site and stimulate an immune response against the cancer cells.",
      "Preclinical studies have indicated CMB305's activity against various types of sarcomas, including osteosarcoma and chondrosarcoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE (Assuming the statement is based on current scientific literature; however, without a specific reference to the preclinical studies, it's taken at face value)\n2. FALSE [correction]: CMB305 is not a bispecific antibody but a cancer vaccine which targets NY-ESO-1 tumor antigen and includes a component to stimulate the immune response.\n3. TRUE (CD138 and CD3 are indeed associated with multiple myeloma, and CD3 is a T-cell co-receptor; however, without specific research, the expression of CD138 on sarcomas may not be as clear-cut)\n4. TRUE (This is consistent with the concept of a cancer vaccine, which is designed to recruit and stimulate T cells to attack cancer cells)\n5. TRUE (Assuming this statement is based on the preclinical studies related to CMB305, although specificity would depend on those studies' findings)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad, also known as the Ehlers-Danlos Syndrome (EDS), is a group of connective tissue disorders that affect the body's collagen production and structure. The manifestations of the Saint's Triad can vary in severity and may include:\n1. Hypermobility: Joints that are overly flexible and can move beyond their normal range of motion.\n2. Skin hyperextensibility: Skin that stretches further than normal and can tear easily.\n3. Tissue fragility: Weakened connective tissue that can lead to bruising, bleeding, and other injuries.\nThese manifestations can affect various parts of the body, including the joints, skin, and internal organs. Some individuals with the Saint's Triad may also experience other symptoms, such as chronic pain, fatigue, and gastrointestinal issues.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Saint's Triad is also known as Ehlers-Danlos Syndrome (EDS).\n2. It affects the body's collagen production and structure.\n3. One manifestation of the Saint's Triad is hypermobility, where joints can move beyond their normal range of motion.\n4. Skin hyperextensibility, where skin stretches further than normal and can tear easily, is another manifestation.\n5. Tissue fragility, which can lead to bruising, bleeding, and other injuries, is also a manifestation of the Saint's Triad.",
    "llama-2-7b-chat-hf_fact": [
      "The Saint's Triad is also known as Ehlers-Danlos Syndrome (EDS).",
      "It affects the body's collagen production and structure.",
      "One manifestation of the Saint's Triad is hypermobility, where joints can move beyond their normal range of motion.",
      "Skin hyperextensibility, where skin stretches further than normal and can tear easily, is another manifestation.",
      "Tissue fragility, which can lead to bruising, bleeding, and other injuries, is also a manifestation of the Saint's Triad."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Saint's Triad is not known as Ehlers-Danlos Syndrome (EDS). Saint's Triad typically refers to a combination of medical conditions, such as hiatal hernia, colonic diverticula, and gallstones, not EDS.\n2. TRUE (However, this statement is true for Ehlers-Danlos Syndrome, not Saint's Triad)\n3. TRUE (Again, this is true for Ehlers-Danlos Syndrome, not Saint's Triad)\n4. TRUE (This statement applies to Ehlers-Danlos Syndrome, not Saint's Triad)\n5. TRUE (This too is a manifestation of Ehlers-Danlos Syndrome, not Saint's Triad)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Yes, overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer (NSCLC) patients. Studies have shown that high levels of LY6K expression are associated with improved overall survival, disease-free survival, and response to chemotherapy in NSCLC patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer patients.\n2. High levels of LY6K expression are associated with improved overall survival in NSCLC patients.\n3. High levels of LY6K expression are associated with improved disease-free survival in NSCLC patients.\n4. High levels of LY6K expression are associated with an improved response to chemotherapy in NSCLC patients.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer patients.",
      "High levels of LY6K expression are associated with improved overall survival in NSCLC patients.",
      "High levels of LY6K expression are associated with improved disease-free survival in NSCLC patients.",
      "High levels of LY6K expression are associated with an improved response to chemotherapy in NSCLC patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Overexpression of LY6K has been associated with a poor prognosis for non-small cell lung cancer (NSCLC) patients.\n2. FALSE [correction]: High levels of LY6K expression are generally associated with a poor overall survival in NSCLC patients.\n3. FALSE [correction]: High levels of LY6K expression are generally associated with a poor disease-free survival in NSCLC patients.\n4. UNKNOWN\n\nThe usual scientific consensus is that overexpression of certain genes like LY6K is correlated with aggressive tumor behavior and poorer prognoses in various cancer types, including NSCLC. However, without specific research data or consensus, the impact of LY6K on the response to chemotherapy in NSCLC patients cannot be accurately determined, hence the \"UNKNOWN\" for statement 4.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "During cytokinesis, the cell cycle regulator Cdk (cyclin-dependent kinase) is inhibited by phosphorylation, leading to the dephosphorylation of its targets. Some of the known Cdk targets that are dephosphorylated during cytokinesis include:\n1. Cdk1: Cdk1 is inhibited by phosphorylation by the Fyzzy protein during cytokinesis, leading to the dephosphorylation of its targets.\n2. Cdk2: Cdk2 is also inhibited by phosphorylation during cytokinesis, leading to the dephosphorylation of its targets.\n3. Cdk4: Cdk4 is inhibited by phosphorylation during cytokinesis, leading to the dephosphorylation of its targets.\n4. Cdk5: Cdk5 is inhibited by phosphorylation during cytokinesis, leading to the dephosphorylation of its targets.\n5. Cdk6: Cdk6 is inhibited by phosphorylation during cytokinesis, leading to the dephosphorylation of its targets.\n6. Cdk7: Cdk7 is inhibited by phosphorylation during cytokinesis, leading to the dephosphorylation of its targets.\n7. Cdk9: Cdk9 is inhibited by phosphorylation during cytokinesis, leading to the dephosphorylation of its targets.\n8. Mks1: Mks1 is a downstream target of Cdk5 and is inhibited by phosphorylation during cytokinesis.\n9. N-Ras: N-Ras is a downstream target of Cdk4 and is inhibited by phosphorylation during cytokinesis.\n10. Scrib: Scrib is a downstream target of Cdk1 and is inhibited by phosphorylation during cytokinesis.\nThese dephosphorylation events are important for the proper progression of cytokinesis, as they allow the cell to transition from the G2 phase of the cell cycle to the M phase, where the cell can undergo mitosis and complete cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cdk (cyclin-dependent kinase) regulation involves inhibition by phosphorylation during cytokinesis.\n2. Cdk1 is inhibited by phosphorylation by the Fyzzy protein during cytokinesis.\n3. Cdk2, Cdk4, Cdk5, Cdk6, Cdk7, and Cdk9 are inhibited by phosphorylation during cytokinesis.\n4. Mks1 is a downstream target of Cdk5 and is inhibited by phosphorylation during cytokinesis.\n5. N-Ras is a downstream target of Cdk4 and is inhibited by phosphorylation during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "Cdk (cyclin-dependent kinase) regulation involves inhibition by phosphorylation during cytokinesis.",
      "Cdk1 is inhibited by phosphorylation by the Fyzzy protein during cytokinesis.",
      "Cdk2, Cdk4, Cdk5, Cdk6, Cdk7, and Cdk9 are inhibited by phosphorylation during cytokinesis.",
      "Mks1 is a downstream target of Cdk5 and is inhibited by phosphorylation during cytokinesis.",
      "N-Ras is a downstream target of Cdk4 and is inhibited by phosphorylation during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Cdk1 is inhibited by phosphorylation by the Wee1 kinase during cytokinesis, not a protein named Fyzzy.\n3. UNKNOWN\n4. TRUE, assuming information provided is correct as Mks1 can be a substrate for Cdk5.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a drug that inhibits the activity of the enzyme protein kinase C (PKC). PKC is involved in a variety of cellular processes, including cell signaling, metabolism, and cell growth, and is implicated in a number of diseases, including cancer and neurodegenerative disorders. Xanamem is being investigated as a potential therapeutic agent for the treatment of these diseases, as well as for the treatment of cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is a drug that inhibits the activity of the enzyme protein kinase C (PKC).\n2. Protein kinase C is involved in cell signaling, metabolism, and cell growth.\n3. Protein kinase C is implicated in a variety of diseases, including cancer and neurodegenerative disorders.\n4. Xanamem is being investigated as a potential therapeutic agent for the treatment of neurodegenerative disorders.\n5. Xanamem is also being investigated as a potential therapeutic agent for the treatment of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is a drug that inhibits the activity of the enzyme protein kinase C (PKC).",
      "Protein kinase C is involved in cell signaling, metabolism, and cell growth.",
      "Protein kinase C is implicated in a variety of diseases, including cancer and neurodegenerative disorders.",
      "Xanamem is being investigated as a potential therapeutic agent for the treatment of neurodegenerative disorders.",
      "Xanamem is also being investigated as a potential therapeutic agent for the treatment of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nWithout context or a specific source, it's difficult to confirm whether Xanamem specifically inhibits the activity of protein kinase C (PKC), as many drugs may target PKC—hence the first statement is marked as UNKNOWN. Statements about the role of PKC and its implication in diseases are generally accurate, based on our knowledge about this family of enzymes. Statement 4 seems plausible if Xanamem is indeed a PKC inhibitor, since there is research interest in targeting PKC for neurodegenerative disorders. However, without specific information about current research on Xanamem, statement 5 remains UNKNOWN regarding its potential use in treating cancer.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "In yeast, the interaction between Hof1 and Cyk3 plays a crucial role in regulating the cell's response to oxidative stress. Hof1 is a protein that helps to maintain genome stability by repairing DNA damage, while Cyk3 is a protein that helps to regulate the cell's redox state. The interaction between these two proteins helps to coordinate the cell's response to oxidative stress by allowing Hof1 to be activated in response to changes in the cell's redox state. This allows the cell to better protect itself against DNA damage and maintain genome stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction in yeast regulates the cell's response to oxidative stress.\n2. Hof1 is a protein involved in repairing DNA damage.\n3. Cyk3 is a protein that helps regulate the cell's redox state.\n4. The interaction between Hof1 and Cyk3 coordinates the cell’s response to oxidative stress.\n5. Activation of Hof1 in response to changes in the cell's redox state is part of this regulatory mechanism.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction in yeast regulates the cell's response to oxidative stress.",
      "Hof1 is a protein involved in repairing DNA damage.",
      "Cyk3 is a protein that helps regulate the cell's redox state.",
      "The interaction between Hof1 and Cyk3 coordinates the cell’s response to oxidative stress.",
      "Activation of Hof1 in response to changes in the cell's redox state is part of this regulatory mechanism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Hof1 is a protein involved in cytokinesis in yeast, not specifically known for repairing DNA damage.\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nGiven the specificity of the biological functions mentioned, the state of knowledge about these proteins could be subject to recent research. Without current context from the mentioned passage, the statements about the Hof1-Cyk3 interaction's role in oxidative stress response and the specific functions of Cyk3 and Hof1 activation by redox state remain unknown. However, it is known that Hof1 is involved in cytokinesis, and thus the statement about it being involved in DNA repair is incorrect.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "T-bet (T-box transcription factor Eomesodermin) and Eomesodermin (Eomes) are T-UCRs that have been implicated in gastric cancer.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a clinical index used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that can affect multiple organ systems. The LSI is a composite measure that takes into account various clinical and laboratory parameters, including:\n1. Physical examination findings, such as rash, joint swelling, and organ involvement.\n2. Laboratory test results, including levels of autoantibodies, complement components, and inflammatory markers.\n3. Disease activity scores, such as the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) or the Lupus Activity Survey (LAS).\n4. Patient-reported outcomes, such as pain, fatigue, and quality of life.\nThe LSI is calculated by assigning weights to each of these parameters based on their relative importance in determining disease severity, and then adding the scores for each parameter. The total score on the LSI ranges from 0 to 100, with higher scores indicating greater disease severity. The LSI has been shown to be a useful tool for assessing disease activity and monitoring treatment responses in SLE patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is a clinical index used to assess the severity of systemic lupus erythematosus (SLE).\n2. SLE is a chronic autoimmune disease that can affect multiple organ systems.\n3. The LSI includes physical examination findings like rash and joint swelling in its assessment.\n4. The LSI incorporates laboratory test results, such as levels of autoantibodies and complement components.\n5. The total score on the LSI ranges from 0 to 100, with higher scores indicating greater disease severity.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is a clinical index used to assess the severity of systemic lupus erythematosus (SLE).",
      "SLE is a chronic autoimmune disease that can affect multiple organ systems.",
      "The LSI includes physical examination findings like rash and joint swelling in its assessment.",
      "The LSI incorporates laboratory test results, such as levels of autoantibodies and complement components.",
      "The total score on the LSI ranges from 0 to 100, with higher scores indicating greater disease severity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The authenticity of the \"Lupus Severity Index\" (LSI) cannot be determined without additional context, as there are various clinical tools that could potentially be abbreviated as LSI, and the specific index referred to might be hypothetical or less well-known.\n2. TRUE: Systemic lupus erythematosus (SLE) is indeed a chronic autoimmune disease that has the potential to affect multiple organ systems.\n3. TRUE: While the LSI is not specified and its existence is uncertain, clinical indices for assessing SLE typically include physical examination findings such as rash and joint swelling, because these are common clinical manifestations of the disease.\n4. TRUE: Again, assuming the LSI is a clinical index for SLE, it would logically include laboratory test results like autoantibody levels and complement components, as these are important indicators used in the diagnosis and monitoring of SLE.\n5. UNKNOWN: Without specific information about the \"Lupus Severity Index\", the total score range cannot be confirmed. Different clinical indices have different scoring systems.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has been associated with several rare genetic disorders, including:\n1. Zellweger syndrome: ZSWIM6 mutations are a common cause of this severe neonatal syndrome, characterized by hypotonia, developmental delay, and various organ system defects.\n2. Cerebral White Matter Disease (CWMD): Some mutations in ZSWIM6 have been identified in patients with CWMD, a rare genetic disorder characterized by white matter degeneration in the brain.\n3. Intellectual Disability: ZSWIM6 mutations have been found in individuals with intellectual disability, often in combination with other genetic alterations.\n4. Autism Spectrum Disorder (ASD): Some studies have suggested that ZSWIM6 mutations may be associated with an increased risk of autism spectrum disorder (ASD).\n5. Epilepsy: ZSWIM6 mutations have been identified in individuals with epilepsy, particularly those with neonatal-onset epilepsy.\nIt is important to note that these disorders are rare and the frequency of ZSWIM6 mutations in these conditions may vary depending on the population studied.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZSWIM6 mutations are a cause of Zellweger syndrome.\n2. Mutations in ZSWIM6 have been identified in patients with Cerebral White Matter Disease (CWMD).\n3. Individuals with intellectual disability have been found to have ZSWIM6 mutations.\n4. ZSWIM6 mutations may be associated with an increased risk of autism spectrum disorder (ASD).\n5. Individuals with epilepsy, particularly those with neonatal-onset epilepsy, have been identified to have ZSWIM6 mutations.",
    "llama-2-7b-chat-hf_fact": [
      "ZSWIM6 mutations are a cause of Zellweger syndrome.",
      "Mutations in ZSWIM6 have been identified in patients with Cerebral White Matter Disease (CWMD).",
      "Individuals with intellectual disability have been found to have ZSWIM6 mutations.",
      "ZSWIM6 mutations may be associated with an increased risk of autism spectrum disorder (ASD).",
      "Individuals with epilepsy, particularly those with neonatal-onset epilepsy, have been identified to have ZSWIM6 mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ZSWIM6 mutations are not the cause of Zellweger syndrome. PEX genes mutations are typically associated with Zellweger syndrome.\n2. TRUE: Mutations in ZSWIM6 have been identified in patients with Cerebral White Matter Disease (CWMD).\n3. TRUE: Individuals with intellectual disability have been found to have ZSWIM6 mutations.\n4. TRUE: ZSWIM6 mutations may be associated with an increased risk of autism spectrum disorder (ASD).\n5. TRUE: Individuals with epilepsy, particularly those with neonatal-onset epilepsy, have been identified to have ZSWIM6 mutations.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is used to classify diseases related to the nervous system, particularly those affecting the brain and spinal cord. It is commonly used to classify neurodegenerative diseases, such as:\n1. Alzheimer's disease\n2. Parkinson's disease\n3. Huntington's disease\n4. Progressive supranuclear palsy\n5. Multiple system atrophy\n6. Corticobasal degeneration\n7. Primary lateral sclerosis\n8. Spinocerebellar ataxia\nThese diseases are characterized by progressive loss of neurons and degeneration of brain tissue, leading to a range of cognitive, motor, and behavioral symptoms. The Koos Classification provides a standardized framework for classifying and diagnosing these diseases, which can help guide treatment and research efforts.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify diseases of the nervous system.\n2. Alzheimer's disease is classified under the Koos Classification.\n3. Parkinson's disease is classified under the Koos Classification.\n4. Huntington's disease is classified under the Koos Classification.\n5. Spinocerebellar ataxia is classified under the Koos Classification.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify diseases of the nervous system.",
      "Alzheimer's disease is classified under the Koos Classification.",
      "Parkinson's disease is classified under the Koos Classification.",
      "Huntington's disease is classified under the Koos Classification.",
      "Spinocerebellar ataxia is classified under the Koos Classification."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Koos Classification is specifically used to classify vestibular schwannomas (also known as acoustic neuromas), not diseases of the nervous system in general.\n2. FALSE [correction]: Alzheimer's disease is not classified under the Koos Classification as it is used for vestibular schwannomas, not general neurological diseases.\n3. FALSE [correction]: Parkinson's disease is not classified under the Koos Classification, as this system is for vestibular schwannomas.\n4. FALSE [correction]: Huntington's disease is not classified under the Koos Classification, which is relevant for vestibular schwannomas.\n5. FALSE [correction]: Spinocerebellar ataxia is not classified under the Koos Classification since it is a classification for vestibular schwannomas.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a potent and selective inhibitor of the enzyme PI3K (phosphatidylinositol 3-kinase), which plays a key role in various cellular signaling pathways, including those involved in cell survival, growth, and migration. In vivo, AZD8601 has been shown to have a range of effects, including:\n1. Inhibition of tumor growth: AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer, both in vitro and in vivo.\n2. Induction of apoptosis: AZD8601 can induce apoptosis (programmed cell death) in cancer cells, which can help to slow or stop the growth of tumors.\n3. Inhibition of angiogenesis: AZD8601 can inhibit the formation of new blood vessels, which are essential for the growth and spread of solid tumors.\n4. Enhancement of chemotherapy: AZD8601 can enhance the effects of chemotherapy drugs, such as paclitaxel, in killing cancer cells.\n5. Immune modulation: AZD8601 can modulate the immune response, including the activation of immune cells and the production of cytokines, which can help to combat cancer.\n6. Neuroprotection: AZD8601 has been shown to have neuroprotective effects in animal models of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.\n7. Cardiovascular protection: AZD8601 has been shown to have cardiovascular protective effects in animal models of heart disease, including reducing inflammation and improving cardiac function.\n8. Metabolic protection: AZD8601 has been shown to have metabolic protective effects in animal models of metabolic disorders, including reducing insulin resistance and improving glucose tolerance.\nIt is important to note that the specific in vivo effects of AZD8601 can vary depending on the specific disease or condition being studied, as well as the",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 inhibits the growth of various tumors, including breast, lung, and colon cancer, in vivo.\n2. AZD8601 induces apoptosis in cancer cells.\n3. AZD8601 inhibits angiogenesis, the formation of new blood vessels.\n4. AZD8601 enhances the effects of chemotherapy drugs such as paclitaxel in killing cancer cells.\n5. AZD8601 has cardio-protective effects in animal models of heart disease.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 inhibits the growth of various tumors, including breast, lung, and colon cancer, in vivo.",
      "AZD8601 induces apoptosis in cancer cells.",
      "AZD8601 inhibits angiogenesis, the formation of new blood vessels.",
      "AZD8601 enhances the effects of chemotherapy drugs such as paclitaxel in killing cancer cells.",
      "AZD8601 has cardio-protective effects in animal models of heart disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: AZD8601 is actually known for its potential in cardiovascular disease treatment by promoting the expression of the protein VEGF-A, which can enhance heart function. There's no information provided in the context regarding its effect on tumor growth.\n2. UNKNOWN: The context does not provide specific information on whether AZD8601 induces apoptosis in cancer cells.\n3. UNKNOWN: Although AZD8601 is associated with the promotion of VEGF-A which is involved in angiogenesis, whether it inhibits or promotes angiogenesis is not specified in the context provided.\n4. UNKNOWN: Without information from the context, it's unclear if AZD8601 enhances the effects of chemotherapy drugs.\n5. TRUE: AZD8601 is designed to have cardio-protective effects, as it promotes the expression of VEGF-A, which has been shown to improve cardiac function in animal models of heart disease.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "SAHFs (SWI/SNF-associated histone-fold proteins) are created through a process called \"chromatin remodeling,\" which involves the movement of nucleosomes along DNA strands. This process is mediated by protein complexes called SWI/SNF complexes, which use energy from ATP hydrolysis to move nucleosomes along DNA strands, creating more accessible chromatin structures. As a result, SAHFs are formed through the collective action of multiple SWI/SNF complexes working together to remodel chromatin structures.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFs are created through a process called \"chromatin remodeling.\"\n2. Chromatin remodeling involves the movement of nucleosomes along DNA strands.\n3. SWI/SNF complexes mediate the chromatin remodeling process.\n4. SWI/SNF complexes use energy from ATP hydrolysis to move nucleosomes along DNA strands.\n5. The formation of SAHFs involves multiple SWI/SNF complexes working together.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFs are created through a process called \"chromatin remodeling.\"",
      "Chromatin remodeling involves the movement of nucleosomes along DNA strands.",
      "SWI/SNF complexes mediate the chromatin remodeling process.",
      "SWI/SNF complexes use energy from ATP hydrolysis to move nucleosomes along DNA strands.",
      "The formation of SAHFs involves multiple SWI/SNF complexes working together."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Senescence-associated heterochromatin foci (SAHFs) are typically formed through changes that lead to condensed chromatin structures, which may involve chromatin remodeling, but they are not solely created by this process.\n2. TRUE\n3. TRUE: SWI/SNF complexes are one of the complexes that mediate chromatin remodeling.\n4. TRUE\n5. UNKNOWN: The formation of SAHFs could involve multiple complexes, but without specific information regarding SWI/SNF complexes in this context, the involvement of multiple SWI/SNF complexes is uncertain.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "The PDZ (PSD-95, Discs-large, ZO-1) domain is a structural motif found in the SATB1 protein that plays a crucial role in its function. The PDZ domain is involved in the binding of SATB1 to specific protein partners, such as the transcription factor p53, and regulates the localization and activity of these proteins. Specifically, the PDZ domain of SATB1 can interact with the transcriptional activation domain of p53, leading to the suppression of p53-dependent transcription and the regulation of p53 stability. This suggests that the PDZ domain of SATB1 may play a role in regulating the tumor suppressor function of p53 in certain contexts.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain is a structural motif found in the SATB1 protein.\n2. The PDZ domain in SATB1 is involved in binding to specific protein partners.\n3. One of the proteins that the PDZ domain of SATB1 binds to is the transcription factor p53.\n4. Interaction of the SATB1 PDZ domain with p53 can lead to suppression of p53-dependent transcription.\n5. The PDZ domain of SATB1 may regulate the stability of p53.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain is a structural motif found in the SATB1 protein.",
      "The PDZ domain in SATB1 is involved in binding to specific protein partners.",
      "One of the proteins that the PDZ domain of SATB1 binds to is the transcription factor p53.",
      "Interaction of the SATB1 PDZ domain with p53 can lead to suppression of p53-dependent transcription.",
      "The PDZ domain of SATB1 may regulate the stability of p53."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The PDZ domain is a structural motif found in various proteins, and it could potentially be found in the SATB1 protein as well, given that SATB1 is known to interact with various proteins.\n2. TRUE: PDZ domains are generally known for binding to specific protein partners, often through interactions with the C-terminus of other proteins.\n3. FALSE [correction]: There is no widely recognized interaction between the PDZ domain of SATB1 and the transcription factor p53. SATB1 is mainly known for its role in chromatin organization and gene regulation, but this specific interaction with p53 via its PDZ domain is not established in scientific literature.\n4. UNKNOWN: Given that the direct interaction between the PDZ domain of SATB1 and p53 is not established, the effect on p53-dependent transcription is also not known.\n5. UNKNOWN: Since there's no established interaction between SATB1's PDZ domain and p53, the statement regarding regulation of the stability of p53 by the PDZ domain of SATB1 cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The basis of the BLISS (Bias-free Learning of Incremental Support Vector Machines) technique is to address the problem of bias in incremental learning, which can occur when an incremental learning algorithm is trained on a dataset that is not representative of the true distribution of the data. BLISS uses a novel regularization term to encourage the incremental learning algorithm to learn a representation that is robust to changes in the data distribution, and thus avoids bias in the learning process.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique stands for Bias-free Learning of Incremental Support Vector Machines.\n2. The BLISS technique is designed to address the problem of bias in incremental learning.\n3. Bias in incremental learning can occur when an algorithm is trained on a dataset not representative of the true distribution of the data.\n4. BLISS uses a novel regularization term to encourage robustness to changes in data distribution.\n5. The goal of BLISS is to avoid bias in the learning process of an incremental learning algorithm.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique stands for Bias-free Learning of Incremental Support Vector Machines.",
      "The BLISS technique is designed to address the problem of bias in incremental learning.",
      "Bias in incremental learning can occur when an algorithm is trained on a dataset not representative of the true distribution of the data.",
      "BLISS uses a novel regularization term to encourage robustness to changes in data distribution.",
      "The goal of BLISS is to avoid bias in the learning process of an incremental learning algorithm."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: BLISS stands for Bias Less Incremental Learning for Support Vector Machines, not Bias-free Learning of Incremental Support Vector Machines.\n2. TRUE\n3. TRUE\n4. UNKNOWN [justification]: Without more context on the specifics of the BLISS technique, it’s not possible to confirm whether it uses a novel regularization term for robustness to changes in data distribution.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Here are three known NK3R antagonists:\n1. A-83-01: A potent and selective NK3R antagonist that has been shown to reduce food intake and body weight in animal models of obesity.\n2. BIBN4096: A highly selective and potent NK3R antagonist that has been shown to reduce food intake and body weight in animal models of obesity.\n3. MK-0594: A potent and selective NK3R antagonist that has been shown to reduce food intake and body weight in animal models of obesity.",
    "llama-2-7b-chat-hf_fact_raw": "1. A-83-01 is a selective NK3R antagonist.\n2. BIBN4096 is a highly selective and potent NK3R antagonist.\n3. MK-0594 is a selective NK3R antagonist.",
    "llama-2-7b-chat-hf_fact": [
      "A-83-01 is a selective NK3R antagonist.",
      "BIBN4096 is a highly selective and potent NK3R antagonist.",
      "MK-0594 is a selective NK3R antagonist."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nThe provided statements might be accurate descriptions of pharmaceutical compounds concerning their function and specificity as NK3R (neurokinin 3 receptor) antagonists. However, without specific and reliable scientific references or context to confirm these assertions, the veracity of these statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is called BMS-986177.",
    "llama-2-7b-chat-hf_fact_raw": "1. BMS-986177 is an oral ghrelin receptor inverse agonist.\n2. BMS-986177 was the first of its kind to be profiled in healthy subjects.",
    "llama-2-7b-chat-hf_fact": [
      "BMS-986177 is an oral ghrelin receptor inverse agonist.",
      "BMS-986177 was the first of its kind to be profiled in healthy subjects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: BMS-986177 is an oral, direct Factor XIa inhibitor, not a ghrelin receptor inverse agonist.\n2. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora, a cholera vaccine made by Sanofi Pasteur, has been shown to provide protection against moderate to severe cholera in clinical trials. The protective efficacy of Vaxchora against moderate to severe cholera has been estimated to be around 70-80% in adults and 50-60% in children, based on the results of Phase 3 clinical trials conducted in Bangladesh, Haiti, and Indonesia. It is important to note that the vaccine does not provide 100% protection against cholera, and it is still possible to contract the disease even after vaccination. Therefore, it is important to continue practicing good hygiene and sanitation practices, such as proper handwashing and water treatment, to reduce the risk of cholera infection.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is a cholera vaccine produced by Sanofi Pasteur.\n2. The protective efficacy of Vaxchora against moderate to severe cholera in adults has been estimated to be around 70-80%.\n3. The protective efficacy of Vaxchora against moderate to severe cholera in children has been estimated to be around 50-60%.\n4. The results of the Vaxchora's efficacy come from Phase 3 clinical trials conducted in Bangladesh, Haiti, and Indonesia.\n5. The vaccine does not provide 100% protection against cholera.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is a cholera vaccine produced by Sanofi Pasteur.",
      "The protective efficacy of Vaxchora against moderate to severe cholera in adults has been estimated to be around 70-80%.",
      "The protective efficacy of Vaxchora against moderate to severe cholera in children has been estimated to be around 50-60%.",
      "The results of the Vaxchora's efficacy come from Phase 3 clinical trials conducted in Bangladesh, Haiti, and Indonesia.",
      "The vaccine does not provide 100% protection against cholera."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Vaxchora is a cholera vaccine produced by PaxVax, not Sanofi Pasteur.\n2. TRUE\n3. UNKNOWN: Without specific data from credible sources regarding the protective efficacy of Vaxchora in children, the accuracy of this statement cannot be determined.\n4. UNKNOWN: Without access to detailed clinical trial reports or reliable sources confirming the locations of Phase 3 clinical trials for Vaxchora, the accuracy of this statement cannot be determined.\n5. TRUE: No vaccine offers 100% protection against disease, including Vaxchora. It is common for vaccines to be effective but not to provide complete immunity to every individual.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US was the oral cholera vaccine (OCV), also known as the killed oral cholera vaccine, which was approved in 1981 by the Food and Drug Administration (FDA).",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US was an oral cholera vaccine (OCV).\n2. The oral cholera vaccine approved in the US was a killed oral cholera vaccine.\n3. The US Food and Drug Administration (FDA) approved the oral cholera vaccine in 1981.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US was an oral cholera vaccine (OCV).",
      "The oral cholera vaccine approved in the US was a killed oral cholera vaccine.",
      "The US Food and Drug Administration (FDA) approved the oral cholera vaccine in 1981."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The US Food and Drug Administration (FDA) approved the oral cholera vaccine called Vaxchora in 2016.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is mutations in the IL21R gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the IL21R gene are the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the IL21R gene are the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the IL21R gene can cause CVID, but the most common genetic cause of CVID in Europeans involves mutations in the TNFRSF13B gene, which encodes the TACI protein.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene has been found to be mutated in some patients with Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease. The IFIT1 gene encodes for a protein called interferon-induced protein with tetraloop-forming domain 1 (IFIT1), which plays a role in the antiviral response and the regulation of immune cell function.\nMutations in the IFIT1 gene have been associated with an increased risk of developing SLE, as well as with more severe disease manifestations and a higher risk of organ damage. IFIT1 mutations may lead to an imbalance in the immune system, allowing for the overproduction of autoantibodies and the development of autoimmune responses.\nAdditionally, IFIT1 has been shown to be involved in the regulation of the immune response to DNA, and mutations in the IFIT1 gene may affect the ability of the immune system to recognize and respond to DNA from viruses and other foreign molecules, leading to an increased risk of infection and autoimmune diseases.\nOverall, the IFIT1 gene plays a critical role in the regulation of the immune response and its mutation can lead to the development of SLE and other autoimmune diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the IFIT1 gene have been found in some patients with Systemic Lupus Erythematosus (SLE).\n2. The IFIT1 gene encodes for a protein called interferon-induced protein with tetraloop-forming domain 1, which is involved in the antiviral response and immune cell function regulation.\n3. Mutations in the IFIT1 gene are associated with an increased risk of developing SLE.\n4. Patients with IFIT1 mutations may experience more severe disease manifestations and a higher risk of organ damage in the context of SLE.\n5. The IFIT1 gene is involved in the regulation of the immune response to DNA, and mutations can affect the immune system's ability to respond to viral DNA and other foreign molecules.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the IFIT1 gene have been found in some patients with Systemic Lupus Erythematosus (SLE).",
      "The IFIT1 gene encodes for a protein called interferon-induced protein with tetraloop-forming domain 1, which is involved in the antiviral response and immune cell function regulation.",
      "Mutations in the IFIT1 gene are associated with an increased risk of developing SLE.",
      "Patients with IFIT1 mutations may experience more severe disease manifestations and a higher risk of organ damage in the context of SLE.",
      "The IFIT1 gene is involved in the regulation of the immune response to DNA, and mutations can affect the immune system's ability to respond to viral DNA and other foreign molecules."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements regarding the IFIT1 gene and its relationship to SLE rely on knowledge of specific genetic associations and clinical observations that require referencing medical research literature. Without specific sources cited for these particular details about the IFIT1 gene and SLE, their veracity cannot be determined from common knowledge alone. Therefore, while statement 2 seems plausible as it describes a general role of a protein encoded by IFIT1, the exact relationship of the gene with SLE as described in statements 1, 3, 4, and 5 cannot be verified without additional information.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a patient-reported outcome measure used to assess the severity of elbow symptoms and disability in patients with elbow problems, such as tennis elbow (lateral epicondylitis) or golfer's elbow (medial epicondylitis). The LES assesses the impact of elbow symptoms on daily activities and quality of life, and can be used to monitor the effectiveness of treatment interventions. The score is based on a series of questions that ask patients to rate their level of agreement with statements related to elbow symptoms and function, such as \"I am able to perform my usual activities without pain\" or \"I am unable to perform activities that I enjoy due to my elbow symptoms.\" The LES is a useful tool for clinicians to evaluate the severity of elbow symptoms and to track changes in symptoms over time, as well as to compare outcomes between different treatment groups.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to assess the severity of elbow symptoms and disability.\n2. It is a patient-reported outcome measure.\n3. LES can be used for conditions such as tennis elbow (lateral epicondylitis) or golfer's elbow (medial epicondylitis).\n4. The tool evaluates the impact of elbow symptoms on daily activities and quality of life.\n5. The LES helps clinicians monitor the effectiveness of treatment interventions and track changes in symptoms over time.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to assess the severity of elbow symptoms and disability.",
      "It is a patient-reported outcome measure.",
      "LES can be used for conditions such as tennis elbow (lateral epicondylitis) or golfer's elbow (medial epicondylitis).",
      "The tool evaluates the impact of elbow symptoms on daily activities and quality of life.",
      "The LES helps clinicians monitor the effectiveness of treatment interventions and track changes in symptoms over time."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nIt should be noted that while the statements 2 through 5 are generally true for patient-reported outcome measures assessing conditions affecting joints like the elbow, the first statement's accuracy depends on whether a \"Liverpool Elbow Score\" exists and is actually used for that purpose. Without specific knowledge or a reliable source confirming the existence and use of the LES, the truth of statement 1 cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project was a major initiative launched in the UK in 2012 to sequence 100,000 human genomes, including those of patients with rare and aggressive cancers such as sarcoma. The project aimed to identify genetic variations associated with these cancers and develop new diagnostic and therapeutic approaches. Here are some key efforts on sarcoma from the 100,000 Genomes Project:\n1. Genomic analysis of sarcoma subtypes: The project analyzed the genomes of over 1,000 sarcoma tumors, including different subtypes such as osteosarcoma, chondrosarcoma, and soft tissue sarcoma. These analyses identified recurrent mutations and copy number alterations that are specific to each subtype.\n2. Identification of new therapeutic targets: The project identified potential therapeutic targets for sarcoma, including genes involved in DNA damage repair, cell cycle regulation, and angiogenesis. These targets could be explored for the development of new sarcoma therapies.\n3. Development of diagnostic tests: The project developed new diagnostic tests for sarcoma based on genetic markers identified in the genomic analysis. These tests could help improve the accuracy of sarcoma diagnosis and enable more targeted and effective treatment.\n4. Improved understanding of sarcoma evolution: The project provided insights into the evolution of sarcoma, including the mechanisms of resistance to chemotherapy and the role of genetic mutations in tumor progression. This knowledge could be used to develop new treatment strategies and improve patient outcomes.\n5. Collaboration with clinical partners: The project collaborated with clinical partners to validate the findings and translate them into clinical practice. This collaboration helped ensure that the research was relevant and useful for patients and clinicians.\nIn summary, the 100,000 Genomes Project has made significant efforts to improve our understanding of sarcoma and develop new diagnostic and therapeutic approaches. The project's findings have the potential to improve patient outcomes and advance the field of sarcoma research.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in the UK in 2012 to sequence 100,000 human genomes.\n2. The project analyzed the genomes of over 1,000 sarcoma tumors, including subtypes such as osteosarcoma, chondrosarcoma, and soft tissue sarcoma.\n3. Genomic analysis from the project identified potential therapeutic targets for sarcoma.\n4. New diagnostic tests for sarcoma were developed based on genetic markers identified from the 100,000 Genomes Project.\n5. The project collaborated with clinical partners to validate findings and integrate them into clinical practice.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in the UK in 2012 to sequence 100,000 human genomes.",
      "The project analyzed the genomes of over 1,000 sarcoma tumors, including subtypes such as osteosarcoma, chondrosarcoma, and soft tissue sarcoma.",
      "Genomic analysis from the project identified potential therapeutic targets for sarcoma.",
      "New diagnostic tests for sarcoma were developed based on genetic markers identified from the 100,000 Genomes Project.",
      "The project collaborated with clinical partners to validate findings and integrate them into clinical practice."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 100,000 Genomes Project was launched in the UK in 2013 to sequence 100,000 human genomes.\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Yes, protein ALEX1 (Armadillo-like Expressed in Xenopus 1) contains multiple armadillo repeats. Armadillo repeats are a structural motif found in proteins that are involved in protein-protein interactions and are characterized by a conserved pattern of amino acid residues. ALEX1 is a protein that is involved in the regulation of gene expression and contains multiple armadillo repeats in its structure.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 contains multiple armadillo repeats.\n2. Armadillo repeats are a structural motif involved in protein-protein interactions.\n3. Armadillo repeats are characterized by a conserved pattern of amino acid residues.\n4. ALEX1 is involved in the regulation of gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 contains multiple armadillo repeats.",
      "Armadillo repeats are a structural motif involved in protein-protein interactions.",
      "Armadillo repeats are characterized by a conserved pattern of amino acid residues.",
      "ALEX1 is involved in the regulation of gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n\nExplanation:\nWithout a specific and recognized scientific context or reference for \"Protein ALEX1,\" the statement about its characteristics such as containing armadillo repeats and its function in gene expression regulation cannot be verified as true or false. The properties of armadillo repeats as structural motifs involved in protein-protein interactions and having a conserved pattern of amino acid residues are accurately described. Therefore, statements 2 and 3 are true. However, without specific information on ALEX1, we cannot confirm the specifics of statement 1 or 4.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Enzymes that remove histone modifications include:\n1. Histone demethylases: These enzymes remove methyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of histone demethylases include KDM5A, KDM5B, and JMJD2A.\n2. Histone acetyltransferases (HATs): These enzymes add acetyl groups to histone proteins, leading to changes in chromatin structure and gene expression. Examples of HATs include p300 and CBP (CREB-binding protein).\n3. Histone deacetylases (HDACs): These enzymes remove acetyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of HDACs include HDAC1, HDAC2, and HDAC6.\n4. Lysine-specific demethylase 1 (LSD1): This enzyme removes methyl groups from histone H3 lysine 4, leading to changes in chromatin structure and gene expression.\n5. Arginine methyltransferases: These enzymes add methyl groups to histone arginine residues, leading to changes in chromatin structure and gene expression. Examples of arginine methyltransferases include PRMT5 and PRMT1.\n6. Prolyl isomerases: These enzymes rearrange the chemical bonds in histone proteins, leading to changes in chromatin structure and gene expression. Examples of prolyl isomerases include PIN1 and PIN2.\n7. Chromodomains-containing proteins: These proteins recognize and bind to specific histone modifications, leading to changes in chromatin structure and gene expression. Examples of chromodomains-containing proteins include CHD1 and CHD4.\n8. Sirtuins: These enzymes remove acetyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of sirtuins include SIRT1 and SIRT6.\n9. Ubiquitin-protein ligases (E3s): These enzymes ubiquitinate histone proteins, leading to changes in chrom",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases remove methyl groups from histone proteins.\n2. Histone acetyltransferases (HATs) add acetyl groups to histone proteins.\n3. Histone deacetylases (HDACs) remove acetyl groups from histone proteins.\n4. Lysine-specific demethylase 1 (LSD1) removes methyl groups from histone H3 lysine 4.\n5. Sirtuins remove acetyl groups from histone proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases remove methyl groups from histone proteins.",
      "Histone acetyltransferases (HATs) add acetyl groups to histone proteins.",
      "Histone deacetylases (HDACs) remove acetyl groups from histone proteins.",
      "Lysine-specific demethylase 1 (LSD1) removes methyl groups from histone H3 lysine 4.",
      "Sirtuins remove acetyl groups from histone proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Head CT (computed tomography) scans are diagnostic imaging tests that use X-rays to produce detailed cross-sectional images of the brain. While head CT scans are valuable for diagnosing and monitoring various conditions affecting the brain, there is some evidence to suggest that repeated exposure to CT radiation may increase the risk of developing a brain tumor.\nThe International Agency for Research on Cancer (IARC) has classified CT scans as \"possibly carcinogenic to humans,\" based on limited evidence in humans and sufficient evidence in animals. However, it's important to note that the overall risk of developing a brain tumor from a single head CT scan is still relatively low, and the benefits of the test often outweigh the potential risks.\nStudies have suggested that exposure to CT radiation may increase the risk of developing a brain tumor, particularly for children and adolescents, who are more sensitive to radiation. The risk may be higher for people who have had multiple CT scans over time. However, the exact mechanisms by which CT radiation increases the risk of brain tumors are not yet fully understood, and more research is needed to determine the precise risk.\nTo minimize the risks associated with head CT scans, healthcare providers are advised to use the lowest possible dose of radiation necessary to produce diagnostic images, and to consider alternative imaging modalities when possible. Additionally, patients can help reduce their exposure to CT radiation by avoiding unnecessary scans and discussing any concerns they may have with their healthcare provider.\nIn summary, while head CT scans may increase the risk of developing a brain tumor, the overall risk is still relatively low, and the benefits of the test often outweigh the potential risks. However, it's important to be aware of the potential risks and to take steps to minimize exposure to CT radiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Head CT scans use X-rays to produce detailed cross-sectional images of the brain.\n2. The International Agency for Research on Cancer has classified CT scans as \"possibly carcinogenic to humans.\"\n3. Repeated exposure to CT radiation may increase the risk of developing a brain tumor, especially in children and adolescents.\n4. Healthcare providers are advised to use the lowest possible dose of radiation necessary for diagnostic images from head CT scans.\n5. The overall risk of developing a brain tumor from a single head CT scan is relatively low.",
    "llama-2-7b-chat-hf_fact": [
      "Head CT scans use X-rays to produce detailed cross-sectional images of the brain.",
      "The International Agency for Research on Cancer has classified CT scans as \"possibly carcinogenic to humans.\"",
      "Repeated exposure to CT radiation may increase the risk of developing a brain tumor, especially in children and adolescents.",
      "Healthcare providers are advised to use the lowest possible dose of radiation necessary for diagnostic images from head CT scans.",
      "The overall risk of developing a brain tumor from a single head CT scan is relatively low."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is associated with neural pluripotency.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with neural pluripotency.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with neural pluripotency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Otx2 is not directly associated with neural pluripotency. Otx2 is a homeobox transcription factor involved in the development of the brain and sensory systems, but the term \"neural pluripotency\" generally refers to the capability of cells to develop into all types of neural cells, which is more often attributed to stem cell factors than to Otx2.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The murine beta globin locus region has several DNase I hypersensitive sites (DHS), which are regions of chromatin that are more accessible to DNase I digestion due to the lack of nucleosomes or other chromatin structures. The exact number of DHS sites at the murine beta globin locus region can vary depending on the specific method used to identify them, but there are typically several dozen to several hundred DHS sites located throughout the region. Some of the most well-characterized DHS sites at the beta globin locus include:\n1. DHS1: located at the 5' end of the beta globin gene cluster, near the promoter and enhancer elements.\n2. DHS2: located in the intron 1 of the beta globin gene, near the splice site.\n3. DHS3: located in the 3' untranslated region (UTR) of the beta globin gene.\n4. DHS4: located near the polyadenylation site of the beta globin mRNA.\n5. DHS5: located in the intergenic region between the beta globin gene and the alpha globin gene.\n6. DHS6: located in the 5' end of the alpha globin gene.\nThese DHS sites play important roles in regulating the expression of the beta globin gene, including recruiting transcription factors, chromatin remodelers, and other regulatory proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. The murine beta globin locus region typically has several dozen to several hundred DNase I hypersensitive sites (DHS).\n2. DHS1 is located at the 5' end of the beta globin gene cluster, near promoter and enhancer elements.\n3. DHS2 is located in the intron 1 of the beta globin gene, near the splice site.\n4. DHS3 is located in the 3' untranslated region (UTR) of the beta globin gene.\n5. DHS5 is located in the intergenic region between the beta globin gene and the alpha globin gene.",
    "llama-2-7b-chat-hf_fact": [
      "The murine beta globin locus region typically has several dozen to several hundred DNase I hypersensitive sites (DHS).",
      "DHS1 is located at the 5' end of the beta globin gene cluster, near promoter and enhancer elements.",
      "DHS2 is located in the intron 1 of the beta globin gene, near the splice site.",
      "DHS3 is located in the 3' untranslated region (UTR) of the beta globin gene.",
      "DHS5 is located in the intergenic region between the beta globin gene and the alpha globin gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The murine beta globin locus region typically has a few key DNase I hypersensitive sites (DHS), not several dozen to several hundred.\n2. TRUE\n3. FALSE [correction]: DHS sites typically do not reside within introns near splice sites; rather, they are often located in regulatory regions such as promoters, enhancers, and silencers. Without explicit evidence for the DHS2 location, the specific claim of its intronic location is incorrect.\n4. UNKNOWN: Without specific literature or context for the murine beta globin locus, the precise location of DHS3 cannot be confirmed.\n5. FALSE [correction]: DHS elements are found near regulatory regions, and the intergenic region between the beta globin gene and the alpha globin gene is not a typical location for a DHS, especially given that the beta and alpha globin genes are located on different chromosomes in humans and likely similarly in mice. DHS5 is typically near the locus control region (LCR) of the beta globin gene cluster, not between beta globin and alpha globin genes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "There are several European influenza vaccines available in the market. Here are some of them:\n1. Fluarix Tetra: This is a quadrivalent vaccine that protects against four strains of influenza: two A strains and two B strains. It is manufactured by GlaxoSmithKline (GSK) and is approved for use in individuals aged 6 months and older.\n2. Fluad: This is a quadrivalent vaccine that protects against four strains of influenza: two A strains and two B strains. It is manufactured by Novartis and is approved for use in individuals aged 65 years and older.\n3. Fluvirin: This is a trivalent vaccine that protects against three strains of influenza: two A strains and one B strain. It is manufactured by Novartis and is approved for use in individuals aged 6 months and older.\n4. Fluzone: This is a trivalent vaccine that protects against three strains of influenza: two A strains and one B strain. It is manufactured by Sanofi Pasteur and is approved for use in individuals aged 6 months and older.\n5. Aggripulse: This is a quadrivalent vaccine that protects against four strains of influenza: two A strains and two B strains. It is manufactured by Sanofi Pasteur and is approved for use in individuals aged 6 months and older.\n6. Vaxigrip: This is a quadrivalent vaccine that protects against four strains of influenza: two A strains and two B strains. It is manufactured by Sanofi Pasteur and is approved for use in individuals aged 6 months and older.\n7. Fluarix: This is a quadrivalent vaccine that protects against four strains of influenza: two A strains and two B strains. It is manufactured by GSK and is approved for use in individuals aged 6 months and older.\n8. Flu-Tetra: This is a quadrivalent vaccine that protects against four strains of influenza: two A strains and two B strains. It is manufactured by Bio-Medica and is approved for use in individuals",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluarix Tetra is a quadrivalent influenza vaccine approved for use in individuals aged 6 months and older, manufactured by GlaxoSmithKline (GSK).\n2. Fluad is a quadrivalent influenza vaccine approved for use in individuals aged 65 years and older, manufactured by Novartis.\n3. Fluvirin is a trivalent influenza vaccine approved for use in individuals aged 6 months and older, manufactured by Novartis.\n4. Fluzone is a trivalent influenza vaccine approved for use in individuals aged 6 months and older, manufactured by Sanofi Pasteur.\n5. Vaxigrip is a quadrivalent influenza vaccine approved for use in individuals aged 6 months and older, manufactured by Sanofi Pasteur.",
    "llama-2-7b-chat-hf_fact": [
      "Fluarix Tetra is a quadrivalent influenza vaccine approved for use in individuals aged 6 months and older, manufactured by GlaxoSmithKline (GSK).",
      "Fluad is a quadrivalent influenza vaccine approved for use in individuals aged 65 years and older, manufactured by Novartis.",
      "Fluvirin is a trivalent influenza vaccine approved for use in individuals aged 6 months and older, manufactured by Novartis.",
      "Fluzone is a trivalent influenza vaccine approved for use in individuals aged 6 months and older, manufactured by Sanofi Pasteur.",
      "Vaxigrip is a quadrivalent influenza vaccine approved for use in individuals aged 6 months and older, manufactured by Sanofi Pasteur."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Fluad is a trivalent influenza vaccine approved for use in individuals aged 65 years and older, and as of my knowledge cutoff date, it is manufactured by Seqirus, not Novartis.\n3. UNKNOWN: Fluvirin has been a trivalent influenza vaccine, but without a current year reference and manufacturing details subject to change, the approval status and manufacturer cannot be confirmed.\n4. FALSE [correction]: Fluzone is available in both trivalent (Fluzone High-Dose) and quadrivalent formulations. Fluzone High-Dose is approved for use in individuals aged 65 years and older, while other Fluzone quadrivalent vaccines are approved for younger ages.\n5. UNKNOWN: Vaxigrip is indeed a name associated with influenza vaccines, but without a current year reference, the specific formulation (trivalent or quadrivalent) and the age indications cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the paramyxovirus geneome is segmented, negative-sense RNA. Paramyxoviruses are a family of viruses that include the measles virus, mumps virus, and respiratory syncytial virus (RSV), among others. Their genome is composed of several segments of negative-sense RNA, each of which encodes a different protein. The segments are connected by non-coding regions called introns, and the entire genome is transcribed in a 3' to 5' direction. The negative-sense RNA genome is then translated into protein through a process called transcriptional translation, in which the RNA is first transcribed into a complementary RNA (cRNA) and then translated into protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. The paramyxovirus genome is segmented.\n2. The paramyxovirus genome consists of negative-sense RNA.\n3. Paramyxoviruses include the measles virus, mumps virus, and respiratory syncytial virus (RSV).\n4. Each segment of the paramyxovirus genome encodes a different protein.\n5. The genome of paramyxoviruses is transcribed in a 3' to 5' direction.\n\nNote: The response provided in the original answer contains inaccuracies that need to be addressed. The paramyxovirus genome is not segmented; it is a single strand of non-segmented, negative-sense RNA. The correct factual statement should be that the paramyxovirus genome consists of negative-sense RNA, rather than being segmented. The following is a corrected response based on accurate scientific knowledge:\n\nCorrected Response:\n1. The paramyxovirus genome consists of negative-sense RNA.\n2. Paramyxoviruses include the measles virus, mumps virus, and respiratory syncytial virus (RSV).\n3. The paramyxovirus genome is non-segmented.\n4. The paramyxovirus genome is transcribed in a 3' to 5' direction.",
    "llama-2-7b-chat-hf_fact": [
      "The paramyxovirus genome is segmented.",
      "The paramyxovirus genome consists of negative-sense RNA.",
      "Paramyxoviruses include the measles virus, mumps virus, and respiratory syncytial virus (RSV).",
      "Each segment of the paramyxovirus genome encodes a different protein.",
      "The genome of paramyxoviruses is transcribed in a 3' to 5' direction.",
      "te: The response provided in the original answer contains inaccuracies that need to be addressed. The paramyxovirus genome is not segmented; it is a single strand of non-segmented, negative-sense RNA. The correct factual statement should be that the paramyxovirus genome consists of negative-sense RNA, rather than being segmented. The following is a corrected response based on accurate scientific knowledge:",
      "rrected Response:",
      "The paramyxovirus genome consists of negative-sense RNA.",
      "Paramyxoviruses include the measles virus, mumps virus, and respiratory syncytial virus (RSV).",
      "The paramyxovirus genome is non-segmented.",
      "The paramyxovirus genome is transcribed in a 3' to 5' direction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The paramyxovirus genome is non-segmented.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The entire paramyxovirus genome is a single, non-segmented strand, so it does not have segments each encoding a different protein.\n5. FALSE [correction]: The genome of paramyxoviruses is transcribed in a 5' to 3' direction. RNA polymerases generally transcribe RNA in a 5' to 3' direction.\n6. UNKNOWN\n7. UNKNOWN\n8. TRUE\n9. TRUE\n10. TRUE\n11. FALSE [correction]: See answer to statement 5.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false",
      "unknown",
      "unknown",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is effective for the treatment of psoriasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used for the treatment of psoriasis.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used for the treatment of psoriasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Roflumilast is a drug known for its use in the treatment of chronic obstructive pulmonary disease (COPD). As of my last update, there is a form called Roflumilast cream that is being studied for the treatment of plaque psoriasis, but it is not primarily known or used for this purpose. If recent developments have led to its approval for this use, the statement could be true, but based on the information I have, it is not the established treatment for psoriasis.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Several tools have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters. Here are some of the commonly used tools:\n1. RNAhybrid: This tool uses a combination of sequence and structural information to predict the secondary and tertiary structure of RNA molecules, including ncRNA promoters.\n2. PICTAR: This tool uses a machine learning approach to identify putative promoter regions in ncRNA transcripts based on their sequence features.\n3. Prognosticate: This tool uses a Bayesian framework to predict the location and strength of ncRNA promoters based on their sequence and structural features.\n4. RNAProM: This tool uses a combination of machine learning and structural modeling to predict the promoter regions of ncRNAs.\n5. NCPromoterFinder: This tool uses a combination of sequence and structural features to identify putative promoter regions in ncRNAs.\n6. RNApromoter: This tool uses a machine learning approach to predict the promoter regions of ncRNAs based on their sequence features.\n7. DeepPromoter: This tool uses deep learning techniques to predict the promoter regions of ncRNAs based on their sequence features.\n8. Prodigal: This tool uses a combination of sequence and structural features to predict the location and strength of ncRNA promoters.\n9. RNApromoterFinder: This tool uses a combination of sequence and structural features to identify putative promoter regions in ncRNAs.\n10. NCRNApromoter: This tool uses a machine learning approach to predict the promoter regions of ncRNAs based on their sequence features.\nThese tools can be used to identify and visualize ncRNA promoters in various organisms, including humans, and can help researchers understand the regulatory mechanisms of ncRNA expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNAhybrid is a tool that predicts the secondary and tertiary structure of RNA molecules, including ncRNA promoters.\n2. PICTAR is a tool that identifies putative promoter regions in ncRNA transcripts using a machine learning approach based on sequence features.\n3. Prognosticate is a tool that predicts the location and strength of ncRNA promoters using a Bayesian framework based on sequence and structural features.\n4. RNAProM uses machine learning and structural modeling to predict promoter regions of ncRNAs.\n5. DeepPromoter uses deep learning techniques to predict the promoter regions of ncRNAs based on their sequence features.",
    "llama-2-7b-chat-hf_fact": [
      "RNAhybrid is a tool that predicts the secondary and tertiary structure of RNA molecules, including ncRNA promoters.",
      "PICTAR is a tool that identifies putative promoter regions in ncRNA transcripts using a machine learning approach based on sequence features.",
      "Prognosticate is a tool that predicts the location and strength of ncRNA promoters using a Bayesian framework based on sequence and structural features.",
      "RNAProM uses machine learning and structural modeling to predict promoter regions of ncRNAs.",
      "DeepPromoter uses deep learning techniques to predict the promoter regions of ncRNAs based on their sequence features."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RNAhybrid is a tool that predicts the interactions between a microRNA and a target RNA, not the secondary and tertiary structure of RNA molecules, including ncRNA promoters.\n2. FALSE [correction]: PICTAR is a tool used to predict microRNA targets and does not specifically identify promoter regions in ncRNA transcripts using machine learning.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "SWIM (Systematic Workflow for the Identification of Mutational Mechanisms) is a tool that can be used to identify genes that are differentially expressed between two or more conditions, such as a disease state and a normal state. Here are some examples of genes that SWIM has identified as down-regulated in glioblastoma:\n1. TP53: A tumor suppressor gene that is frequently mutated in glioblastoma.\n2. PTEN: A tumor suppressor gene that is frequently mutated or deleted in glioblastoma, leading to increased PI3K signaling.\n3. CDKN2A: A tumor suppressor gene that is frequently mutated or deleted in glioblastoma, leading to increased CDK activity.\n4. STK11: A tumor suppressor gene that is frequently mutated in glioblastoma, leading to increased AKT signaling.\n5. ARID1A: A gene that is frequently mutated in glioblastoma, leading to increased chromatin remodeling and transcriptional regulation.\n6. PIK3R1: A gene that is frequently mutated in glioblastoma, leading to increased PI3K signaling.\n7. MAP3K5: A gene that is frequently mutated in glioblastoma, leading to increased MAPK signaling.\n8. CDKN2B: A tumor suppressor gene that is frequently mutated or deleted in glioblastoma, leading to increased CDK activity.\n9. BRCA1: A tumor suppressor gene that is frequently mutated in glioblastoma, leading to increased DNA repair and transcriptional regulation.\n10. PTENP1: A gene that is frequently mutated in glioblastoma, leading to increased PI3K signaling.\nIt's important to note that the list of genes identified by SWIM may vary depending on the specific dataset used and the parameters set for the analysis. Additionally, the functional impact of each mutation may also vary depending on the context in which it occurs and the other mutations present in the tumor.",
    "llama-2-7b-chat-hf_fact_raw": "1. SWIM has identified TP53 as a gene that is down-regulated in glioblastoma.\n2. SWIM has identified PTEN as a gene that is down-regulated in glioblastoma.\n3. SWIM has identified CDKN2A as a gene that is down-regulated in glioblastoma.\n4. SWIM has identified STK11 as a gene that is down-regulated in glioblastoma.\n5. SWIM has identified ARID1A as a gene that is down-regulated in glioblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "SWIM has identified TP53 as a gene that is down-regulated in glioblastoma.",
      "SWIM has identified PTEN as a gene that is down-regulated in glioblastoma.",
      "SWIM has identified CDKN2A as a gene that is down-regulated in glioblastoma.",
      "SWIM has identified STK11 as a gene that is down-regulated in glioblastoma.",
      "SWIM has identified ARID1A as a gene that is down-regulated in glioblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TP53 is often mutated or altered in glioblastoma, but it is known as a tumor suppressor gene, and its down-regulation is not typically the focus when discussing its role in cancer.\n2. TRUE: PTEN is a tumor suppressor gene that is often down-regulated in glioblastoma.\n3. TRUE: CDKN2A is a tumor suppressor gene that is frequently deleted or down-regulated in glioblastoma.\n4. UNKNOWN: While STK11 is a tumor suppressor gene, there isn’t enough information provided to determine its status in glioblastoma without additional context.\n5. UNKNOWN: ARID1A is a gene that can be mutated in various cancers, including glioblastoma; however, whether it's specifically down-regulated in glioblastoma is not stated, so the status is unknown without further context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "Several R packages have been developed for studying Topologically Associating Domains (TADs), including:\n1. TADbit: This package provides a comprehensive set of tools for the analysis of TADs, including the detection of TAD boundaries, the analysis of chromatin accessibility, and the identification of TAD-associated genes.\n2. TADtrack: This package allows users to identify and track TADs across different cell types and conditions, and to analyze the dynamics of TADs over time.\n3. TADseq: This package provides a comprehensive workflow for the analysis of TADs in RNA sequencing data, including the detection of TAD-associated genes and the analysis of TAD-specific expression patterns.\n4. TAD-tools: This package provides a collection of tools for the analysis of TADs, including the detection of TAD boundaries, the analysis of chromatin accessibility, and the identification of TAD-associated genes.\n5. ChromHMM: This package provides a framework for the analysis of chromatin structure and TADs, including the prediction of TAD boundaries and the analysis of chromatin accessibility.\n6. TAD-seq-workflow: This package provides a comprehensive workflow for the analysis of TADs in RNA sequencing data, including the detection of TAD-associated genes and the analysis of TAD-specific expression patterns.\n7. TAD-analysis: This package provides a collection of tools for the analysis of TADs, including the detection of TAD boundaries, the analysis of chromatin accessibility, and the identification of TAD-associated genes.\n8. TAD-predict: This package provides a tool for the prediction of TAD boundaries based on chromatin accessibility data.\n9. TAD-detect: This package provides a tool for the detection of TADs in ChIP-seq data.\n10. TAD-profile: This package provides a tool for the analysis of TAD profiles in RNA sequencing data.\nPlease note that this is not an exhaustive list and there are many other R packages available for studying TADs, each with their own specific functions and features.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package TADbit provides tools for analyzing Topologically Associating Domains (TADs), including TAD boundary detection and gene identification.\n2. The TADtrack R package is used for identifying and tracking TADs across different cell types and analyzing their dynamics over time.\n3. TADseq is an R package that offers a comprehensive workflow for TAD analysis in RNA sequencing data.\n4. ChromHMM is an R package designed for analyzing chromatin structure and predicting TAD boundaries.\n5. TAD-predict is an R package that predicts TAD boundaries based on chromatin accessibility data.",
    "llama-2-7b-chat-hf_fact": [
      "The R package TADbit provides tools for analyzing Topologically Associating Domains (TADs), including TAD boundary detection and gene identification.",
      "The TADtrack R package is used for identifying and tracking TADs across different cell types and analyzing their dynamics over time.",
      "TADseq is an R package that offers a comprehensive workflow for TAD analysis in RNA sequencing data.",
      "ChromHMM is an R package designed for analyzing chromatin structure and predicting TAD boundaries.",
      "TAD-predict is an R package that predicts TAD boundaries based on chromatin accessibility data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: TADseq is not traditionally associated as an R package for analyzing TADs in RNA sequencing data. RNA sequencing data relates to gene expression analysis rather than chromatin organization.\n4. FALSE [correction]: ChromHMM is not an R package, but a Java tool used for understanding chromatin states. It is not designed specifically for predicting TAD boundaries, although it may be used in a broader context of chromatin analysis which could complement TAD studies.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "The Bioconductor package \"Rregulon\" has been developed for accessing bacterial regulatory networks.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bioconductor package named \"Rregulon\" is designed for accessing bacterial regulatory networks.",
    "llama-2-7b-chat-hf_fact": [
      "The Bioconductor package named \"Rregulon\" is designed for accessing bacterial regulatory networks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Bioconductor package named \"Rregulon\" is not designed for accessing bacterial regulatory networks; instead, it is a package designed for discovering, scoring, and visualizing the transcriptional regulatory networks in eukaryotic genomes using motif and track enrichments.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The end products of the shikimate pathway are aromatic amino acids, including:\n1. Tyrosine\n2. Tryptophan\n3. Phenylalanine\n4. Tyramine\n5. Histidine\nThese amino acids are important building blocks for various biological molecules, such as proteins, neurotransmitters, and hormones. The shikimate pathway is a metabolic pathway that produces these aromatic amino acids from the amino acid precursor chorismate, which is derived from the breakdown of the amino acid tryptophan.",
    "llama-2-7b-chat-hf_fact_raw": "1. The shikimate pathway produces aromatic amino acids.\n2. Tyrosine is an end product of the shikimate pathway.\n3. Tryptophan is an end product of the shikimate pathway.\n4. Phenylalanine is an end product of the shikimate pathway.\n5. The precursor for the aromatic amino acids produced by the shikimate pathway is chorismate.",
    "llama-2-7b-chat-hf_fact": [
      "The shikimate pathway produces aromatic amino acids.",
      "Tyrosine is an end product of the shikimate pathway.",
      "Tryptophan is an end product of the shikimate pathway.",
      "Phenylalanine is an end product of the shikimate pathway.",
      "The precursor for the aromatic amino acids produced by the shikimate pathway is chorismate."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is sometimes used to treat Nelson's syndrome, which is a rare condition that can occur after treatment with dopamine agonists, such as bromocriptine or ropinirole, for conditions such as Parkinson's disease or hyperprolactinemia (elevated prolactin levels). Nelson's syndrome is characterized by the rapid growth of a pituitary tumor after treatment with dopamine agonists, leading to amenorrhea (loss of menstruation), infertility, and other hormonal imbalances. Cabergoline, a dopamine receptor agonist, has been shown to be effective in reducing the size of the pituitary tumor and reversing the hormonal imbalances associated with Nelson's syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is sometimes used to treat Nelson's syndrome.\n2. Nelson's syndrome can occur after treatment with dopamine agonists.\n3. Conditions such as Parkinson's disease or hyperprolactinemia may be treated with dopamine agonists like bromocriptine or ropinirole.\n4. Nelson's syndrome is characterized by the rapid growth of a pituitary tumor following treatment with dopamine agonists.\n5. Cabergoline has been shown to be effective in reducing the size of the pituitary tumor and reversing hormonal imbalances associated with Nelson's syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is sometimes used to treat Nelson's syndrome.",
      "Nelson's syndrome can occur after treatment with dopamine agonists.",
      "Conditions such as Parkinson's disease or hyperprolactinemia may be treated with dopamine agonists like bromocriptine or ropinirole.",
      "Nelson's syndrome is characterized by the rapid growth of a pituitary tumor following treatment with dopamine agonists.",
      "Cabergoline has been shown to be effective in reducing the size of the pituitary tumor and reversing hormonal imbalances associated with Nelson's syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used to treat Nelson's syndrome but is used to treat conditions such as Parkinson's disease and hyperprolactinemia.\n2. FALSE [correction]: Nelson's syndrome can occur after the surgical removal of the adrenal glands (adrenalectomy), notably in patients who have previously had Cushing's disease and not as a result of treatment with dopamine agonists.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare genetic disorder characterized by the following main manifestations:\n1. Distal myopathy: Muscle weakness and wasting, primarily affecting the muscles in the arms and legs.\n2. Spasticity: Muscle stiffness and spasms, which can lead to difficulty with movement and balance.\n3. Scoliosis: Curvature of the spine, which can lead to postural problems and difficulty with breathing.\n4. Neuropathy: Nerve damage, which can cause numbness, tingling, and pain in the hands and feet.\n5. Cognitive impairment: Difficulty with cognitive function, including memory, attention, and problem-solving.\n6. Seizures: Seizures are a common complication of Liebenberg syndrome, particularly in children.\n7. Vision problems: Visual impairment, including cataracts, glaucoma, and optic atrophy.\n8. Hearing loss: Hearing loss or deafness can occur in some individuals with Liebenberg syndrome.\n9. Sleep disturbances: Sleep disorders, such as sleep apnea and insomnia, can occur in individuals with Liebenberg syndrome.\n10. Autism spectrum disorder: Some individuals with Liebenberg syndrome may also have autism spectrum disorder, which can affect social interaction, communication, and behavior.\nIt is important to note that the severity and specific manifestations of Liebenberg syndrome can vary widely between individuals, and some individuals may have a more mild or severe form of the disorder. A comprehensive diagnostic evaluation and multidisciplinary care can help manage the symptoms and improve the quality of life for individuals with Liebenberg syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is a rare genetic disorder.\n2. One of the main manifestations of Liebenberg syndrome is distal myopathy, affecting the muscles in the arms and legs.\n3. Liebenberg syndrome can cause spasticity, resulting in muscle stiffness and spasms.\n4. Scoliosis, which is the curvature of the spine, is a manifestation of Liebenberg syndrome.\n5. Individuals with Liebenberg syndrome may experience cognitive impairments.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is a rare genetic disorder.",
      "One of the main manifestations of Liebenberg syndrome is distal myopathy, affecting the muscles in the arms and legs.",
      "Liebenberg syndrome can cause spasticity, resulting in muscle stiffness and spasms.",
      "Scoliosis, which is the curvature of the spine, is a manifestation of Liebenberg syndrome.",
      "Individuals with Liebenberg syndrome may experience cognitive impairments."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Liebenberg syndrome primarily causes limb malformations, where the forearm bones resemble those of the leg, not distal myopathy.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nLiebenberg syndrome is indeed a rare genetic disorder; however, it is characterized mainly by the elbow joint developing similarly to a knee. There is limited public information on all manifestations of this syndrome, so answers to the manifestations such as spasticity, scoliosis, and cognitive impairments cannot be confirmed without additional specific medical literature.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "There are several orally bioavailable MPS1 kinase inhibitors that have been identified and developed for the treatment of various diseases, including cancer. Here are some examples:\n1. Vorinostat (Zolinza): Vorinostat is an oral histone deacetylase (HDAC) inhibitor that has been shown to inhibit MPS1 activity in various cell types, including cancer cells. It is approved for the treatment of cutaneous T-cell lymphoma.\n2. Romidepsin (Istodax): Romidepsin is an oral HDAC inhibitor that has been shown to inhibit MPS1 activity in various cell types, including cancer cells. It is approved for the treatment of cutaneous T-cell lymphoma.\n3. Panobinostat (Farydak): Panobinostat is an oral inhibitor of the enzyme PI3K (phosphatidylinositol 3-kinase), which is involved in the PI3K/AKT signaling pathway. This pathway is activated by MPS1 in various cell types, including cancer cells. Panobinostat is approved for the treatment of multiple myeloma.\n4. GDC-0980 (GDC-0980): GDC-0980 is an oral PI3K inhibitor that has been shown to inhibit MPS1 activity in various cell types, including cancer cells. It is currently being investigated for the treatment of various cancers, including breast, lung, and ovarian cancer.\n5. BAY 80-6946 (Bay 80-6946): BAY 80-6946 is an oral PI3K inhibitor that has been shown to inhibit MPS1 activity in various cell types, including cancer cells. It is currently being investigated for the treatment of various cancers, including breast, lung, and ovarian cancer.\n6. PI-103 (PI-103): PI-103 is an oral PI3K inhibitor that has been shown to inhibit MPS1 activity in various cell types, including cancer cells. It is currently being",
    "llama-2-7b-chat-hf_fact_raw": "1. Vorinostat (Zolinza) is an oral histone deacetylase (HDAC) inhibitor approved for the treatment of cutaneous T-cell lymphoma.\n2. Romidepsin (Istodax) is an oral HDAC inhibitor approved for the treatment of cutaneous T-cell lymphoma.\n3. Panobinostat (Farydak) is an oral inhibitor of PI3K, approved for the treatment of multiple myeloma.\n4. GDC-0980 is an oral PI3K inhibitor that is being investigated for the treatment of various cancers, including breast, lung, and ovarian cancer.\n5. BAY 80-6946 is an oral PI3K inhibitor that is being investigated for the treatment of various cancers, including breast, lung, and ovarian cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Vorinostat (Zolinza) is an oral histone deacetylase (HDAC) inhibitor approved for the treatment of cutaneous T-cell lymphoma.",
      "Romidepsin (Istodax) is an oral HDAC inhibitor approved for the treatment of cutaneous T-cell lymphoma.",
      "Panobinostat (Farydak) is an oral inhibitor of PI3K, approved for the treatment of multiple myeloma.",
      "GDC-0980 is an oral PI3K inhibitor that is being investigated for the treatment of various cancers, including breast, lung, and ovarian cancer.",
      "BAY 80-6946 is an oral PI3K inhibitor that is being investigated for the treatment of various cancers, including breast, lung, and ovarian cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Romidepsin (Istodax) is not an oral medication but an intravenous (IV) HDAC inhibitor approved for the treatment of cutaneous T-cell lymphoma.\n3. FALSE [correction]: Panobinostat (Farydak) is not an inhibitor of PI3K, but, like vorinostat, it is an HDAC inhibitor. It is approved for the treatment of multiple myeloma in combination with bortezomib and dexamethasone.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Yes, golimumab has been studied for the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. However, it has not been specifically approved for the treatment of diabetes.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Yes, progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by an autosomal recessive mutation in the LMNA gene. The LMNA gene provides instructions for making a protein called lamin A, which is involved in the structure and maintenance of chromosomes. Mutations in the LMNA gene can lead to the production of a faulty lamin A protein, which accumulates in the nucleus of cells and disrupts normal cellular function, leading to the characteristic features of progeria, including accelerated aging and death.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by an autosomal recessive mutation in the LMNA gene.\n2. The LMNA gene provides instructions for making a protein called lamin A.\n3. Lamin A is involved in the structure and maintenance of chromosomes.\n4. Mutations in the LMNA gene can result in a faulty lamin A protein.\n5. Accumulation of the faulty lamin A protein in the nucleus disrupts normal cellular function and leads to accelerated aging and death characteristic of progeria.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by an autosomal recessive mutation in the LMNA gene.",
      "The LMNA gene provides instructions for making a protein called lamin A.",
      "Lamin A is involved in the structure and maintenance of chromosomes.",
      "Mutations in the LMNA gene can result in a faulty lamin A protein.",
      "Accumulation of the faulty lamin A protein in the nucleus disrupts normal cellular function and leads to accelerated aging and death characteristic of progeria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by a mutation in the LMNA gene, but it is not autosomal recessive; it is typically a de novo (new) mutation that occurs during the early stages of embryogenesis.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Variants at chromosome 12q14 and 12q24 have been associated with several diseases and conditions, including:\n12q14:\n* Bipolar disorder: Variants in this region have been identified as risk factors for bipolar disorder.\n* Schizophrenia: Some studies have found an increased risk of schizophrenia in individuals with variants in this region.\n* Major depressive disorder: Some studies have found an increased risk of major depressive disorder in individuals with variants in this region.\n* Autism spectrum disorder: Some studies have found an increased risk of autism spectrum disorder in individuals with variants in this region.\n12q24:\n* Prostate cancer: Variants in this region have been identified as risk factors for prostate cancer.\n* Breast cancer: Some studies have found an increased risk of breast cancer in individuals with variants in this region.\n* Ovarian cancer: Some studies have found an increased risk of ovarian cancer in individuals with variants in this region.\n* Type 2 diabetes: Some studies have found an increased risk of type 2 diabetes in individuals with variants in this region.\nIt is important to note that the associations between these variants and disease risk are complex and may involve multiple genetic and environmental factors. More research is needed to fully understand the relationships between these variants and disease risk.",
    "llama-2-7b-chat-hf_fact_raw": "1. Variants in the 12q14 region have been identified as risk factors for bipolar disorder.\n2. An increased risk of schizophrenia has been associated with variants in the 12q14 region, as found by some studies.\n3. Some studies suggest that variants at chromosome 12q24 are linked to an increased risk of prostate cancer.\n4. An increased risk of breast cancer has been associated with variants in the 12q24 region, according to some studies.\n5. An increased risk of type 2 diabetes in individuals with variants at chromosome 12q24 has been reported by some studies.",
    "llama-2-7b-chat-hf_fact": [
      "Variants in the 12q14 region have been identified as risk factors for bipolar disorder.",
      "An increased risk of schizophrenia has been associated with variants in the 12q14 region, as found by some studies.",
      "Some studies suggest that variants at chromosome 12q24 are linked to an increased risk of prostate cancer.",
      "An increased risk of breast cancer has been associated with variants in the 12q24 region, according to some studies.",
      "An increased risk of type 2 diabetes in individuals with variants at chromosome 12q24 has been reported by some studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - Studies have identified that variants in the 12q14 region are among the genetic risk factors for bipolar disorder.\n2. TRUE - Research has found associations between schizophrenia and genetic variations in various regions of the genome, including the 12q14 region.\n3. UNKNOWN - Without specific studies or evidence provided, it is difficult to confirm the association between chromosome 12q24 and prostate cancer. This information might be true or false, but without context or references, the accuracy cannot be determined.\n4. UNKNOWN - As with the previous statement, without specific research citations or evidence, the association between chromosome 12q24 variants and an increased risk of breast cancer cannot be confirmed or denied.\n5. TRUE - There has been research suggesting that variants in the 12q24 region are associated with an increased risk of type 2 diabetes.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "The ligands of the Roundabout (Robo) receptors are the Robo ligands, which include:\n1. Robo1 ligand (RALBP1): This ligand is a membrane-bound protein that binds to Robo1 and regulates its activity.\n2. Robo2 ligand (RALBP2): This ligand is also a membrane-bound protein that binds to Robo2 and regulates its activity.\n3. Robo3 ligand (RALBP3): This ligand is a secreted protein that binds to Robo3 and regulates its activity.\n4. Robo4 ligand (RALBP4): This ligand is a membrane-bound protein that binds to Robo4 and regulates its activity.\nThese ligands play a crucial role in regulating the activity of the Robo receptors and modulating the behavior of cells in various tissues, including the nervous system, immune system, and cancer cells.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Yes, TFII-I plays a role in megakaryopoiesis. TFII-I is a transcription factor that is involved in the regulation of gene expression during megakaryocyte differentiation. It is required for the proper expression of genes involved in platelet function and platelet membrane protein synthesis. TFII-I is also important for the maintenance of platelet function and survival, and its dysregulation has been implicated in platelet disorders such as thrombocytopenia and platelet dysfunction.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I is a transcription factor involved in the regulation of gene expression.\n2. TFII-I plays a role in megakaryocyte differentiation during megakaryopoiesis.\n3. It is required for the proper expression of genes involved in platelet function and platelet membrane protein synthesis.\n4. TFII-I is important for the maintenance of platelet function and survival.\n5. Dysregulation of TFII-I has been implicated in platelet disorders such as thrombocytopenia and platelet dysfunction.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I is a transcription factor involved in the regulation of gene expression.",
      "TFII-I plays a role in megakaryocyte differentiation during megakaryopoiesis.",
      "It is required for the proper expression of genes involved in platelet function and platelet membrane protein synthesis.",
      "TFII-I is important for the maintenance of platelet function and survival.",
      "Dysregulation of TFII-I has been implicated in platelet disorders such as thrombocytopenia and platelet dysfunction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided describe the general functions and importance of a transcription factor, which can be applicable to various transcription factors. In this case, TFII-I is stated to be involved in gene regulation, megakaryocyte differentiation, platelet function, and implicated in platelet disorders. Without specific evidence to refute these claims and assuming they are based on accurate scientific information, it is reasonable to accept them as true. However, it should be noted that for a non-expert, the specific roles and implications of TFII-I in these processes may not be precisely known without consulting the relevant scientific literature. If this were a specialized query in molecular biology, a professional in the field or a detailed literature search would be necessary to confirm the veracity of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Yes, atenolol is metabolized by the cytochrome P450 enzyme CYP2D6. CYP2D6 is responsible for the metabolism of approximately 20-30% of drugs in clinical use today, including atenolol.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.\n2. The CYP2D6 enzyme is responsible for the metabolism of approximately 20-30% of drugs in clinical use today.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.",
      "The CYP2D6 enzyme is responsible for the metabolism of approximately 20-30% of drugs in clinical use today."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the cytochrome P450 system; it is primarily excreted unchanged in the urine.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "ExpansionHunter is a tool used for detecting gene fusions in RNA-seq data. Here are some versions of ExpansionHunter:\n1. ExpansionHunter 1.0: This is the original version of ExpansionHunter, which was released in 2015.\n2. ExpansionHunter 2.0: This version was released in 2017 and includes several improvements over the original version, including improved sensitivity and specificity, as well as the ability to detect fusions in both tumor and normal samples.\n3. ExpansionHunter 3.0: This is the latest version of ExpansionHunter, which was released in 2020. It includes several new features, including the ability to detect fusions in single cells, and improved performance in detecting fusions in complex genomic regions.\n4. ExpansionHunter-Lite: This is a simplified version of ExpansionHunter that is designed for use with smaller datasets. It includes a reduced set of algorithms and is optimized for faster computation.\n5. ExpansionHunter-Pipeline: This is a version of ExpansionHunter that is integrated into a larger pipeline for genomic analysis. It includes tools for data preprocessing, fusion detection, and downstream analysis.\n6. ExpansionHunter-Cloud: This is a cloud-based version of ExpansionHunter that allows users to access the tool from any computer with an internet connection. It includes a web-based interface and is designed for use with large datasets.\n7. ExpansionHunter-Python: This is a Python package for ExpansionHunter that allows users to integrate the tool into their own pipelines and workflows. It includes a set of pre-built functions for performing fusion detection and analysis.\n8. ExpansionHunter-R: This is a version of ExpansionHunter for use with the R programming language. It includes a set of pre-built functions for performing fusion detection and analysis, as well as a user-friendly interface for interacting with the tool.",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter 1.0 was released in 2015.\n2. ExpansionHunter 2.0 was released in 2017 and includes improvements over the original version.\n3. ExpansionHunter 3.0 was released in 2020 and introduced the ability to detect fusions in single cells.\n4. ExpansionHunter-Lite is optimized for faster computation and is designed for use with smaller datasets.\n5. ExpansionHunter-Cloud is a cloud-based version that offers a web-based interface for use with large datasets.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter 1.0 was released in 2015.",
      "ExpansionHunter 2.0 was released in 2017 and includes improvements over the original version.",
      "ExpansionHunter 3.0 was released in 2020 and introduced the ability to detect fusions in single cells.",
      "ExpansionHunter-Lite is optimized for faster computation and is designed for use with smaller datasets.",
      "ExpansionHunter-Cloud is a cloud-based version that offers a web-based interface for use with large datasets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: ExpansionHunter 3.0 was released in 2020 and does not specifically introduce the ability to detect fusions in single cells; rather, it generally improves variant detection algorithms and efficiency over earlier versions.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 (a disintegrin and metalloproteinase domain-containing protein 18) plays a role in regulating hormone receptor signaling by modulating the activity of the estrogen receptor (ER). Adamts18 can bind to the ER and inhibit its activity, thereby reducing the signaling response to estrogen. This can have implications for the regulation of various cellular processes, including cell growth, differentiation, and survival.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is involved in regulating hormone receptor signaling.\n2. Adamts18 can bind to the estrogen receptor (ER).\n3. Adamts18 inhibits the activity of the estrogen receptor.\n4. The inhibition by Adamts18 can reduce the signaling response to estrogen.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is involved in regulating hormone receptor signaling.",
      "Adamts18 can bind to the estrogen receptor (ER).",
      "Adamts18 inhibits the activity of the estrogen receptor.",
      "The inhibition by Adamts18 can reduce the signaling response to estrogen."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ADAMTS18 is known as a disintegrin and metalloproteinase with thrombospondin motifs; it is generally involved in the structural organization of the extracellular matrix, not specifically in hormone receptor signaling.\n2. UNKNOWN: There is limited information available in common knowledge related to direct binding of ADAMTS18 to the estrogen receptor (ER).\n3. UNKNOWN: Due to the lack of specific information regarding the effect of ADAMTS18 on the estrogen receptor’s activity, it cannot be definitively stated that it inhibits the receptor.\n4. UNKNOWN: Since the interaction and potential inhibition of the estrogen receptor by ADAMTS18 are not established in the provided context, the effect on signaling response to estrogen is also unknown.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a small molecule inhibitor of the histone acetyltransferase (HAT) enzyme p300. It works by binding to the p300 protein and preventing it from acetylating histones, which leads to the repression of gene transcription. Thiazovivin can be used to study the function of p300 in various cellular processes, including cell proliferation, differentiation, and survival, and it has also been investigated as a potential therapeutic agent for the treatment of cancer and other diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is a small molecule inhibitor of the histone acetyltransferase enzyme p300.\n2. Thiazovivin functions by preventing the p300 protein from acetylating histones.\n3. The inhibition of histone acetylation by Thiazovivin leads to the repression of gene transcription.\n4. Thiazovivin can be used to study the roles of p300 in cell proliferation, differentiation, and survival.\n5. Thiazovivin has been investigated as a potential therapeutic agent for cancer and other diseases.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is a small molecule inhibitor of the histone acetyltransferase enzyme p300.",
      "Thiazovivin functions by preventing the p300 protein from acetylating histones.",
      "The inhibition of histone acetylation by Thiazovivin leads to the repression of gene transcription.",
      "Thiazovivin can be used to study the roles of p300 in cell proliferation, differentiation, and survival.",
      "Thiazovivin has been investigated as a potential therapeutic agent for cancer and other diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is not an inhibitor of the histone acetyltransferase enzyme p300; it is actually a small molecule inhibitor that acts to enhance the survival and cloning efficiency of human embryonic stem cells by inhibiting Rho-associated kinase (ROCK).\n2. FALSE [correction]: Since Thiazovivin is not an inhibitor of p300, it does not function by preventing the p300 protein from acetylating histones.\n3. FALSE [correction]: As Thiazovivin does not inhibit p300 or its histone acetyltransferase activity, it does not lead to repression of gene transcription via inhibition of histone acetylation.\n4. UNKNOWN: Without specific literature references or further context on studies involving the roles of p300 and Thiazovivin, it is not possible to accurately verify this statement.\n5. UNKNOWN: While Thiazovivin has been used in stem cell research, its investigation as a potential therapeutic agent for cancer and other diseases cannot be verified without additional context or specific references to such studies.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  }
]